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The generation of induced pluripotent stem cells (iPSCs) presents a 
challenge to normal developmental processes. The low efficiency and heterogeneity 
of most methods have hindered understanding of the precise molecular 
mechanisms promoting, and roadblocks preventing, efficient reprogramming. 
While several intermediate populations have been described, it has proved difficult 
to characterize the rare, asynchronous transition from these intermediate stages to 
iPSCs. The rapid expansion of a minor population of reprogrammed cells can also 
obscure investigation of relevant processes. Understanding of the biological 
mechanisms essential for successful iPSC generation requires both accurate capture 
of cells undergoing the reprogramming process and identification of the associated 
global gene expression changes. Here we demonstrate that reprogramming follows 
an orderly sequence of stage transitions marked by changes in cell surface markers 
CD44 and ICAM1, and a Nanog-GFP reporter. RNA-sequencing (RNA-seq) analysis 
of these populations demonstrates two waves of pluripotency gene up-regulation, 
and unexpectedly, transient up-regulation of multiple epidermis-related genes, 
demonstrating that reprogramming is not simply the reversal of normal 
developmental processes. This novel high-resolution analysis enables the 
construction of a detailed reprogramming route map, and this improved 
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CHAPTER 1 - Introduction 
 
1.1 Changing cellular potential: The road to iPS cells 
1.1.1 Early developments in re-establishing pluripotency 
 The idea that a differentiated cell, with defined characteristics and limited, if 
any, plasticity could in some way change its cellular identity and become 
pluripotent was first demonstrated in the seminal work of Prof. John Gurdon 
(Gurdon, 1962). It was shown that introduction of nuclei from tadpole intestinal 
epithelial cells to unfertilized, enucleated Xenopus eggs could lead to the generation 
of normal tadpoles, from which in turn further nuclei were isolated and the 
experiment successfully repeated. These results suggested that cells retain their 
genetic information throughout development, and that the effects of differentiation 
on somatic nuclei could be reversed. Subsequently, the birth of Dolly the sheep, 
cloned from an adult cell, provided clear evidence that there is no permanent, 
irreversible genetic modification of genetic information in cells, and these cloned 
cells can generate viable offspring (Wilmut et al., 1997). However, the low frequency 
of successful cloning using nuclear-transfer techniques led to speculation that 
contaminating, or rare, tissue stem cells may be responsible for this phenomenon. 
Wabl et al. (1975) generated cloned tadpoles from lymphocytes and used 
karyotyping to ensure the cloned tadpoles were derived from the differentiated 
nuclei. The Jaenisch group (Hochedlinger and Jaenisch, 2002) demonstrated that 
differentiated cells could be used to generate adult cloned mice. In this study, 
terminally differentiated B-cell nuclei were transferred into enucleated oocytes from 
which cloned blastocysts and embryonic stem (ES) cells could be isolated. These ES 
cells carried the characteristic immunoglobulin locus rearrangement of the original 
B-cells, and could be used to generate cloned mice.  
2 
 
1.1.2 Embryonic stem cells 
The derivation of mouse embryonic stem (ES) cells was a major 
breakthrough in developmental biology. The discovery of these cells stemmed from 
the identification of the pluripotent nature of cells isolated from teratocarcinomas, 
termed embryonic carcinoma (EC) cells (reviewed in Evans, 2011). ES cell lines are 
derived from the inner cell mass (ICM) of the pre-implantation embryo which 
continues to develop into the epiblast and primitive endoderm in vivo, with the 
latter cells in turn giving rise to the visceral and parietal endoderm (Gardner, 1982). 
Given their similarity to EC cells, ES cells were likewise initially maintained and 
expanded on fibroblast feeder cells (Evans and Kaufman, 1981; Martin, 1981). It was 
subsequently discovered that the spontaneous differentiation induced upon feeder-
free culture of ES cells could be prevented by addition of leukaemia inhibitory factor 
(LIF) and foetal calf serum (FCS) (Smith et al., 1988; Williams et al., 1988; Ying et al., 
2003). These advances enable long term maintenance and expansion of ES cells in a 
culture in the absence of feeder cells, which, unlike EC cells, retain normal 
karyotypes upon extended passaging. Additionally, their ability to contribute to 
chimeric mice and for germline transmission heralded ES cells as a powerful tool 
with which to investigate the mechanisms of development and differentiation 
(Bradley et al., 1984). 
It was a number of years later before similar humans embryonic stem (hES) 
cells could be isolated (Thomson et al., 1998). While it was shown that these cells 
could give rise to cells from all three germ-layers, hES cells differed from their 
murine counterparts in that they could not be maintained by LIF and BMP, and 
instead required basic fibroblast growth factor (FGF2) for maintenance of the 
undifferentiated state (Thomson et al., 1998; Amit et al., 2000; Reubinoff et al., 2000; 
Daheron et al., 2004) Subsequent experiments determined the transforming growth 
factor beta (TGF-β)/Activin signalling pathway is required to maintain hES in 
feeder- and serum-free conditions (Amit et al., 2004). 
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Interestingly, it was subsequently demonstrated that culturing post-
implantation mouse embryos in FGF2/Activin A enabled the derivation of cell lines 
which shared similar characteristics with hES cells, including morphological 
appearance, inability to be passaged at single-cell density, and differentiation to 
primitive endoderm and trophectoderm upon exposure to BMP4 (Brons et al., 2007; 
Tesar et al., 2007). Notably these cells, although capable of differentiation into cell 
types from all three germ-layers, did not contribute at all to developing blastocysts 
in one of these studies, and only at a very low frequency in the other. These cells 
were also shown to display some similarity in gene expression to mES cells, but also 
up-regulated expression of epiblast associated factors, and were termed epiblast 
stem cells (EpiSCs). It was also shown that murine genetic backgrounds, as well as 
other species, which were previously thought to be non-permissive for ES cell 
derivation, could be induced to produce these EpiSCs (Wang et al., 2008a; Alberio et 
al., 2010). Most recently, it has been shown that EpiSCs can in fact be derived from 
pre-implantation embryos, even those which fail to give rise to ES cell lines (Najm et 
al., 2011). 
The isolation of pluripotent cells from both mouse and human sources has 
lead to the development of myriad techniques and culture systems which have 
enable derivation of a variety of differentiated cell types (reviewed in Keller, 2005). 
While this has no doubt greatly increased our understanding of development and 
enabled screening of compounds which can be used in patients, certain limitations 
remain. For example, the generation of human ES cell lines, which requires 
generation and subsequent destruction of a fertilized embryo, is ethically 
contentious, and also somewhat limits the availability of diseased cell lines for 
study. One approach to overcome the latter obstacle has been the use of ES cell 
fusion. It was initially shown that fusion of a male mouse ES cell with a female 
thymocyte carrying an Oct4-GFP reporter lead to GFP activation, destabilisation of 
the X-chromosome silencing factor Xist and the fused cell could contribute to 
chimeric mice (Tada et al., 2001). This reactivation of pluripotency genes was 
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subsequently demonstrated in human cells by fusing hES cells and human 
fibroblasts carrying a Rex1-GFP reporter (Cowan et al., 2005). More certain analysis 
of the modification of the somatic genome is made possible through the use of 
heterokaryons which involve the fusion of cells from different species. Fusion of 
human B-lymphocytes or fibroblasts with mouse ES cells enabled identification of 
nascent  pluripotency gene expression from the somatic genome, and identification 
of factors required for reacquisition of a pluripotent state (Pereira et al., 2008; 
Bhutani et al., 2010). However, these techniques are limited in their appeal in that 
the resulting cells carry genetic content from both fused cells, and the success of the 
technique appears to be correlated with the relative differentiation of the non-ES 
cell, with embryonic germ cell (GC) and neural stem cell (NSC) fusions more 
successful than fully differentiated cells (Silva et al., 2006). However, as outlined by 
the work of Gurdon, these results confirmed that differentiated cells are capable of 
acquiring an earlier, ES cell-like state both in terms of pluripotency gene re-
expression and also therefore at an epigenetic level. However, identification of the 
precise mechanism by which this occurred was hindered by the sheer number of 
factors, both known and unknown, present in oocytes and ES cells that may play a 
role in this process. 
 
1.1.3 iPS cells 
 In 2006, many of the above issues were addressed by the discovery that just 
four transcription factors could be used to induce an ES cell-like state in a somatic 
cell (Takahashi and Yamanaka, 2006). In this groundbreaking study, a set of 24 
candidate genes, identified based on their expression and documented importance 
in ES cells, were over-expressed through retroviral infection of both mouse 
embryonic fibroblasts (MEF) and adult fibroblasts. Subsequent culture of the 
infected cells in the ES cell conditions lead to major changes in cell morphology, and 
eventually clusters of ES cell-like colonies were identified, from which cell lines 
could be derived and maintained similarly to ES cells. These were termed induced 
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pluripotent stem (iPS) cells. Through the process of elimination the initial list of 
candidates was reduced to just four factors: c-Myc, Oct4, Sox2 and Klf4. Some of the 
iPS cell lines showed reactivation of ES cell associated genes, demethylation of 
certain pluripotency promoters and the ability to give rise to cells from all three 
germ layers in teratomas and in vivo from iPS cell-injected blastocysts, although no 
full-term chimeric mice were obtained. This result provided, for the first time a 
defined set of factors which could be used to induce pluripotency in the process of 
somatic cell reprogramming. Further work from this group and by Jaenisch and 
colleagues reported the generation of iPS cells which displayed more fully 
demethylated Oct4 and Nanog promoters and were both chimera and germline 
competent (Okita et al., 2007; Wernig et al., 2007).  
It was subsequently shown that iPS cells could be derived from cultures of 
human dermal fibroblasts, neonatal fibroblasts, human mesenchymal stem cells 
(MSCs) and foetal lung fibroblasts (Takahashi et al., 2007; Park et al., 2008). These 
human iPS (hiPS) cells could be maintained in human ES cell culture conditions, 
and similarly displayed demethylation of pluripotency gene promoters, ES cell-like 
morphology, and ability to differentiate into derivatives of all germ layers in both 
tumour formation and embryoid body differentiation. 
It had been noted that in mice generated using iPS cells, failure to 
appropriately silence expression of the c-Myc transgene resulted in the development 
of tumours (Okita et al., 2007). Thereafter it was reported that both mouse and 
human iPS cells could be generated by Klf4, Oct4 and Sox2 alone (Nakagawa et al., 
2008). Notably, in all cases the removal of c-Myc resulted in a lower total number of 
iPS cell colonies, but those that did develop were of a high quality. It was also 
demonstrated that with the exception of Oct4, each of the reprogramming factors 
could be individually replaced by a related family member such as the substitution 
of Klf4 with Klf1, Klf2 or Klf5 (Nakagawa et al., 2008). Further substitution of 
reprogramming factors in human iPS cell generation was demonstrated by the use 
of NANOG and LIN28 with OCT4 and SOX2 (Yu et al., 2007). The orphan nuclear 
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receptor Esrrb was reported to substitute Klf4 during reprogramming and iPS cells 
were also generated in combination with Oct4 and Sox2 (Feng et al., 2009a). Another 
screen for factors that replace Klf4 identified the maternal factor Glis1 as improving 
reprogramming in both MEF and human fibroblasts (Maekawa et al., 2011). Most 
significantly, it was shown that Oct4 could be replaced by the nuclear receptor 
Nr5a2, which enabled reprogramming of MEF when introduced with Klf4 and Sox2 
(Heng et al., 2010). This was an important milestone as Oct4 activity during 
reprogramming cannot be substituted by its closely related family members Oct1 
and Oct6 (Nakagawa et al., 2008). Nr5a2 was found to activate both Oct4 and Nanog 
during reprogramming from MEF, with Nanog over-expression capable of rescuing 
the reduced iPS cell colony formation observed upon endogenous Nr5a2 
knockdown (Heng et al., 2010).  
The advent of defined transcription factor based reprogramming of cell fate 
also lead to attempts to interconvert different multipotent stem cells to an earlier 
developmental state. It was shown that neural stem (NS) cells which express high 
levels of endogenous Sox2 could be reprogrammed to an ES cell-like state using 
only Oct4 and either Klf4 or c-Myc (Kim et al., 2008b). Subsequently reprogramming 
was demonstrated using both mouse and human NS cells using Oct4 alone (Kim et 
al., 2009b; Kim et al., 2009c). A number of factors were also found to be capable of 
inducing an ES-like state from EpiSCs, including Nanog, Esrrb, Klf4 and Nr5a2 
(Guo et al., 2009; Silva et al., 2009; Guo and Smith, 2010; Festuccia et al., 2012). 
Interestingly, the latter two factors, Klf4 and Nr5a2, were also capable of inducing 
both mouse ES cell-like clonogenicity and LIF/Stat3 dependence when utilised 
during human iPS cell derivation (Hanna et al., 2010; Wang et al., 2011b). 
These results revealed that reprogramming to iPS cells is an important tool 
for investigation of the interactions between and requirements for various factors in 




1.2 Strategies to generate iPS cells 
1.2.1 Virus based delivery of reprogramming factors 
 The first set of reprogramming studies utilised gammaretroviruses to deliver 
the reprogramming factors to the target cells, a system which was shown to also be 
successful for the derivation of human iPS cells (Takahashi and Yamanaka, 2006; 
Maherali et al., 2007; Okita et al., 2007; Takahashi et al., 2007; Wernig et al., 2007; 
Park et al., 2008).  
Subsequently it was shown that lentiviruses could also be used to generate 
human iPS cells, which unlike gammaretroviruses do not require cells to be 
dividing for successful transduction (Yu et al., 2007; Mali et al., 2008; Zhao et al., 
2008). In order to reduce abrogation of the host cell genome, many laboratories 
developed polycistronic vectors which encoded all the reprogramming factors in 
one transcript (Carey et al., 2009; Shao et al., 2009; Sommer et al., 2009). In these 
vectors the reprogramming factors are separated by 2A peptide linkers which 
enable “ribosome skipping” and the translation of multiple proteins from a single 
mRNA molecule (Donnelly et al., 2001). iPS cells were also generated by lentiviruses 
using vectors carrying the individual reprogramming factors encoding a loxP site in 
the 3’ LTR (Soldner et al., 2009). Upon proviral replication this site was duplicated 
into the 5’ LTR, thus resulting in integrated, loxP flanked transgenes which could 
subsequently be removed upon transient Cre recombinase expression. Interestingly, 
this study revealed that post-excision iPS cells were more similar to hES cells than 
before the removal of the transgenes. This method was similarly applied to the 
polycistronic lentivirus vectors, enabling the generation of iPS cells with a low 
number of transgene integrations, thus reducing the chance of introducing 
detrimental genomic rearrangements upon Cre-mediated excision of the 
reprogramming factors (Chang et al., 2009; Somers et al., 2010; Sommer and 
Mostoslavsky, 2010; Papapetrou and Sadelain, 2011).  
Two of these studies delivered the Cre recombinase vector through the use 
of the non-integrating adenovirus (Chang et al., 2009; Sommer and Mostoslavsky, 
8 
 
2010). This strategy has also been used for the delivery of the reprogramming 
factors, and iPS cells have been derived from mouse hepatocytes, fibroblasts and 
human fibroblasts using adenoviruses (Stadtfeld et al., 2008b; Gonzalez et al., 2009; 
Zhou and Freed, 2009). However, the rapid clearing of viruses from dividing cells 
means that reprogramming via this method requires multiple subsequent rounds of 
infection, and iPS cells are generated at a low frequency. While the removal of 
transgenes from the host genome through the use of Cre-recombinase removes the 
majority of foreign genetic information, the inactive LTR fragment (~250bp) 
remains. 
The sendai virus, which replicates exclusively in the cytoplasm has also been 
used to generate iPS cells. A number of human cell-types have been shown to 
undergo reprogramming using sendai virus vectors (Fusaki et al., 2009; Seki et al., 
2010). However, as outlined in the former study, high levels of the virus persist in 
the reprogrammed cells. Two recent studies have addressed this issue with the use 
of temperature sensitive viral vectors or by using viral replication- and 
transcription-interfering iPS cells (Ban et al., 2011; Nishimura et al., 2011). These 
techniques allow relatively efficient generation of virus-negative iPS cell colonies.  
 
1.2.2 Non viral delivery of reprogramming factors 
In order to generate truly fully transgene-free iPS cells, the piggyBac 
transposon has been used for delivery of reprogramming factors (Kaji et al., 2009; 
Woltjen et al., 2009; Yusa et al., 2009). Transposons are genetic elements which occur 
naturally in the genome and can introduce mutation and genomic rearrangement as 
they are mobile, moving from one position in the genome to another (McClintock, 
1950). The piggyBac transposable element is flanked by 13-bp terminal inverted 
repeats, and insertion into the genome duplicates its TTAA target site (Cary et al., 
1989). Its activity is reliant on co-expression of the transposase enzyme, with early 
experiments showing seamless insertion and excision of a lacZ reporter gene into 
the viral genome, and subsequently it was used for efficient germ-line mutagenesis 
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in the mouse (Fraser et al., 1996; Ding et al., 2005; Wu et al., 2007). In mouse ES cell 
colonies bearing an integrated piggyBac transposon, it was shown that upon 
expression of the transposase enzyme roughly 40% of colonies displayed re-
insertion of the transposon, with complete excision from the host genome in the 
remainder (Wang et al., 2008b). Kaji et al. (2009) demonstrated virus-free 
reprogramming of MEF via nucleofection of a floxed polycistronic vector which was 
subsequently flanked by piggyBac transposons and delivered to human embryonic 
fibroblasts to generate iPS cells. Woltjen et al. (2009) also utilised piggyBac 
technology to deliver separate vectors encoding each of the Yamanaka 
reprogramming factors to both MEF and human embryonic fibroblasts. Upon re-
expression of transposase enzyme, complete transposon removal occurred in 66% of 
the mouse iPS cell colonies tested, and 90% showed no post-excision-aberrations at 
the site of transposon insertion. The use of negative selection to enrich for 
successfully excised colonies has also been demonstrated (Yusa et al., 2009). 
It has been demonstrated that the direct delivery of proteins fused to a poly-
argenine tag which enables crossing of the cellular membrane can be used to 
generate mouse iPS cells, albeit at a highly reduced efficiency compared to other 
methods (Zhou et al., 2009). Reprogramming of human fibroblasts was also 
demonstrated using this technique, however the argenine-tagged reprogramming 
factors were expressed in a human embryonic kidney (HEK) cell-line from which 
whole cell extracts were isolated (Kim et al., 2009a). Whole mouse ES cell extracts, 
delivered by streptolysin O-mediated reversible permeabilisation, were also 
demonstrated to generate mouse iPS cells from fibroblasts which were competent to 
generate chimera (Cho et al., 2010). A major caveat with these techniques is that all 
operate at a low frequency of success and also require large amounts of starting 
protein or cell extract. 
More recently, using in vitro transcription (IVT) to generate modified mRNA 
molecules, Warren et al. (2010) demonstrated highly efficient derivation of iPS cells 
from human fibroblasts. In this study it was found that transfection of the synthetic 
mRNA lead to activation of single strand RNA (ssRNA) sensor RIG-I, resulting in a 
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high level of cytotoxicity. To reduce this immune response a number of 
modifications were made to the synthetic mRNAs including treatment with 
phosphatase and substitution of cytidine and puridine with 5’methylcytidine and 
pseudouridine respectively. Culture media was also supplemented with an 
inhibitor of interferon signalling. In these conditions transfection efficiencies of up 
to 90% were achievable and ES cell-derived, foetal, postnatal and adult human 
fibroblasts were all successfully reprogrammed,  with the ES cell-derived fibroblasts 
shown to generate iPS cell colonies at a faster rate (two-fold greater) and higher 
efficiency (36-fold greater) than fibroblasts infected with the reprogramming factors 
in parallel. However successful reprogramming using this technique requires daily 
transfection of the reprogramming factor mRNA due to the low stability and high 
turnover of these molecules, and involves a high level of technicality thus making 
this system less widely accessible. 
Another approach has been the use of oriP/EBNA1 vectors which have been 
derived from the Epstein-Barr virus which can be introduced to cells in the absence 
of viral packaging. In the presence of drug selection these vectors replicate extra-
chromosomally once per cell cycle and are established stably in ~1% of transfected 
cells, and lost at a rate of 5% per cell cycle upon removal of selection (Leight and 
Sugden, 2001; Nanbo et al., 2007). Yu at al. (2009) demonstrated that using a 
combination of OCT4, SOX2, NANOG, LIN28, c-MYC, KLF4, and SV40LT, iPS cell 
colonies could be derived from human foreskin fibroblasts, and upon removal of 
selection about 30% of established iPS sub-clones lost the episomal vectors. While 
successful, this technique was limited in that the efficiency of reprogramming was 
more than three orders of magnitude lower than reprogramming using lentiviruses 
in the same study, and utilized the oncoprotein SV40LT. It has since been 
demonstrated that higher efficiency reprogramming using episomal vectors can be 
achieved without the use of SV40LT by either the inclusion of shRNA against p53 or 
the replacement of NANOG and c-MYC by L-MYC (Okita et al., 2011). Another 
recent study used minicircle episomal vectors and demonstrated reprogramming of 
human adipose stem cells (Jia et al., 2010). These are stripped-back versions of the 
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larger standard episomal vectors and contain only a eukaryotic expression cassette, 
lacking the bacterial backbone elements enabling both an increased transfection 
efficiency and duration of transgene expression. 
 
 
Figure 1.1 Overview of methods used for delivery of reprogramming factors. 
Adapted from O’Malley et al. (2009). 
 
1.2.3 Secondary reprogramming systems 
 The previously described lentiviral reprogramming strategy was 
demonstrated to successfully generate mouse iPS cells with expression of the 
reprogramming factors under the control of the tetO doxycycline (dox) inducible 
promoter (Brambrink et al., 2008; Stadtfeld et al., 2008a). This approach was 
subsequently used to develop a system termed secondary (2°) reprogramming 
(Wernig et al., 2008). This system is based on the requirement for doxycycline 
binding of the reverse tetracycline transactivator protein for interaction and 
expression from the tetO operator sequence (Tet-On system) (Gossen and Bujard, 
1992). In this 2° reprogramming system, iPS cells generated using the dox-inducible 
lentiviruses from transgenic MEF expressing rtTA from the Rosa26 locus, were used 
to generate chimeric mice. Cells isolated from these chimeras could subsequently be 
cultured in dox-containing media, thus inducing re-expression of the 
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reprogramming factors and generating 2° iPS cells. A variety of cell types were 
successfully reprogrammed using this system including MEF, MSCs, neural 
progenitors, epithelial cells and keratinocytes. Interestingly, despite the genetic 
homogeneity of these cells, the maximum efficiency of MEF reprogramming was 
roughly 1% (although it should be noted that this was 30 times greater than parallel 
retrovirus reprogramming), and the reprogramming of various cell types revealed 
greatly different temporal requirements of transgene expression before iPS cell 
colonies could be isolated. The results of this study indicated 2° reprogramming was 
a useful system for investigating the mechanism of reprogramming, and was 
subsequently used to reprogram fully mature B-cells (Hanna et al., 2008). Secondary 
reprogramming systems were also developed for human cells, with reprogramming 
of fibroblasts and keratinocytes derived from iPS cells generated using dox-
inducible lentiviruses (Hockemeyer et al., 2008; Maherali et al., 2008). 
 Polycistronic vectors carrying dox-inducible versions of the reprogramming 
factors were also demonstrated, both in viral and piggyBac transposon systems 
which generated 2° iPS cells from MEF (Sommer et al., 2009; Woltjen et al., 2009). 
Further to this two studies used targeting of the Col1a1 locus in mouse ES cells with 
dox-inducible polycistronic vectors containing the reprogramming factors (Carey et 
al., 2010; Stadtfeld et al., 2010b). Carey at al. demonstrated that while a single copy 
of the transgene-containing Col1a1 locus was sufficient to generate iPS cells from 
MEF, iPS cells could not be derived from any adult tissue. Crossing of transgenic 
mice produced mice carrying two copies of the transgenic locus and adult liver and 
keratinocytes readily underwent reprogramming. However, reprogramming of 
other adult cell types including fibroblasts, macrophages and pro-B cells did not 
require an additional copy of the reprogramming factor containing locus, but rather 
two copies of the rtTA expressing Rosa26 locus. Furthermore, two copies of both 
transgenic loci were required before MSC and gut epithelial cells gave rise to iPS 
cells. Similarly, while Stadtfeld et al. also generated iPS cells from MEF bearing 
single copies of the reprogramming factor- and rtTA-loci, MEF homozygous for 
rtTA generated three-times more iPS cells. In addition, echoing a study in which it 
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was discovered that more differentiated hematopoetic lineages undergo 
reprogramming less efficiently, it was found that while heterozygous rtTA 2° 
hematopoietic stem cells (HSCs) gave rise to iPS cells, this was only possible in B-
cells, T-cell and granulocytes carrying two rtTA loci (Eminli et al., 2009). Taken 
together, these results that suggest that high expression of the reprogramming 
factors is important for successful generation of iPS cells, and certain cell types 
undergo reprogramming more readily than others. However it is important to note 
that the “Yamanaka factors” used in these studies were identified for their ability to 
reprogram MEF, and as has been demonstrated, other combinations of factors could 
increase the efficiency of iPS cell generation from other cell types (Takahashi and 
Yamanaka, 2006; Hanna et al., 2008). Nevertheless, 2° reprogramming systems have 
been widely implemented and have aided identification of important aspects of 
reprogramming including the role of BMP, the stochiometry of the reprogramming 
factors, splicing mechanisms and epigenetic regulation (Samavarchi-Tehrani et al., 
2010; Carey et al., 2011; Gabut et al., 2011; Koche et al., 2011). More recently, 2° 
systems have been used to combine large-scale analysis and modern high-
throughput technology to generate vast amounts of information about the process 
of reprogramming (Buganim et al., 2012; Golipour et al., 2012; Polo et al., 2012; 
O'Malley et al., 2013). 
 
1.2.4 Micro-RNA mediated reprogramming 
 Micro-RNAs (mi-RNAs) are short (20-25 nucleotide) non-coding RNAs 
which repress mRNAs by interfering with the expression and stability of their 
targets. It was shown that over-expression of mouse ES cell specific mi-RNAs 
during retroviral reprogramming of MEF enhanced iPS cell generation, and when 
used in the absence of c-Myc, produced colonies which homogeneously expressed 
an Oct4-GFP reporter (Judson et al., 2009). Human orthologs of these mouse ES cell 
mi-RNAs were also shown to enhance reprogramming factor-mediated iPS cell 
generation from human fibroblasts, and were reported to affect multiple targets and 
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pathways associated with reprogramming (Subramanyam et al., 2011). However, 
the most striking results were reported by Anokye-Danso et al. (2011) in a study 
which demonstrated reprogramming of both mouse and human somatic cells via 
lentiviral over-expression of the miR302/367 cluster in the absence of exogenous 
reprogramming factors. This method increased the number of iPS cell colonies 
generated in the order of two to four magnitudes greater compared to lentiviral 
reprogramming using the Yamanaka factors. Interestingly the reprogramming of 
MEF, but not human fibroblasts, via this method was dependent on the presence of 
the histone deacetylase inhibitor (HDAC) Valproic acid (VPA), and it was suggested 
that the lower levels of the VPA target HDAC2 in human cells compared to MEF 
was responsible for this difference. A second study which transfected mouse and 
human cells with mature double-stranded mi-RNAs also demonstrated 
reprogramming in the absence of exogenous transcription factors, but this non-
integrative approach was much less efficient (Miyoshi et al., 2011). mi-RNA-
mediated reprogramming, despite these reports, has yet to become commonplace, 
possibly reflecting a difficulty in replicating these results in other labs and under 







1.3 Cell culture conditions and reprogramming 
1.3.1 Mouse embryonic stem cell culture conditions 
 Initial cultures of mouse ES cells could be maintained only by culturing in 
the presence of mitotically inactivated fibroblast feeder layers. Addition of 
leukaemia inhibitory factor (LIF) was found to prevent the characteristic 
spontaneous differentiation which occurred in feeder-free culture of ES cells (Smith 
et al., 1988; Williams et al., 1988). The exact mechanism by which LIF was able to 
maintain ES cells was subsequently elucidated through investigation of the LIF 
receptor (LIF-R) dimerisation partner gp130 (Niwa et al., 1998). Phosphorylation of 
specific cytoplasmic domains of gp130 as a result of LIF activity results in 
interaction with and activation of STAT3 causing its dimerisation, relocation to the 
nucleus and transcription of its associated targets. Subsequently, serum-free culture 
of mouse ES cells was demonstrated using the chemically defined N2B27 media 
supplemented with LIF and BMP4 or BMP2 (Ying et al., 2003). Derivation of ES cell 
lines from blastocysts was also demonstrated in this serum-free culture, and it was 
observed that undifferentiated ES cells expressed high levels of BMP receptor 
(Bmpr)Ia and BmprII as well as Bmp4, highlighting the important role of BMP 
signalling in stem cell maintenance. In addition, it was found that BMP signalling 
was responsible for induction of the helix-loop-helix inhibitor of DNA binding (Id) 
proteins Id1/2/3, with Id1 over-expression and LIF sufficient for ES cell self-renewal 
in serum-free conditions (Ying et al., 2003). Interestingly, in N2B27 alone, ES cells 
differentiate into neural lineages, however in the absence of LIF Id1-overexpressing 
cells differentiated into non-neural lineages, indicating the requirement for both 
BMP and LIF signalling in ES cell maintenance. 
 
1.3.2 2i and reprogramming 
A number of small molecules have increasingly been utilised in order to 
enhance or assist the reprogramming process from somatic cell to iPS cell. Ying et al. 
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defined “ground state pluripotency” in ES cells as the innate programme for self 
replication independent of extrinsic instruction (Ying et al., 2008). By culturing ES 
cells in a defined media in the presence of the selective Glycogen Synthase Kinase-3 
(GSK3) inhibitor CHIR99021 (CHIR), an inhibitor of FGF receptor tyrosine kinase 
activity SU5402 and an inhibitor of the ERK cascade PD184352 (3i conditions), it was 
shown that small molecules could maintain pluripotency and self-renewal similarly 
to less defined culture factors e.g. serum (Ying et al., 2008). Subsequently, culture in 
the presence of the more potent ERK inhibitor PD0325901 (PD03) and CHIR (2i 
conditions) enabled neural stem cells (NSCs) and MEF-derived partially 
reprogrammed cells which had failed to undergo complete reprogramming to gain 
expression of endogenous Oct4, reactivate inactive X chromosomes in XX cells, and 
contribute to chimeras, thus becoming fully reprogrammed (Silva et al., 2008). It was 
also highlighted in this report that genetic background had a significant effect on 
reprogramming frequency, with inbred strain 129 yielding more iPS cells compared 
to hybrid background cells (129/outbred MF1). The Non-obese Diabetic (NOD) 
mouse is an animal model of the human disease type I diabetes which has enabled 
analysis of the onset of this disease (Wicker et al., 1995). This strain of mouse was 
widely considered as non-permissive for the derivation of iPS cells, but permissive 
for Epiblast Stem Cell (EpiSC) isolation (Brons et al., 2007). It was found that culture 
of inner cell masses (ICMs) from NOD mice in 2i conditions plus LIF enabled the 
derivation of ES cell lines from this strain (Nichols et al., 2009a). Hanna et al. also 
showed derivation of NOD ES cell lines, however, this was achieved via infection of 
ICM outgrowths with constitutive lentiviruses encoding Klf4 and c-Myc (2009a). 
This group also generated iPS cells from NOD MEF, which were similarly shown to 
require constitutive expression of Klf4 and cMyc. These iPS cells could be stabilised 
in mouse ES medium (mESM) in the presence of the GSK3 and CDK1/cyclin B 
inhibitor Kenpaullone (KP) which had previously been shown to replace Klf4 




1.3.3 Small molecules reprogram rat and human ES/iPS cells to a mES cell state  
Human ES/iPS cells are more similar to mEpiS cells than mES cells; in terms 
of cellular signalling, LIF is insufficient to support self-renewal, rather bFGF and 
Activin A are required, and BMP induces their differentiation (Yu and Thomson, 
2008). Tesar et al. (2007) demonstrated that SB431542, an inhibitor of activin 
receptor-like kinase (ALK)5/4/7, induced differentiation in EpiS cells but not ES 
cells. Another ALK receptor inhibitor, A-83-01, was subsequently used in order to 
develop culture conditions suitable for the propagation of human iPS (hiPS) cells 
and rat iPS (riPS) cells in a more mES cell-like context (Li et al., 2009b). In this study, 
2i conditions were shown to be insufficient to maintain riPS cells in mES cell media, 
even in the presence of the FGF receptor inhibitor PD17304. However a combination 
of CHIR, PD03 (2i), ALKi and LIF enabled long-term propagation and survival of 
these “mES cell conditioned” h/riPS cells, as well as expression of the mES cell 
associated transcription factor Rex-1 (which is not expressed in regular h/riPS cells), 
and resistance to differentiation despite inhibition of the FGF and Activin signalling 
pathways. More recently, constitutive activity of the reprogramming factors 
cMyc/Klf4/Oct4/Sox2 (MKOS) in addition to PD03, CHIR and LIF were also shown 
to support propagation of hiPS/ES cells in mES cell-like conditions, with the 
adenylate cyclase activating compound Forskolin (FK) shown to replace MKOS 
(Hanna et al., 2010). Transcriptional profiling showed these “naïve” hiPS/ES cells 
were more similar to mES/iPS cells than more traditional hiPS/ES cells. These 
reports show that the culture conditions used to propagate or isolate pluripotent 
cells whether they are iPS or ES cells can be suitably manipulated using small 
molecules in order to increase or enable full reprogramming to a “naïve” mES cell-
like state, and thus lead new insights into the acquisition of pluripotency. 
 
1.3.4 The mesenchymal-to-epithelial transition and reprogramming 
The above studies highlight that in naïve rat and human iPS cells the 
reprogrammed state displayed continued reliance on small molecules, therefore it 
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may not be the case that these cells have altered intrinsically and rather what occurs 
may simply be selection of cells which can appropriately respond to such signalling 
cues. This selective process could therefore not only be detrimental to those cells 
which have not yet reached an appropriate stage of the reprogramming process, 
thus reducing iPS cell yield, but may also generate unstable iPS cells with incorrect 
or insufficient (re-)establishment of ES cell-like signalling pathways. In 
reprogramming from mouse cells, conversely, it has been shown that relatively 
short-term (24hr-4d) inhibition of the TGFβ signalling pathway during 
reprogramming appears to enhance the generation of iPS cells (Ichida et al., 2009; 
Maherali and Hochedlinger, 2009). Both studies used “RepSox” a molecule reported 
by both to have the ability to substitute for Sox2 during reprogramming with c-Myc, 
Klf4 and Oct4. Although these studies presented conflicting data with regards the 
timing of inhibitor treatment, in both cases the iPS cells generated were stable, with 
Maherali and Hochedlinger (2009) even increasing the yield of reprogrammed cells 
obtained in the absence of the reprogramming factor c-Myc. Ichida and colleagues 
(2009) also demonstrated that similar results could be acquired through the use of 
another TGFβ receptor inhibitor or receptor-blocking antibodies. This study also 
isolated reprogramming “intermediates”; iPS cell-like colonies which could be 
expanded, but failed to express an Oct4-GFP reporter, similar to those 
reprogrammed by culture in 2i conditions (Silva et al., 2008). Expression of the Oct4-
GFP reporter was demonstrated upon culture of these cell lines in the presence of 
RepSox, and although this effect appeared to be highly line-specific, interestingly, 
kinase activity assays indicated 2i targets were not inhibited. 
The importance of TGFβ/BMP signalling during reprogramming was further 
highlighted with the back-to-back publication of two recent studies identifying the 
mesenchymal-to-epithelial (MET) transition as a conserved stage of reprogramming 
from MEF (Li et al., 2010; Samavarchi-Tehrani et al., 2010). Samavarchi-Tehrani and 
colleagues identified up-regulation of a large number of epithelial-associated genes 
and down-regulation of mesenchymal-associated transcription factors within the 
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first five days of reprogramming. Mimics of miRNAs miR200b and miR200c, which 
are induced upon reprogramming factor expression in MEF, were shown to down-
regulate mesenchymal-associated factors Zeb1 and Zeb2, as well as up-regulate 
epithelial factors Cdh1, Epcam and Ocln. This switch in cell character was also 
linked with a gain in BMP signalling-associated factors, with a threefold increase in 
reprogramming efficiency upon addition of BMP7 to culture media, while inhibition 
of BMP signalling decreased reprogramming efficiency. Li at al. (2010) 
demonstrated a similar gain of epithelial and loss of mesenchymal gene expression 
during reprogramming from MEF. This study also demonstrated inhibition of 
colony formation through the addition of TGFβ ligands TGFβ1 and TGFβ2 to the 
culture media, and reported high levels of TGFβ1 in bovine serum commonly used 
in media for iPS cell generation and maintenance. It was also reported that Klf4 
activity during reprogramming is important in inducing Ecad expression and this 
reprogramming factor could be substituted by an Alk receptor inhibitor, A-83-01, 
during reprogramming of mammary gland epithelial cells (MECs). While these 
studies highlighted the importance of this transition, it was reported to occur within 
the first 5 days of reprogramming factor expression and before activation of most 




1.4 Epigenetics of Reprogramming 
1.4.1 Modulation of epigenetic factors to influence reprogramming 
 During reprogramming cells not only acquire a similar transcriptional state 
as ES cells, but also a similar epigenetic landscape. Chromatin modifications have 
been intensively studied in order to determine the extent and effect of epigenetic 
regulation during reprogramming to iPS cells. The initial iPS cells generated by 
Takahashi and Yamanaka (2006) would not be considered of a high-quality today, 
displaying a number of differences compared to ES cells including high levels of 
DNA methylation at the promoters of pluripotency genes. Subsequent studies 
generated iPS cells which displayed full ES cell-like demethylation of promoters 
while maintaining imprinting patterns, ES cell-like tolerance to global DNA 
demethylation and loss of X inactivation in XX cells (Maherali et al., 2007; Wernig et 
al., 2007). 
 A recent study attempted to identify epigenetic changes occurring within the 
first cell-cycles after reprogramming factor expression in MEF (Koche et al., 2011). 
This study reported that histone 3 lysine 4 dimethylation (H3K4me2), the precursor 
to H3K4me3 which is associated with locus accessibility and active gene expression, 
is gained and increased at loci crucial for reprogramming, before changes to other 
histone modifications. However some of these loci do not display a similar pattern 
of H3K4me2 as in ES cells, and after just three cell divisions the level of K4me2 
detected is identical to that of ES cells, thus given the low efficiency of 
reprogramming, it is not certain that this event represents a significant barrier to 
reprogramming. In agreement, a recent study based on isolation of intermediate 
reprogramming populations using the ES cell-associated marker stage-specific 
embryonic antigen 1 (SSEA-1) identified major changes in H3K4me3 at early stages 
of reprogramming, but also identified a second, later wave of H3K4me3 acquisition 
when cells were closer to a more reprogrammed state, and this may bear more 
correlation to reprogramming success (Polo et al., 2012). This study also revealed 
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both gain and loss of the gene expression silencing-associated marker H3K27me3 
early in reprogramming, and an early establishment of bivalency - the co-
localization of both active (H3K4me3) and repressive (H3K27me3) histone marks at 
developmentally important genes which is a feature of ES cells (Bernstein et al., 
2006). Bivalency is established and maintained by the activity of two distinct 
complexes; the trithorax group (TrxG) which is involved in establishing H3K4me3 
and the polycomb group proteins (PcGs) which form polycomb repressive 
complexes (PRCs) which mediate H3K27me3 generation. A number of studies have 
shown the important role these factors play in reprogramming. Knockdown of the 
TrxG member Wdr5 in ES cells resulted in a loss of self-renewal, global loss of 
H3K4me3, and inhibition of iPS cell generation (Ang et al., 2011). Interestingly, 
depletion of another sub-unit of H3K4 methylation complexes, Dpy-30, in mouse 
ESCs leads to a defect in lineage specification but does not significantly affect ESC 
self-renewal (Jiang et al., 2011). In addition, ES cells which lack the CpG-binding 
factor Cfp1 and show loss of H3K4 methylation are viable and can self-renew, but 
again demonstrate differentiation defects (Clouaire et al., 2012). These findings 
suggest that while the establishment of H3K4 methylation may be important during 
reprogramming, formation of bivalent domains may not be crucial for the 
maintenance of pluripotency. Also a number of members of PRC1 and PRC2 have 
also been shown to be vital for reprogramming from human fibroblasts (Onder et 
al., 2012). The nucleosome remodelling and deacetylation (NuRD) complex 
deacetylates H3K27, thus enabling binding of PRC2. Mbd3, which is a component of 
the NuRD complex and has been shown to be important in controlling 
differentiation of ES cells, has been shown to inhibit the efficiency of 
reprogramming from MEF, however in the above study Onder et al. (2012) found 
that knockdown of this factor actually slightly reduced human iPS cell colony 
formation (Kaji et al., 2006; Kaji et al., 2007; Luo et al., 2013; see Section 6.3 for 
dicussion of novel data regarding Mbd3 and reprogramming). Despite this 
accumulated evidence, Sridharan et al. (2009) reported pre-iPS cells which fail to 
express key pluripotency genes had already acquired ES cell-like bivalent 
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methylation patterns, and while it has been shown that the efficiency of 
reprogramming from MEF is unaffected in the absence of the de-novo DNA 
methyltransferases Dnmt3a and Dnmt3b, preventing maintenance of DNA 
methylation via inhibition of Dnmt1 transferase activity can increase 
reprogramming efficiency from pre-iPS cells (Mikkelsen et al., 2008; Pawlak and 
Jaenisch, 2011). This suggests failure to demethylated DNA represents a greater 
barrier to reprogramming than establishment of bivalent domains. Interestingly, in 
human fibroblasts the initial binding of the reprogramming factors c-Myc, Klf4, 
Oct4 and Sox2 occurs across both methylated and unmethylated DNA (Soufi et al., 
2012). However, megabase regions which are bound by the reprogramming factors 
in ES and iPS cells were found to be refractory to binding in the early stages of 
reprogramming. These regions were enriched for H3K9 methylation, and 
knockdown of H3K9 methyltransferases enhanced Oct4 and Sox2 binding at these 
sites and increased reprogramming efficiency. Other factors which influence 
chromatin have also been implicated in reprogramming including the SWI/SNF 
complex that destabilises histone-DNA interactions, members of which have been 
shown to increase the efficiency of reprogramming upon over expression in MEF 
(Singhal et al., 2010). One other group of factors recently gaining much interest are 
the ten-eleven translocation (TET) family methycytosine hydroxylases TET1 and 
TET2. These proteins modify DNA via changing 5-methylcytosine (5mC) to 5-
hydroxymethylcytosine (5hmC), with the latter modification being found at 
pluripotency gene regulatory elements in ES cells (Ito et al., 2010). It was reported 
that knockdown of TET2 prevented acquisition of 5hmC at the loci of pluripotency 
associated genes Nanog and Esrrb, and resulted in a reduction in the efficiency of 
reprogramming from MEF (Doege et al., 2012). More recently Costa et al. (2013) 
reported that TET1 and TET2 mediate reprogramming from intermediate cell types 
as well as MEF but only in the presence of Nanog which is required to direct their 
enzymatic activity to pluripotency-related loci. The significance of this modification 
compared to other epigenetic changes occurring during reprogramming has yet to 
be fully explored, however there is evidence to suggest that in conventional 
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reprogramming the modification of 5mC to 5hmC occurs early in reprogramming as 
it appears to precede H3K4me3 recruitment to loci (Costa et al., 2013). Interestingly, 
the TET enzyme’s catalytic domain binds iron and therefore their activity may be 
enhanced by the presence of Vitamin C in reprogramming cultures (see section 
1.4.3).  
 
1.4.2 Small molecule modification of epigenetic state during reprogramming 
 One of the first studies of the epigenetic state of cells undergoing 
reprogramming identified that fully reprogrammed iPS cells re-established ES cell-
like H3K27 and H3K4 bivalent methylation at the promoters of developmentally 
important genes (Mikkelsen et al., 2008). This study also discovered that in partially 
reprogrammed iPS cell-lines genes which carried K4 methylation or bivalent marks 
in the parental MEF cells were more likely to be re-activated, and this intermediate 
cell type had a lower percentage of bivalent promoters compared to fully 
reprogrammed iPS cells. Addition of the DNA methyltransferase (DNMT) inhibitor 
5’-azacytidine (Aza) for 48 hours to the culture media increased the percentage of 
colonies reactivating expression of an Oct4-GFP reporter, with the resulting iPS cells 
displaying CpG demethylation at pluripotency associated genes. In addition, siRNA 
against Dnmt1 increased the efficiency of reprogramming, indicating loss of DNA 
methylation is an important epigenetic barrier to reprogramming. Interestingly, 
partially reprogrammed iPS cells derived from mature B-cells did not reprogram in 
Aza alone, but did do so when the inhibitor was used in combination with 
knockdown of aberrantly expressed lineage-specific transcription factors. 
Reprogramming from MEF was also shown to be enhanced by short-term Aza 
treatment, and it was separately reported to be capable of replacing c-Myc in three 
factor (Oct4, Sox2 and Klf4) reprogramming of MEF (Huangfu et al., 2008a). 
Huangfu et al. (2008a) also demonstrated that the histone deacetylase 
(HDAC) inhibitors suberoylanilide hydroxamic acid (SAHA), trichostatin A (TSA) 
and valproic acid (VPA) also increased the efficiency of reprogramming from MEF, 
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with more than a 100-fold increase in colony formation with VPA. VPA was also 
able to facilitate reprogramming in the absence of c-Myc, and a further study from 
this group demonstrated reprogramming of human fibroblasts with only Oct4 and 
Sox2 in the presence of VPA (Huangfu et al., 2008b). Another HDAC inhibitor, 
sodium butyrate (NaB) was also shown to aid reprogramming of both human and 
mouse cells (Liang et al., 2010; Mali et al., 2010). Mali et al. (2010) demonstrated the 
highly dynamic nature of epigenetic remodelling during reprogramming, as the use 
of the histone acetyltransferase (HAT) inhibitor C646 abolished the positive effect of 
NaB. This study also reported NaB capable of replacing c-Myc or Klf4 during three 
factor reprogramming of human fibroblasts. In contrast, Liang et al. (2010) observed 
a loss of reprogramming efficiency when NaB was used during reprogramming 
from MEF in the absence of c-Myc, with microarray analysis comparing NaB-treated 
three (without c-Myc) and four factor reprogramming cultures identifying a number 
of ES cell-associated genes which fail to up-regulate in the former. 
Mali et al. (2010) also reported that the effects of NaB could be enhanced by 
the inclusion of the G9a histone methyltransferase inhibitor BIX-01294 (BIX). This 
molecule was also identified to increase the efficiency of reprogramming from 
mouse neural progenitor cells (NPCs) in a drug screen (Shi et al., 2008b). This 
molecule enabled Oct4 and Klf4 or Klf4, Sox2 and c-Myc mediated reprogramming 
of NPCs. Subsequently it was also demonstrated that Oct4 and Klf4 in combination 
with BIX could generate colonies from MEF (Shi et al., 2008a). Further screening 
with this two factor +BIX system also identified the DNMT inhibitor RG108 as 
increasing the efficiency of reprogramming. 
 
1.4.3 The role of Vitamin C in reprogramming 
 Another small molecule which was found to improve the efficiency of 
generating iPS cells from MEF, Vitamin C (VitC) was identified from a mixture of 
antioxidant compounds (Esteban et al., 2010). Surprisingly, other antioxidants 
present in the mixture were unable to similarly enhance reprogramming; indicating 
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VitC functioned via another mechanism. Conversion of pre-iPS cells to fully 
reprogrammed iPS cells was also demonstrated by the use of VitC in serum-free 
conditions, however unlike the similar conversion observed using 2i culture 
conditions, Erk signalling was found to remain fully active (Silva et al., 2008). 
Proliferation of MEF and pre-iPS cells was also enhanced by the use of VitC, and 
decreased levels of the senescence related proteins p53 and p21 were detected 
compared to untreated cultures. 
 It was subsequently discovered that VitC aided reprogramming via its 
activity as a co-factor of iron-containing enzymes. The activity of these enzymes 
results in their iron atom attaining an oxidative state which is higher than the state 
compatible with continued activity of the enzyme. VitC functions as an electron 
donor, adjusting the redox state of the iron atom and thus enabling further catalytic 
activity of the enzyme. The Jumonji C (JmjC)-domain containing enzymes are one 
such family of enzymes, a sub-class of which display lysine demethylation activity 
(Wang et al., 2011a). Knockdown of Jhdm1b and Jhdm1a, which catalyse 
H3K36me2/3 demethylation, resulted in a 50% decrease in reprogramming from 
MEF. In contrast, over-expression of either factor, but especially Jhdm1b, increased 
the efficiency of reprogramming, and a further increase in reprogramming was 
achieved if VitC was also present in the cell medium and the combination of 
Jhdm1b and VitC was sufficient to enable reprogramming of MEF using Oct4 alone. 
Furthermore, as described by Esteban et al. (2010), VitC enhanced the proliferation 
of MEF in culture, and this was abolished by knockdown of Jhdm1b. This 
modulation of the proliferative potential was found to be as a result of the binding 
of Jhdm1b to the Ink/Arf4 locus resulting in a loss of H3K36 methylation and a gain 
in H3K27 methylation, echoing the results of an earlier study which described up-
regulation of PRC2 component Ezh2 and promotion of PRC1 binding to this locus 
mediated by Jhdm1b activity (Tzatsos et al., 2009). This is significant as products of 
this locus are involved in stabilisation of p53 which has been reported to act as a 
barrier to successful reprogramming (see Section 1.4.3.1). This study also 
demonstrated physical interaction of Oct4 and Jhdm1b and binding in close 
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proximity to each other at the promoter of the micro-RNA cluster mi-R302/367 
which has also been implicated in enhancing reprogramming efficiency from both 
mouse and human cells (see Section 1.2.4). 
 Other members of the JmjC family have also been found to positively 
influence reprogramming, dependent on the presence of VitC (Chen et al., 2013). 
This study identified that the ability of VitC to direct pre-iPS cells to a more 
reprogrammed state was inhibited by the action of BMP signalling, originating 
either from the reprogramming culture (FBS) or upon addition of BMP4 in serum-
free conditions. The repressive activity of BMP4 was found to be linked to 
maintenance of H3K9 methylation, and knockdown of the K9 histone 
methyltransferase Setdb1 increased the efficiency of reprogramming from both pre-
iPS cells and from MEF. Down-regulation of Setdb1 was found to synergise with 
VitC-mediated activation of the lysine 9 demethylases Jhdm2a, Jhdm2b, Jhdm4b 
and Jhdm4c to enable reprogramming, highlighting the dynamic nature of 
epigenetic modification with factors responsible for gain and loss of methylation 
both contributing to the outcome of reprogramming. Demethylation of H3K27me2/3 
mediated by JmjC family member Utx was also found to be crucial for 
reprogramming (Mansour et al., 2012). MEF and pre-B cells which did not express 
Utx could only undergo reprogramming in the presence of shRNA against Eed, a 
member of the PRC2 complex responsible for establishing H3K27me3 at 
developmentally important loci. In contrast to wt MEF, Utx null cells displayed a 
gain of K27 methylation at a number of ES cell-associated genes during 
reprogramming and chimeras generated from null ES cells failed to contribute to the 
germline. Notably, during reprogramming, Utx expression is not required once the 
pluripotency network has been established, reflecting the precise nature of 
epigenetic regulation during iPS cell generation. 
 Imprinting is the epigenetic mechanism by which expression of certain genes 
occurs only from either the maternally or paternally inherited allele, for example 
differentially methylated regions (DMRs) in the Dlk-Dio3 locus are heavily 
methylated on the paternal allele and expression of Gtl2 and Rian transcripts occurs 
27 
 
only from the maternal allele. Recently it has been shown that iPS cell lines display a 
maternal allele with a methylation pattern similar to the paternal allele. These cell 
lines lack expression of Gtl2 and Rian and contribute poorly to chimeric mice and 
are incapable of contributing to 4n, “all-iPS cell”, mice via tetraploid 
complementation (Stadtfeld et al., 2010a). Treatment of these paternalised cells with 
the histone deacetylase inhibitor VPA could rescue this phenotype in a small 
percentage of sub-clones which became 4n competent; however a failure to correctly 
re-establish the imprinted state and maternally expressed imprinted genes in the 
Dlk1-Dio3 cluster resulted in non-viable mice. Subsequently this group also showed 
that reprogramming in serum-free conditions generated more iPS colonies with 
correct imprinting at this locus (Stadtfeld et al., 2012). It was found that VitC in the 
serum free culture condition was the component responsible for this effect, and in 
its absence Dnmt3a mediated hypermethylation of the differentially methylated 
regions (DMRs), which regulate imprinting, occurred at the latter stages of 
reprogramming after loss of histone 3 K4me2 and a failure to acquire H3K4me3. 
Importantly, it was also demonstrated that while iPS cells generated in the serum-
free condition could be used to generate live born 4n mice, aberrantly imprinted iPS 
cells could not be rescued by VitC treatment. Interestingly, another JmjC family-
member Kdm1b/Aof1 was found to be required for establishment of maternal 
imprinting in oocytes via H3K4me2/1 demethylase activity, suggesting that other 
family members may be required for maintenance of imprinting during 
reprogramming, and are reliant on VitC for their activity (Ciccone et al., 2009). It 
was also discovered that altering the stochiometry of the reprogramming factors 
could also influence the maintenance of proper imprinting at the Dlk1-Dio3 locus, 
and in the presence of elevated levels of Oct4 and Klf4 the number of iPS cell lines 






1.4.3.1 The Ink4/Arf locus during reprogramming to iPS cells 
A number of studies have recently identified p53 and associated 
factors as representing a major barrier to successful reprogramming. Hong et al. 
(2009) reported p53 null (p53-/-) MEF underwent reprogramming 7-12 times more 
efficiently than their wt counterparts, and could even be used to generate 
reprogramming factor-integration-free iPS cells. Human dermal fibroblasts in which 
p53 was knocked down by shRNA also displayed increased reprogramming 
efficiency, and it was discovered that knockdown of p53 target p21 could also 
increase the efficiency of reprogramming. This study also demonstrated that over-
expression of the E3 ligase Mdm2 which degrades p53 also led to greater colony 
formation. Similar results were obtained by Kawamura et al. (2009) who introduced 
a non-degradable version of Mdm4. This study also highlighted the importance of 
the products of the Ink4/Arf locus in reprogramming; Mdm2 and Mdm4 are 
destabilised by p19Arf, and p16Ink4a activity is responsible for stabilisation of the cell 
cycle checkpoint protein Retinoblastoma. Knockdown of both of these factors 
resulted in a 5-fold increase in iPS cell colony formation from MEF. Interestingly, Li 
et al. (2009a) compared the activity of both factors and reported that while p19Arf 
increased reprogramming efficiency in MEF, human fibroblasts reprogrammed 
more efficiently in response to p16Ink4a knockdown. It was also demonstrated that 
the promoters of these genes carry both H3K4 and H3K27 methylation in ES and iPS 
cells, and this is regained during reprogramming. These results highlighted the 
important role that activation of cell-cycle checkpoint regulators plays in 
reprogramming. 
  Another aspect of these studies concerned DNA damage and how it 
affects the reprogramming process. Marion et al. (2009) reported that the efficiency 
of generating iPS cells from p53-/- MEF could be further increased if the cells also 
lacked the telomerase enzyme which is responsible for reducing DNA damage and 
aberrations via the regulation of telomere length. It was also shown that the 
introduction of DNA mutations via UV or ionising radiation resulted in a decrease 
in reprogramming efficiency of wt MEF, but this could be reversed by the 
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knockdown of p53 or over-expression of Bcl2 which inhibits the mechanism of 
apoptosis in cells. Finally, MEF homozygous null for the DNA damage-repair 
factors Atm and 53BP1 displayed decreased reprogramming efficiency compared to 
wt MEF indicating that DNA damage can limit the efficiency of iPS cell generation 
and the damage response may be mediated by p53 activation. While p53 
knockdown can increase the efficiency of reprogramming as described above, the 
resulting iPS cells display damage to their genomic integrity. Utikal et al. (2009) 
demonstrated short term inhibition of p53 activity, even at relatively late time-
points can still increase the efficiency of reprogramming, and so transient inhibition 





1.5 Markers of the reprogramming process 
1.5.1 Cell surface markers 
 A number of studies of the reprogramming process have utilised the ES cell-
associated marker SSEA-1/Fut-9 which was identified from the antisera of mice 
immunized with irradiated EC cells, and was found to be expressed on ES cells 
(Solter and Knowles, 1978). Similarly, the expression of the MEF-associated marker 
Thy1 (CD90) has also been used to determine reprogramming stage. Stadfeld et al. 
(2008a) identified the expression kinetics of these markers during reprogramming of 
MEF. Thy1 was rapidly down-regulated followed by up-regulation of SSEA-1 
expression, and reprogramming associated retrovirus silencing increased as cells 
gained a Thy-1-/SSEA-1+ phenotype. The SSEA-1 positive population appeared to 
give rise to cells which had re-activated the inactive X chromosome of XX MEF, and 
an increase in SSEA-1 expression was correlated with an increase in colony forming 
potential before the activation of endogenous Oct4 activity. However, it was 
subsequently reported that pre-iPS cells which are reliant on continued expression 
of exogenous reprogramming factors express SSEA-1 and that introduction of c-Myc 
alone can result in down-regulation of Thy1 expression (Sridharan et al., 2009). In 
addition, sorting of pre-iPS cells based on SSEA-1 expression revealed that both 
fractions carried reprogramming inhibitory DNA methylation at pluripotency gene 
loci, and responded equally to treatment with a DNA methyltransferase inhibitor, 
suggesting that SSEA-1 expression has a poor correlation to successful iPS cell 
generation in the latter stages of reprogramming (Mikkelsen et al., 2008). Finally, 
during reprogramming of p53 null cells, Thy1-, Thy1+ and SSEA1+ cells were found 
to have very similar colony forming potential, suggesting in highly efficient systems 
these markers may not be useful (Utikal et al., 2009). Recently a study utilised both 
of these markers to carry out thorough analysis of the reprogramming process (Polo 
et al., 2012). This study identified SSEA-1 positive populations which eventually 
give rise to cells expressing endogenous pluripotency genes, and these were used 
for comparison across different reprogramming time-points. Principal component 
31 
 
analysis carried out in this study not only included these subpopulations but also 
pre-iPS cells derived from a variety of sources. Interestingly, despite also expressing 
SSEA-1, the pre-iPS cells were found to cluster completely separately from the 
SSEA-1+ populations identified in this study, casting some doubt on the use of this 
marker to define populations undergoing reprogramming. Another study of 
populations undergoing reprogramming from MEF identified up-regulation of 
epithelial cell adhesion molecule (EpCAM) to be correlated with a higher level of 
Nanog expression compared to SSEA-1 sorted cells, and EpCAM over-expression 
has also been reported to increase the efficiency of reprogramming (Chen et al., 
2011; Huang et al., 2011). Another recent study aimed to identify ES cell-specific 
glycoprotein-binding surface proteins and generated a cluster of differentiation 
(CD) “barcode” for pluripotent cells (Gundry et al., 2012). A number of these 
markers, including CD326 and CD31 were described to enrich for cells expressing 
higher levels of endogenous pluripotency genes during reprogramming, however 
how this correlated to iPS cell generation was not demonstrated. 
 
1.5.2 Pluripotency genes as reporters of reprogramming 
 The first iPS cells generated by Takahashi and Yamanaka (2006) were 
isolated based on selection for reactivation of Fbx15, an ES cell-associated gene, and 
downstream target of Oct4. However, these iPS cells were found to display a 
number of differences compared to ES cells, including an inability to give rise to 
adult chimeric mice. However, selection for expression of Nanog or endogenous 
Oct4 was shown to enable the isolation of iPS cells that could contribute to chimeras 
which also displayed germline transmission (Maherali et al., 2007; Okita et al., 2007; 
Wernig et al., 2007). It was also discovered that delayed selection resulted in a 
higher yield of iPS cells, highlighting the heterogeneous nature of reprogramming 
from MEF (Wernig et al., 2007). Brambrink et al. (2008) integrated expression of 
these pluripotency gene reporters into the timeline of SSEA-1 expression during 
reprogramming and discovered poor enrichment for Nanog and Oct4 expressing 
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SSEA-1+ cells. Isolation of colonies based on morphology alone without using 
selective agents was also carried out, and upon expansion these cells expressed an 
Oct4-GFP reporter and chimera competent iPS cell lines generated (Blelloch et al., 
2007). Finally, this non-selective approach in combination with an Oct4-GFP 
reporter was also used to isolate lines which could contribute to 4n, “all-iPS cell”, 
embryos (Meissner et al., 2007). 
 
1.5.3 Nanog in ES cells and reprogramming 
 Reprogramming to the pluripotent state requires re-establishment of the 
network of factors responsible for maintenance of the pluripotent self-renewing 
state. Central among these factors are Oct4, Sox2 and Nanog. Nanog was identified 
in both a screen of factors capable of bestowing LIF-independent self-renewal on 
LIF receptor null ES cells upon over-expression, and a screen of factors that are 
over-represented in ES cells compared to somatic cells (Chambers et al., 2003; Mitsui 
et al., 2003). Nanog null ES cells could be generated via gene targeting and 
maintained on feeders but null embryos generated by crossing heterozygous null 
mice were not viable due to loss of the ICM, highlighting the importance of this 
factor in development. Subsequently it was demonstrated that Nanog null ES cells 
aggregated with wt cells could contribute to chimeras, but primordial germ cells 
(PGCs) failed to mature, in line with the expression of Nanog in these cells 
(Chambers et al., 2007). Niwa et al. (2000) used an inducible system to show that 
Oct4 expression must be maintained at precise levels in ES cells with differentiation 
to primitive endoderm and mesoderm upon Oct4 over-expression, and under-
expression inducing cells to differentiate to trophectoderm. Similarly, Sox2 silencing 
causes differentiation of ES cells to multiple lineages including trophectoderm 
(Masui et al., 2007). Interestingly, Sox2 and Oct4 have been shown to co-bind the 
promoters of many genes expressed in pluripotent cells, but these factors were not 
down-regulated in Sox2 null cells due to substitution by Sox family members Sox4, 
Sox5 and Sox11. However, loss of Sox2 decreases expression of positive- and 
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increases expression of negative-regulators of Oct4 and genes associated with 
differentiation, resulting in the observed differentiation phenotype, which can be 
rescued by Oct4 over-expression. The interaction between these factors is further 
strengthened by identification of SOX2 binding to the Pou5f1 promoter which 
regulates expression of Oct4, and binding of OCT4 to the Sox2 promoter in mouse 
and human ES cells (Chew et al., 2005; Okumura-Nakanishi et al., 2005). 
Subsequently the Oct4/Sox2 binding motif was identified in the promoter region of 
Nanog in mouse and human ES cells, mutation of which lead to a decrease in Nanog 
expression, as did knock-down of Oct4 or Sox2 (Rodda et al., 2005). This finding 
linked these three crucial factors and indicated the importance of their interaction in 
order to maintain ES cell identity. Interestingly, Nanog expression was found to be 
heterogeneous in ES cells, with cells transitioning between Nanog negative and 
positive states (Chambers et al., 2007). Navarro at al. (2012) demonstrated this 
phenomenon occurred independently of Oct4 and Sox2, and NANOG protein 
binding to the Nanog promoter prevents Nanog expression in an auto-repression 
loop. It was also shown that Zfp281 knockdown increased Nanog expression and 
was required for recruitment of the silencing-associated NuRD complex to the 
Nanog locus (Fidalgo et al., 2012). Similarly, knockdown of Zfp281 enhanced 2i 
mediated reprogramming of pre-iPS cells to iPS cells by enhancing Nanog 
expression without the NANOG associated self-inhibition. 
 Chromatin immunoprecipitation (ChIP) analysis revealed that about half of 
identified Oct4 targets in ES cells were also bound by Nanog (Loh et al., 2006). 
Another analysis of Sox2 and Oct4 binding sites in human ES cells identified Nanog 
co-occupation at a high percentage (>90%) of targets including factors involved in 
chromatin remodelling and ES cell specific transcription factors as well as factors 
important for lineage specification, indicating Nanog, Oct4 and Sox2 may 
negatively, as well as positively regulate their common targets (Boyer et al., 2005). 
ChIP analysis carried out via pull-down of biotinylated Nanog, Oct4 and Sox2 
identified enrichment for bivalent marks at common target sites, with a correlation 
found between the number of pluripotency associated genes binding to a site and 
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presence of H3K4me3 (Kim et al., 2008a). Interestingly, genes rapidly and highly up-
regulated upon ES cell differentiation were found to usually be bound by only a 
single ES cell-associated factor, and enriched for K27me3 in ES cells, indicating 
while ES cell-factor interaction may be required to maintain the pluripotent state, 
individual factors may repress key lineage specifiers. Multiple ES cell factor binding 
was also identified via ChIP-sequencing (ChIP-seq) analysis carried out in ES cells, 
and it was also discovered that short fragment sequences derived from sites of 
Nanog, Oct4 and Sox2 co-binding contained enhancer activity (Chen et al., 2008). 
The large number of individual and common targets for these genes in ES cells 
highlights the important role they each play in maintenance of the pluripotent state. 
The central role of Nanog has been investigated with a large number of factors 
reported to comprise the NANOG interactome, including proteins related to 
processes as diverse as RNA processing, cell cycle control and DNA replication and 
repair (Gagliardi et al., 2013). 
 The role of Nanog in reprogramming is also a source of much interest. Silva 
et al. (2006) demonstrated that reprogramming of neural stem (NS) cells, MEF and 
thymocytes via ES cell fusion was enhanced upon over-expression of Nanog. 
Reprogramming from EpiSCs to iPS cells was also demonstrated in the presence of 
Nanog over-expression which was possible in both 2i and LIF/serum ES cell 
conditions (Silva et al., 2009). Subsequently it was also found that Nanog could 
reprogram pre-iPS cells and EpiSCs in 2i media in the absence of LIF, echoing its 
activity in fully reprogrammed ES cells (Theunissen et al., 2011). 
Another marker of completed reprogramming to an ES cell-like state is the 
reactivation of the inactive X (Xi) chromosome in XX cells. X inactivation is a 
compensatory mechanism in female embryos which is reversed in cells of the ICM. 
One of the active X (Xa) chromosomes is inactivated randomly during 
differentiation of the epiblast, resulting in all somatic differentiated cells bearing a 
Xa and Xi. It has been shown that culturing blastocysts in 2i conditions results in an 
increase in the number of NANOG positive cells, enabling expansion of the epiblast 
(Nichols et al., 2009b). In XX embryos Nanog expression after E4.5 was identified to 
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correlate with reactivation of the inactive X (Xi) chromosome, and mark cells with 
both active X (Xa) chromosomes (XaXa cells) (Silva et al., 2009). In the absence of 
Nanog, the ICM was found to rapidly degenerate and Xi failed to reactivate. The 
link between these events was confirmed by Navarro et al. (2008) who identified not 
only NANOG, but also OCT4 and SOX2 binding and repression of the promoter 
region of the non-coding RNA Xist which is responsible for coating and inactivating 
the paternal X chromosome from which it is expressed. While Nanog null ES cells 
up-regulate Xist expression, this is only to a level many fold lower than that 
observed under normal conditions. It was found that effective levels could be 
achieved by the disruption of the hierarchy of repressive-factor removal from the 
promoter via rapid loss of OCT4, indicating that loss of Nanog, Oct4 and Sox2 
expression and subsequent differentiation regulates Xist expression. In addition, it 
has also been demonstrated that expression of the repressor of Xist activity, Tsix, is 
reliant on other ES cell factors Rex1, Klf4 and c-Myc (Navarro et al., 2010). This 
demonstrates the numerous and inter-connected roles that the core factors Nanog, 
Oct4 and Sox2 carry out in co-operation with other ES cell-associated proteins, and 
suggests in order to achieve complete reprogramming a highly complex network 
must be re-established. 
 
 
Figure 1.2 Overview and timing of appearance of previously described 
markers and indicators of the reprogramming process. 
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1.6 Transdifferentiation and reprogramming 
1.6.1 Inducing changes in cell behaviour 
 The ability to use transcription factors to change the fate of a cell to that of 
another somatic cell, transdifferentiation, was demonstrated by Davis et al (1987) 
with the identification of MyoD. This was the result of comparing proliferating 
myoblasts and fibroblasts in order to identify factors capable of inducing myogenic 
lineage specification from mouse fibroblasts at a high efficiency. This was based on 
the earlier observation that myofibroblast DNA treated with the methyltransferase 
inhibitor Aza was capable of converting fibroblasts to myofibroblasts at a low 
efficiency (Lassar et al., 1986). Together this data indicated that transdifferentiation 
requires cells to overcome the epigenetic barriers required for the normal 
maintenance of cellular lineage. The over-expression of Gata-1 was found to 
similarly convert myeloblasts to hematopoetic lineages in the chicken (Kulessa et al., 
1995). Other transcription factors identified to induce transdifferentation include 
C/EBPα and C/EBPβ which induced B cell transformation to macrophages, and 
mature B cell conversion was demonstrated in vitro and in vivo (Kan et al., 2004). 
Subsequently it was shown that these factors along with their interacting partner 
PU1 were capable of transdifferentiating primary mouse fibroblasts to 
macrophages, indicating how these studies can enhance understanding of the 
processes required for cell specification and lineage determination (Feng et al., 
2008). However, continued expression of the exogenous factors was required as 
endogenous levels failed to become sufficiently up-regulated, highlighting a 
potential issue for the use of transdifferentiated cells in a therapeutic context. 
Interestingly, another study which demonstrated transdifferentiation of exocrine 
pancreatic cells into β cells found that cells did not appear to de-differentiate into a 





1.6.2 Transdifferentiation towards specific lineages 
 Transdifferentiation to cardiomyocytes has been intensively studied due to 
the potential use of these cells for the treatment of infarct damaged cardiac tissue. 
Screening of transcription factors using a cardiomyocyte-specific reporter identified 
three factors capable of generating beating cardiomyocytes from mouse dermal 
fibroblasts (Ieda et al., 2010). A further study also identified micoRNAs involved in 
cardiac muscle development and differentiation capable of inducing direct 
reprogramming to cardiomyocyte-like cells (Jayawardena et al., 2012). In vivo 
injection of these miRNAs into injured cardiac tissue showed these cells were 
capable of incorporation to the heart. Similarly, cardiac fibroblasts could be 
transformed into cardiomyocytes in vivo using the factors identified by Ieda et al. 
(2010), and this was shown to improve heart function after infarction, with this 
beneficial affect enhanced by the addition of an additional factor (Qian et al., 2012; 
Song et al., 2012). 
 Induction of neural lineages from more readily accessible tissues has also 
been heavily investigated. Wernig and colleagues identified three transcription 
factors (3Fs) capable of transdifferentiating MEF to mature neural cells (Vierbuchen 
et al., 2010). This conversion occurred relatively rapidly with morphology changes 
obvious after three days, indicating this method may be relatively epigenetically 
favourable compared to reprogramming to iPS cells from MEF. Human fibroblasts 
could be induced to become neuronal cells by altering one of the previously 
identified 3Fs (Qiang et al., 2011). These cells were capable of migrating from 
ventricles throughout injected mouse brains indicating their complete gain of 
functional properties of neuronal cells. In addition, this study reported generation of 
neurons from Parkinson’s Disease (PD) patients which were subsequently used to 
identify processes pertinent to treatment of the diseased cells, indicating the 
usefulness of this technique. Both transcription factors NeuroD1 and NeuroD2 and 
microRNAs, factors required for neuronal specification, were subsequently 
identified to induce neurons from both murine and human fibroblasts (Vierbuchen 
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et al., 2010; Ambasudhan et al., 2011). Transdifferentiation towards more specific 
neural cell types has also been demonstrated, providing a more accurate method of 
production of desired lines, including dopaminergic and spinal motor neurons 
(Caiazzo et al., 2011; Pfisterer et al., 2011; Son et al., 2011).  
While these reports stressed that cells did not pass through a de-
differentiated, neural stem cell-like state, the generation of multipotent neural 
progenitor cells (NPCs) has also been demonstrated. Two factors were shown to 
generate bi-potent NPCs from mouse fibroblasts, and the addition of an extra factor 
was shown to be capable of generating tri-potent NPCs (Lujan et al., 2012). One of 
these factors included the commonly used reprogramming factor Sox2. 
Subsequently it was shown that Sox2 alone could induce NPCs from human and 
mouse fibroblasts (Ring et al., 2012). In combination with another reprogramming 
factor, c-Myc, Sox2 could induce neurons from cord blood, and both of these factors 
with yet another reprogramming factor, Klf4 could induce MEF to become NSCs 
capable of in vivo differentiation to all three neural lineages (Giorgetti et al., 2012; 
Han et al., 2012). Interestingly, Oct4, another reprogramming factor, could be used 
to transdifferentiate cells from human fibroblasts to hematopoetic fates (Szabo et al., 
2010). Hematopoetic growth factors were used to induce fibroblasts to attain a 
hematopoetic stem cell (HSC) marker, CD45. By modulating the culture 
environment progenitors could be expanded and many lineages established 
including monocytes which matured to macrophages. These progenitors could 
engraft in vivo and were functionally competent. A combination of all the above 
reprogramming factors (c-Myc, Klf4, Oct4 and Sox2) has also been used in 
transdifferentiation of MEF to both NPCs and cardiomyocytes (Efe et al., 2011; Kim 
et al., 2011). In both cases lineage specific reporters and transient expression of the 
factors was required to generate the desired cell types at a high efficiency. These 
results demonstrated that the reprogramming factors may be used to induce de-
differentiation to a required point from which progenitor cells can be derived, 
without complete reprogramming to pluripotency. Transdifferentiation provides 
39 
 
another method by which differentiation and derivation of desired cell types can be 
improved, and with some methods reporting efficiencies of over 20% for certain 
lineages, this technique should be investigated in a complimentary manner with iPS 
cell studies in order to understand the plasticity and potential of cell fate. 
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1.7 Aims of this thesis 
 The aim of my thesis is to identify and utilise novel cell surface markers in 
order to accurately investigate the molecular mechanism of reprogramming from 
mouse embryonic fibroblasts (MEF). Despite intensive study of reprogramming, 
generation of induced pluripotent stem (iPS) cells remains a highly inefficient 
process. 
 Microarray analysis of transgenic MEF undergoing reprogramming 
previously carried out in our lab identified a number of cell surface markers which 
displayed dynamic expression patterns during the reprogramming process. In order 
to investigate the potential usefulness of these markers I initially employed an in 
vitro reprogramming system using Nanog-GFP reporter MEF and monitored 
changes in marker expression in relation to the widely-used ES cell marker, SSEA-1. 
This analysis was capable of correlating the expression of these novel markers with 
iPS cell colony formation and re-acquisition of Nanog-GFP expression, and 
identified a number of sub-populations which arose during reprogramming. 
 In order to validate these observations during MEF reprogramming, a highly 
efficient secondary system was utilised. Reprogramming sub-populations were 
isolated from a single time-point based on expression of the novel markers and 
Nanog-GFP. Each of the sub-populations displayed distinct potentials to generate 
iPS cells. The transition from one sub-population to the next was monitored and 
revealed the major routes available to cells undergoing reprogramming from MEF. 
 RNA sequencing analysis of the isolated sub-populations revealed the 
differentially expressed genes between each stage of reprogramming. A number of 
gene expression patterns could be identified from this set of genes. Further 
investigation revealed that epidermis-associated genes are transiently up-regulated 
exclusively in the intermediate stages of reprogramming. This revealed that the 




 In addition, this reprogramming marker system was also shown to be 
capable of identifying differences between different reprogramming systems and 
culture conditions. Comparison of a less efficient system also identified two novel 
genes which could be used to increase the efficiency of reprogramming. 
 Further investigation of the features of reprogramming identified in this 
study can potentially contribute to important insights into the molecular mechanism 
of the process of iPS cell generation.  
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CHAPTER 2 - Materials and Methods 
 
2.1 Culture and Maintenance of mammalian cell lines 
2.1.1 Cell culture materials 
GMEM Complete medium: 
Glasgow Minimal Essential Medium (GMEM, Sigma G5154) 
Foetal Calf Serum (10%)  
Non-essential amino acids (1x, Gibco 11140-035)  
L-Glutamine (2mM, Invitrogen) 
Sodium pyruvate (Invitrogen) 
β-mercaptoethanol (100μM, BDH 441413) 
1000U LIF (human recombinant) 
Penicillin/Streptomycin (100 units/100ug, Sigma P4333) 
 
MEF expansion medium: 
 GMEM complete medium 
 bFGF/FGF2 (5ng/mL, Peprotech 100-18-B) 
 Heparin (1ng/mL, Sigma) 
 
Reprogramming medium: 
 GMEM complete medium 
 A-83-01/ALKi (500nM, TOCRIS Bioscience #2934) 
 Ascorbic Acid/VitaminC (10ug/mL, Sigma 1000731348) 
 Doxycycline (dox) (various concentrations as outlined in results, Sigma) 
Freezing solution: 
 DMSO (10%, VWR International) 




Other cell culture solutions: 
 Gelatine (0.1% in PBS, Sigma G5154) 
Trypsin (0.25%,, Gibco 15090-046) 
EDTA (0.1%, Sigma 03620) 
PBS (Sigma D8537) 
 
2.1.2 Cell lines used in this study 
E14 ES cell line 
Mouse embryonic stem cell line which demonstrates high contribution to 
chimeric embryos derived in by Dr. Martin Hooper (Hooper et al., 1987). 
 
6c iPS cell line 
iPS cell line generated through the use of piggyBac mediated delivery of 
individual reprogramming factors from Rosa26M2rtTA/+ MEF (Woltjen et al., 
2009). 
 
IRI1 iPS cell line 
 iPS cell line derived from primary reprogramming of Rosa26M2rtTA/+ MEF 
using polycistronic vector pB  TAP IRI MKOSimO. 
 
D6s4B5 iPS cell line 
iPS cell line derived from Rosa26M2rtTA/+ Nanog+/GFP MEF using polycistronic 
vector pB TAP IRI MKOSimO. Vector was integrated to Sp3 locus as 
identified via splinkerette PCR. 
 
TANGO ES cell line 
iPS cell line derived from targeting Rosa26M2rtTA/+ Nanog+/GFP ES cells with pB 





129 MEF cell line 
 MEF derived from the widely used 129/SvEv strain of mice. 
D6s4B5 and TANGO chimera-derived MEF lines 
2.1.3 ES cell and iPS cell culture technique 
 ES cells and established iPS cell line D6s4B5 were cultured in GMEM 
complete medium. Cells were cultured at 37°C at 7.5% CO2 in humidified incubators. 
Cells were passaged upon reaching ~80% confluency via harvesting in trypsin, re-
suspension in GMEM complete medium, collection by centrifugation at 300g and 
resuspension in GMEM complete medium. Cells were passaged every 2-3 days. 
 
2.1.4 Reprogramming from retinoic acid differentiated iPS cells 
iPS cell clones were plated in at a density of 1X104 cells per well of a 
gelatinized 6 well dish in low LIF (10 units) GMEM complete media supplemented 
with retinoic acid (10-6M, Sigma R2625) and cultured for a period of five days 
(Smith, 1991). Thereafter the medium was changed to GMEM complete medium 
supplemented with dox (1.5ug mL-1) and cultures observed. Cells were harvested 
for flow cytometric analysis and fluorescence-activated cell sorting (FACS) at 
desired time-points via harvesting as for ES/iPS cells but re-suspended in PBS at a 
concentration of 1X106 cells per mL for antibody staining. 
 
2.1.5 Generation of chimeric embryos 
 ES and iPS cell lines used to generate chimeras were cultured in GMEM 
complete medium. 48 hours before use, 2X106 cells in 2mL of GMEM complete 
medium were plated in a gelatinized 6-well plate in a doubling dilution series. 
Colonies of the appropriate size (5-8 cells for aggregation, 10-15 cells for injection) 
were identified from each well, harvested and introduced to morulas or blastocysts 
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of C57B1/6 mice. All manipulation of embryos was carried out by the staff of the 
Transgenics Unit including Jan Ure, Lynsey Robertson and Sally Inverarity. 
 
2.1.6 Mouse embryonic fibroblast isolation and cell culture technique 
 Mouse embryonic fibroblasts (MEFs) were isolated from embryonic day 12.5 
(E12.5) embryos. Embryos were decapitated, eviscerated, dissociated with 0.25% 
trypsin, 0.1% EDTA and plated in MEF expansion medium in 10cm2 dishes (Iwaki) 
MEF were cultured at 37°C at 7.5% CO2 in humidified incubators. Upon reaching 
confluence MEF were stocked in the following manner: cells were washed in PBS, 
harvested in trypsin, collected via centrifugation at 300g and re-suspended in 
freezing solution at a concentration of 2 - 5X106 cells per mL. Cells were stored at -
80°C for 24 hours and transferred to liquid nitrogen (LN) thereafter. Cells were 
defrosted at 37°C, re-suspended in MEF expansion medium, collected via 
centrifugation and re-suspended and re-plated as required. 
 
2.1.6.1 Quantification of transgene containing MEF 
  For MEF isolated from chimeric embryos: one twentieth of the 
isolated cells were plated in reprogramming medium in one well of a 12-well 
culture dish (Iwaki). The total percentage of transgenic cells as indicated by 
mOrange reporter expression was quantified after 48 hours via flow cytometry (BD 
Fortessa). 
 
2.1.7 Reprogramming from MEF 
 The following techniques were used depending on the required outcome of 
the reprogramming experiment. As a general rule, transgenic MEF and 129 stocks 
were plated two (D-2) to four (D-4) days before the start of reprogramming in MEF 
expansion medium and passaged as required. MEF beyond passage 3 (p3) were not 




2.1.7.1 Reprogramming for time-course analysis 
  This technique was generally used in order to carry out flow 
cytometric analysis at multiple time-points of the reprogramming process. 1X105 
MEF containing 5% transgenic cells were plated in each well of a gelatinized 6-well 
tissue culture plate (Iwaki). 129 (wt) MEF were used in order to dilute transgenic 
stocks to the required percentage. Cells were plated directly into reprogramming 
medium (2mL/well) = Day 0 of reprogramming (D0). Culture medium was replaced 
every two days. Cells were harvested using trypsin at each desired time-point, 
collected via centrifugation at 300g, re-suspended in an appropriate volume of PBS, 
total cell number quantified, centrifuged again, and re-suspended in PBS for 
antibody staining at a concentration of 1X106 cells per mL. 
 
2.1.7.2 Reprogramming for endpoint analysis 
  This technique was used in order to identify the effect of changes to 
reprogramming conditions e.g. additional small molecules, genes of interest, or to 
examine colony formation during reprogramming. 3X105 MEF containing 1% 
transgenic cells (adjusted as before) were plated in gelatinized 10cm2 tissue culture 
plates, directly into reprogramming medium (8mL/well) = D0. Culture medium was 
replaced every three days. 
 
2.1.7.3 Reprogramming for fluorescence-activated cell sorting (FACS) 
  This technique was used in order to generate sufficient numbers of 
cells for isolation for RNA extraction and functional analysis of desired populations. 
2X105 MEF containing from 10% to 50% transgenic cells were plated on gelatinized 
10cm2 tissue culture plates directly into reprogramming medium. The number of 
dishes required was based on the day of sorting, enrichment of the population 
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required at that time-point (as calculated via time-course experiments) and the 
starting percentage of transgenic MEF. Medium was changed every three days to D5 
and every two days thereafter. Cells were harvested for antibody staining as per 
time-course analysis (see above). 
  
2.1.8 Transfection of MEF with genes of interest 
 TNG MEF were harvested and re-plated in MEF expansion medium in the 
absence of Pen/Strep at a density of 1.5X105 cells per well of a 6-well dish. The 
following day medium was removed and replenished with 500uL fresh medium. 
For each well per over-expression construct the following DNA master mix was 
used: PB-TAP IRI 2LMKOSimO (0.5μg), CAG-rtTA (0.5μg), HyPBase transposase 
helper plasmid (0.5μg). 1ug per well of the over-expression construct was added to 
this mix. 110uL OptiMEM (Sigma 31985-062) was added to this mix and mixed well. 
10uL FugeneHD (Promega E2311) per well was added to this mix and mixed well. 
115uL of this solution was immediately transferred to each well of MEF. The 
following day medium was changed to 2mL of reprogramming medium (1ug/mL 
dox). Wells were observed for differences in colony emergence and mOrange and 
Nanog-GFP expression compared to empty vector control wells. Each experiment 
was carried out in duplicate wells. 
 
2.2 Flow Cytometry and Immunohistochemistry 
2.2.1 Flow cytometry materials 
 FACS Buffer (FB): 2% FCS in PBS 
 Cell strainers (40um, Stemcell Technologies 27305) 
 FACS tubes (BD Falcon 3520)  
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2.2.2 Antibodies used for flow cytometry and FACS analysis 
 
2.2.3 Antibody staining technique for flow cytometry and FACS analysis 
 Harvested cells in PBS were spun down and re-suspended in FB at a 
concentration of 1X106 cells per mL. Primary antibodies were added and samples 
were stored on ice for 15-30 minutes. Cells were collected by centrifugation and re-
suspended in FB and this was repeated. Secondary antibodies were then added to 
the FB-re-suspended samples and samples were incubated for 5-10 minutes on ice. 









































































Wash steps were repeated as before. Finally, cells were transferred to FACS tubes at 
a concentration of 2X106 cells per mL for flow cytometry time-course analysis (BD 
LSRFortessa). For FACS analysis (BD FACSAriaII) cells were re-suspended at a 
concentration of 5X106 cells per mL and passed twice through a cell strainer to 
ensure single-cell suspensions of cells for analysis. 
 
2.2.4 Instrument settings for flow cytometric and FACS analysis 
 
Flow Cytometry 
BD LSR Fortessa 
Excitation Line 
488 nm 561 nm 640 nm 
Band pass (BP) filter 
530±30 GFP     
582±15   mOrange   
780±60   PECy7   
670±30     APC 
 
Figure 2.1 Settings for flow cytometry and FACS analysis. Excitation line refers 
to the laser used to excite the fluorophore of choice. Band pass (BP) filter indicates 
the wavelength of light detected by the instrument, with the range either side of this 




488 nm 405 nm 561 nm 640 nm 
Band pass (BP) filter 
450±50 
 
DAPI     
525±50 GFP 
 
    
582±15     mOrange   
780±60     PECy7   
670±14       APC 
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2.2.5 Data processing and gating strategy of flow cytometric and FACS analysis 
 Gating of cells using forward- and side-scatter (FSC, SSC) parameters was 
broad in line with the diverse morphologies present in cultures of cells undergoing 
reprogramming i.e. larger fibroblastic/differentiated cells and smaller 
reprogramming intermediates/iPS cells. Transgenic cells were identified based on 
mOrange expression. Transgenic cells were then gated based on Nanog-GFP 
reporter expression, with Nanog-GFP+ and –GFP- cells pseudo-coloured green and 
red respectively. An example of the typical gating strategy used, and control MEF 
population is shown in Figure 2.2. Compensation, the correction of overlap or 
interference between different fluorophores during acquisition, was carried out 
electronically using DIVA software (BD). Sample data was analysed using FlowJo 
software (Tree Star). Operation of FACSAria was carried out by Simon Monard and 
Olivia Rodriges. 
 
2.2.6 Collection, processing and analysis of FACS sorted populations 
2.2.6.1 Cells for colony formation assay 
  This procedure was carried out in order to assess differences in the 
colony forming potential between assorted populations. 1X104 cells were sorted into 
FACS tubes containing 2mL GMEM complete medium and stored on ice until all 
populations were isolated. Cells were centrifuged and re-suspended in an 
appropriate amount of reprogramming medium. 3.5X103 cells were plated in a total 
volume of 1mL reprogramming medium on irradiated feeder MEF (4000 rads, 
prepared in-house by tissue culture staff) in a single well of a 12 well plate, in 
duplicate. Medium was changed every two days. mOrange and Nanog-GFP 






Figure 2.2 Gating strategy for flow cytometry and FACS analysis. Cells were 
gated based on size (Intact Cells), mOrange expression (Transgenic Cells), Nanog-
GFP expression (Nanog-GFP gating) and pseudo-coloured based on Nanog-GFP 
expression (Coloured data). SSC = Side scatter. FSC = Forward scatter. 
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2.2.6.2 Cells for population movement analysis 
  This technique was used in order to investigate changes in cell 
surface marker and reporter expression from isolated cell populations. 1X104 cells 
per population, per post-sort time-point required were sorted into 2mL GMEM 
complete medium and stored on ice until all populations were isolated. Cells were 
centrifuged and re-suspended in reprogramming medium. 1X104 cells per post-sort 
time-point were plated in a single well of a gelatinized 48-well plate in a total 
volume of 1mL reprogramming medium. Medium was changed every two days. 
Cells were harvested for flow cytometric analysis as per time-course analysis. 
 
2.2.6.3 Cells for RNA isolation 
  This technique was used to ensure sufficient quantities of cells from 
which RNA could be isolated for further processing. A minimum of 2X105 cells and 
a maximum of 7X105 cells were sorted from the desired populations into 1mL 
GMEM complete medium. Cells were stored on ice until all populations were 
isolated. Cells were washed twice via centrifuge collection and re-suspension in 
PBS. After the second wash the cell pellet was re-suspended in 500uL Trizol 
(Invitrogen) and immediately transferred to -80°C for storage. 
 
2.2.7 Immunohistochemistry solutions 
 PBS 
 PFA/Paraformaldehyde (4% in PBS, Sigma)  
 Triton-X (0.1% in PBS, Sigma) 




2.2.8 Immunohistochemistry antibodies 
 
2.2.9 Immunohistochemistry methods 
 For staining of cells with keratin markers, transgenic MEF were plated as for 
time-course reprogramming. For staining, cells were washed in PBS twice and fixed 
in PFA at room temperature (RT) for 10 minutes. PFA was removed, Triton-X added 
for 1 hour at RT. Triton-X was removed and cells were incubated at RT for 2-3 hours 
in blocking solution. Primary antibodies were diluted in blocking solution and 
added to the fixed cells for incubation overnight at 4°C. The following day the cells 
were washed in PBS three times, with 5 minutes incubation in PBS at RT between 
washes. Secondary antibody was diluted in the blocking solution and incubated 
with the washed cells at 4°C for 1 hour. Cells were washed in PBS three times as 
before and imaged immediately. Cells were stored at 4°C in PBS. 
  

































2.3 RNA sequencing and analysis 
2.3.1 RNA isolation 
 Trizol suspended samples were defrosted on ice. 100uL of chloroform was 
added and samples were vortexed. Samples were left at RT for 15min and 
centrifuged at 12,000g for 15min at 4°C. The upper aqueous layer containing RNA 
was carefully separated from the protein/lipid fraction and the DNA interphase, 
and transferred to a 1.5mL Eppendorf. 250uL of isopropanol was added and 
samples vortexed. Samples were incubated at RT for 10min and centrifuged at 
12,000g for 20min at 4°C. The supernatant was aspirated and the remaining RNA 
pellet was washed in 500uL 75% ethanol, vortexed and centrifuged at 12,000g for 
5min. The supernatant was removed and the pellet allowed to dry at RT for 5-
10min. The pellet was re-suspended in 15uL sterile, RNAse-free water and stored at 
-80°C. 
 
2.3.2 Preparation of samples for RNA sequencing 
2.3.2.1 Measuring sample concentration 
  Due to the highly accurate requirements of the RNA sequencing 
(RNAseq) procedure used in this study, the concentration and quality of the RNA 
samples were measured for using the Bioanalyzer 2100 (Agilent). 1uL of RNA in 
water was diluted in 5uL sterile, RNAse-free water for analysis. In brief, samples are 
loaded onto a chip and run through a polymer gel and mixed with a fluorescent 
dye. Current applied to the chip enables separation of the charged, dye-intercalated, 
RNA based on size. Good quality, intact, RNA will display two distinct peaks 
corresponding to 18S and 28S ribosomal RNA (rRNA) subunits, with a 28s/18S 
rRNA ratio greater than 2. In addition, a software algorithm devises the RNA 
Integrity Number (RIN) which determines the quality of the sample with an RIN of 
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10 representing the most intact, highest quality RNA. All samples used for RNAseq 
analysis in this study had RINs of ≥8.9. 
 
2.3.2.2 Sample dilution for RNAseq analysis 
  Samples were diluted to a concentration of 10ng RNA per μL in the 
running buffer for RNAseq: 10mM Tris pH 7.6 with 0.05% Tween-20. 10uL of each 
diluted sample was aliquoted into RNAse-free 200uL PCR tubes and stored at -
80°C. 
 
2.3.3 Multiplexed RNAseq protocol 
 All RNAseq analysis was carried out by the lab. of Dr. Sten Linnarsson as 
previously described (Islam et al., 2011; Islam et al., 2012). Briefly, for each sample, 
polyA-carrying mRNA undergoes reverse transcription to cDNA via a universal 
oligo-dT primer. The reverse transcriptase enzyme reads through to the 5’ end of the 
mRNA, and is induced to undergo template switching to read from a second primer 
carrying a unique 6-base barcode sequence and sequence for cDNA amplification, 
thus integrating these components into the nascent cDNA strand. The bar-coded 
samples are then pooled therefore all subsequent steps occur simultaneously, 
reducing sample-to-sample variation. The cDNA is then bead purified and full 
length cDNA amplification occurs, and the quality of the cDNA is checked at this 
point. The full-length cDNA is then fragmented, blunted and dA-tailed in order to 
enable ligation of an amplification oligo to the 3’ end of the molecule. cDNA library 
amplification then occurs, and a final oligo introduces the 5’ sequencing motif to the 






2.3.4 RNAseq data analysis  
 All RNAseq data analysis was carried out by members of the Bioinformatics 
core under the supervision of Dr. Simon Tomlinson at the SCRM. Quality control of 
the obtained reads and alignment to the mouse reference genome (NCBI37/mm9) 
was performed using the GeneProf web-based analysis suite with default 
parameters (Halbritter et al., 2012). 
Differentially expressed genes (DEGs) were identified, using the edgeR and 
DESeq Bioconductor libraries (Gentleman et al., 2004; Anders and Huber, 2010; 
Robinson et al., 2010). For both methods, low expression transcripts (less than 13 
reads in all samples) were filtered out and P-values were adjusted using a threshold 
for false discovery rate (FDR) ≤ 0.05. Genes listed as DEGs by both methods in any 
two subpopulation comparison (Figure 5.3a, total 3,171) were used for further 
analysis. Hierarchical clustering and K-means clustering (K=5) of DEGs was 
performed using Cluster 3.0 and Java Treeview was used for visualisation (de Hoon 
et al., 2004; Saldanha, 2004). 
Principal Components Analysis (PCA) was performed in R and plotted with 
the scatterplot3d library (Ligges, 2003). Gene ontology (GO) enrichment was 
calculated using the DAVID functional annotation bioinformatics tool (Huang da et 
al., 2009). GO term enrichment analysis was carried out with a modified Fisher 
Exact p-value. 
The three additional published studies (Sridharan et al., 2009; Samavarchi-
Tehrani et al., 2010; Polo et al., 2012) (GEO accession number GSE21757, GSE14012, 
GSE42379) were analysed in a similar way. For the time course data the analysis was 
performed as following: data were RMA (Irizarry et al., 2003) normalised using the 
Expression Console from Affymetrix and, since no replicates were provided, fold 
changes (FC) between each two samples were calculated in Excel. For the Plath and 
Polo dataset, data were RMA normalised using the ‘affy’ package (Gautier, 2004) in 
R. Selected gene expression data shown as relative expression against the highest 
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2.4 Molecular Biology Techniques 
2.4.1 Plasmids 
ZeroBluntII TOPO Plasmid containing ccdB expression cassettes for negative 
expression, ColE1and F1 origins of replication. Kanamycin 
resistant. 
 
pENTR hCD2 Plasmid containing IRES-linked human CD2 cDNA followed 
by bovine growth hormone polyadenylation site (bpA), and 
flanked by the Gateway recombination sites attL1 and attL2. 
Kanamycin resistant. 
pB TAP IRI Plasmid containing the doxycycline-inducible TetO element 
up-stream of the mCMV promoter. Contains Gateway 
recombination sites attR1 and attR2 which flank the bacterial-
toxic ccdB gene. A human lamin B2 replicator sequence is 
located downstream of the attR2 site. Upstream of the TetO 
element and downstream of the replicator sequence are 
chicken β2 insulator sequences. All of these elements are 
flanked by piggyBac transposon long terminal repeats. 
Ampicillin resistant. 
pB TAP GOI hCD2 PB TAP IRI plasmid after Gateway recombination with 
pENTR hCD2 plasmid containing gene-of-interest (GOI) for 
over-expression. Ampicillin resistant. 
 
2.4.2 cDNA synthesis 
cDNA was synthesised from E14 ES cells RNA isolated using Trizol (see 
section 2.3.1). 1ug RNA was used. Oligo dT (100uM, T24) was added along with 
separate deoxyribonucleotides (100mM each, Invitrogen55082/3/4/5). Samples were 
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made up to 10uL and incubated at 65°C for 5min, followed by 37°C. Buffer (1X, 
Invitrogen Y02321), DTT (Invitrogen Y00147), RNaseIN (NEB, M03141) and the 
reverse transcriptase MMLV (Invitrogen 28025-013) were added. Samples were 
incubated at 37°C for 1hour, 90°C for 10min and cooled to 4°C. Samples were stored 
at -80°C. 
 
2.4.3 Gene of interest cDNA cloning 
2.4.3.1 Primers used for gene amplification 
 
Gene Primer Name Sequence 
Eras Eras-Sal-BstBI F GTCGACTTCGAAATGGCTTTGCCTACAAAGTC 
  Eras-BstZ17I R GTATACACCGGTTCAGGCTACAGAGCAGCCAC 
 
Prdm14 Prdm14-Sal-BstBI F GTCGACTTCGAAATGGCCTTACCGCCCTCTGG 
  Prdm14-BstZ17I R GTATACACCGGTCTAGCAGGTTTTATGAAGCC 
 
Mcm3 Mcm3-Sal-BstBI F GTCGACTTCGAAATGGCGGGCACAGTAGTGCT 
  Mcm3-BstZ17I R GTATACACCGGTTCAGATAAGGAAGACGATGC 
 
Gpr19 Gpr19-Sal-BstBI F GTCGACTTCGAAATGGTTTTTGCTCACAGAAT 
  Gpr19-BstZ17I R GTATACACCGGTTCAGACAAAAGTGTTTGGAG 
 
Phc1 Phc1-Sal-BstBI F GTCGACTTCGAAATGGAAACGGAGAGTGAGCA 







2.4.3.2 cDNA amplification reaction 
  PCR reactions were prepared in 50uL volumes with 200uM dNTP 
(NEB), and 0.3uM of each primer. For the DNA polymerase used, PrimeSTAR HS 
(Takara), concentration was specified by the manufacturer and reactions were 
supplemented with the reaction buffer supplied with the polymerase, 5X 
PrimeSTAR Buffer (Mg2+ plus). 1-5uL of undiluted cDNA was used for each 
reaction. All reactions were performed on the DYAD DNA Engine thermal cycler. 
Three step PCR was used with a denaturation temperature of 98°C for 10sec, an 
annealing temperature 5 degrees lower than the lowest melting temperature for 
each set of primers (as supplied by the oligo provider, IDT) for 5 sec, and an 
extension temperature of 72°C for 1min per kb of template to be amplified. This 
cycle was repeated 30 times, followed by a final incubation at 72°C for 10 minutes, 
followed by incubation at 4°C. Samples were stored at -20°C. 
 
2.4.3.3 Blunt cloning of PCR products 
 PCR products were directly cloned using the Invitrogen Zero Blunt 
TOPO PCR Cloning Kit (Invitrogen 45-0245) according to manufacturer’s 
instructions. 
 
2.4.3.4 Transformation of bacteria 
 DH5α E. coli bacteria were routinely transformed with the following 
amounts of reaction mixture: <1ug plasmid DNA; 5uL ligation mix; 5uL TOPO 
cloning reactions. DNA and freshly thawed bacteria were incubated on ice for ~5 
minutes, bacteria were heat shocked at 42°C for 30sec and immediately incubated 
on ice for 10-15min. 400uL LB broth was added to the tube and incubated at 37°C 
for 1hr. 10-300uL (depending on the source of the DNA) was plated on LB plates 
containing the appropriate antibiotic. Plates were incubated at 37°C overnight. 
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2.4.3.5 Bacterial plasmid isolation 
 Individual bacterial colonies were picked from plates and used to 
inoculate 4mL of LB broth containing the appropriate antibiotic. Colonies were also 
stabbed onto an LB antibiotic plate in triplicate (‘master plate’). The master plate 
was incubated at 37°C overnight, while the inoculated LB broth cultures were 
incubated at 37°C with agitation at 200rpm for 16-18hours. The following day 
bacteria were centrifuged at 4000g for 10min. The bacterial plasmid DNA was 
isolated using the QIAprep Spin Miniprep kit (Qiagen 27106). For larger 
preparations of DNA, 50mL of broth was inoculated and plasmid DNA isolated 
using a QIAprep Spin Midiprep kit (Qiagen 12243). 
 
2.4.3.6 Restriction enzyme digestion of DNA 
 All restriction enzymes used were supplied by NEB. The amount of 
DNA digested varied depending on the quantity of digest product required for the 
next step of cloning, except for confirmation digests for which usually 100-200ng of 
DNA was used. The reaction buffer used was as recommended by the 
manufacturer. The amount of restriction enzyme used was based on the quantity of 
DNA present and was adjusted accordingly in digests using a non-optimal buffer 
(e.g. two different enzymes being used). Reactions were performed at 37°C for 1hr. 
 
2.4.3.7 Isolation of digested DNA fragments 
 DNA fragments were separated via agarose gel electrophoresis. 
Depending on the size of the fragment to be isolated, 0.8-2% (w/v) gels were used. 
Gels contained GelRed (1X, Cambridge BioScience) for visualisation of DNA under 
UV illumination. Samples were run in 1x sucrose loading buffer (OrangeG, NEB, + 
40% sucrose) alongside a 1Kb Plus (Life Technologies) DNA marker. Samples were 
run at 120V for 30-45mins. Samples were extracted from gels using a scalpel and gel 
fragments stored at -20°C if required. DNA was extracted from gels using 
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Zymoclean Gel DNA Recovery Kit (Zymo Research) according to manufacturer’s 
instructions. DNA was eluted in 8uL sterile water. 
 
2.4.3.8 Ligation of DNA fragments 
 Ligations were carried out using T4 DNA Ligase (NEB) as per 
manufacturer’s instructions. For ligations, a molar ratio of insert: plasmid of 3:1 or 
5:1 was used. Reactions were carried out at RT for 1hr, or at 16°C overnight. 
 
2.4.3.9 Gateway Cloning Reaction 





CHAPTER 3 - Identification of novel cell-surface 




 Cell surface markers have long been used in many diverse areas of biology 
to identify distinct populations of cells at different developmental time-points or 
which display specific characteristics, such as identification of hematopoietic lineage 
components (Lin and Goodell, 2011), tracing the maturation of T-cells in the thymus 
(Gordon and Manley, 2011) and isolation of putative tumorigenic cells in a variety 
of cancers (Al-Hajj et al., 2003; Visvader and Lindeman, 2008; Botchkina et al., 2009). 
However, while there have been attempts to apply this approach to reprogramming 
studies, with an indication that known somatic surface-markers are rapidly down 
regulated and the mES cell-associated marker stage-specific embryonic antigen 1 
(SSEA-1) up-regulated early in the reprogramming process, this occurs well in 
advance of pluripotent gene expression, and may not accurately capture 
intermediates stages of reprogramming (Stadtfeld et al., 2008a). In addition, if the 
theory that reprogramming occurs in a stochastic manner is to be believed, it 
suggests that there may be no one suitable surface-marker to identify those cells 
which have the potential to become iPS cells, as this process is highly asynchronous 
(Hanna et al., 2009b). Despite these indications, a number of molecular events have 
been described during reprogramming to occur in an ordered manner, for example 
a mesenchymal-to-epithelial transition (MET) always takes place before cells can 
become fully reprogrammed (Li et al., 2010; Samavarchi-Tehrani et al., 2010). We 
theorized that if such ordered changes can occur on a molecular level, there may 
also be cell surface-markers which also show sequential changes during 
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reprogramming whose expression correlates with changes in iPS cell-forming 
potential. 
 
3.1.1 Background work leading to this project 
3.1.1.1 Microarray analysis of secondary reprogramming. 
  A piggyBac transposon-generated iPS cell line, 6c, was used 
previously in our lab for microarray analysis (Woltjen et al., 2009)(Microarray data 
unpublished, sample preparation carried out by Keisuke Kaji). This line carries 
numerous integrations of the individual reprogramming factors c-Myc, Klf4, Oct4 
and Sox2 which are under the control of the Tet-O, doxycycline (dox)-inducible 
promoter, with rtTA expressed from the Rosa26 locus. This clone was used for 
morula aggregation, and MEF were isolated from chimeric mice at embryonic day 
12.5 (E12.5). These MEF were used for “secondary” (2˚) reprogramming, with cells 
cultured in the presence of dox (1.5ug mL-1) to induce re-expression of 
reprogramming factors from the transgene containing cells (Figure 3.1a). Samples 
for microarray analysis were isolated at various time-points throughout the time-




Sample Name Description 
Secondary (2°) 
MEF 
6c MEF isolated from chimeric embryos 
Day 5 6c MEF cultured for 5 days in dox, sorted for SSEA-1+ cells 
Day 8 Day 5 sorted cells, plus 3 days in dox 
Day 11 Day 5 sorted cells, plus 6 days in dox 
Day 14 Day 5 sorted cells, plus 9 days in dox 
Day 17 
Day 5 sorted cells, plus 12 days in dox, harvested and floating 
after 45min on gelatine 
2° iPSC 
Dox independent iPSC derived from day 23 by passaging for 20 
days in the absence of dox 
 
Table: 3.1: 6c reprogramming samples for microarray analysis. Samples were 
isolated at the time-points indicated 
 
3.1.1.2 Identification of cell surface-markers. 
  Bioinformatic processing of the 6c 2˚ reprogramming microarray data 
was carried out by Dr. Simon Tomlinson. From this data, we could observe a 
number of interesting results (Figure 3.1b). Firstly, despite including only cells 
positive for the ES cell-associated marker SSEA-1 from day 5 onwards, it was 
observed that pluripotency gene up-regulation did not show a significant increase 
until around day 11. This suggested that SSEA-1 expression is an early marker of 
cells undergoing reprogramming.  
In addition, the expression of the pluripotency genes themselves, 
despite modestly increasing up to day 17, did not reach the high levels of expression 
found in ES cells until after numerous passages in the absence of dox, possibly 
corresponding to the expansion of the already-reprogrammed cells present at day 
17. Of note, the previously described MEF marker Thy1 was found to be rapidly 
down-regulated, with expression dropping within the first five days of the 
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reprogramming process. Thy1 expression was also down-regulated in the SSEA-1 
negative cells at day 5, indicating the loss of this marker may not represent a 
significant barrier to reprogramming (data not shown). Similarly, the epithelial cell 
marker Ecad was found to be rapidly up-regulated, with expression reaching fully 
reprogrammed iPS cell levels by day 8 in the SSEA-1+ population. These results 
indicated that neither of these markers would be suitable for examining cells at 
intermediate or later-stages of the reprogramming process as they would not be 
capable of discriminating between the large numbers of cells which would 
ultimately fail to generate iPS cells. 
It was possible to identify a number of cell-surface markers whose 
expression, in contrast to known or associated markers of reprogramming, appeared 
to be far more dynamic in nature. Sca1 expression was found to gradually increase 
until day 14 of reprogramming, after which expression rapidly decreased as cells 
reached an iPS cell-like state. CD44 expression appeared to be relatively highly 
expressed in the starting MEF population, and this expression was rapidly down-
regulated throughout the reprogramming process, showing a much slower loss in 
expression when compared to fellow MEF marker Thy1. Finally, Icam-1 expression 
appeared to be relatively low for the majority of the reprogramming time-course, 
but was greatly up-regulated at later stage, echoing the expression pattern of key 
pluripotency genes Nanog, Utf1 and Dppa4. A number of other cell surface-markers 
were also identified to display similar patterns of expression, however the majority 
of these were not suitable for further investigation as either their fold expression 
change was low, commercial antibodies were not available for immediate use or the 






Figure 3.1. Identification of cell surface markers from secondary 
reprogramming time-course analysis. a. Schematic overview of piggyBac 
transposons mediated generation of 6c cell line, secondary reprogramming samples 
for microarray analysis and E14 ES cells. b. Expression pattern of pluripotency 
genes Klf2, Nanog, Utf1, Dppa4, previously described surface markers Thy1, Ecad 





3.1.1.3 Retinoic Acid differentiation as an in vitro model of reprogramming 
Using Sca1, CD44 and Icam-1 as candidate genes for further analysis, 
it was next key to establish a 2˚ reprogramming system which could ensure 
consistent, high expression of the reprogramming factors after differentiation. It had 
previously been shown that 6c-derived MEF cells could successfully reactivate 
expression of the reprogramming factors (Woltjen et al., 2009). However retinoic 
acid (RA)-mediated differentiation of iPS cell lines generated using the dox-
inducible MKOS-ires-geo polycistronic vector indicated poor re-expression and low 
efficiency reprogramming upon culture in dox (Kaji et al., 2009) (data not shown). 
This may have been due to the presence of the lacZ reporter component of the β-geo 
gene which is –C-phosphate-G- (CpG) rich and may be a target of silencing 
methylation during in vivo or in vitro differentiation (Chevalier-Mariette et al., 2003). 
In order to maintain high levels of transgene expression throughout 
reprogramming, new iPS cell lines were generated from Rosa26M2rtTA/+ MEF 
nucleofected with a modified version of the previously described vector 
pCAG2LMKOSimO (Kaji et al., 2009). This modified vector, PB-TAP IRI 
2LMKOSimO retained the 2A-peptide-linked reprogramming cassette c-Myc-Klf4-
Oct4-Sox2 (MKOS), and the mOrange transgene reporter which followed, but was 
placed under the control of the dox-inducible TetO promoter and also contained a 
number of genetic elements which have been reported to maintain transgene 
expression (Figure 3.2a). Insulator sequences are commonly found in the genome 
and depending on the type, generally have two major functions; protecting genes 
from external signals which may aberrantly effect their normal expression and 
acting as barriers which prevent the spread of heterochromatin and epigenetic 
silencing (Gaszner and Felsenfeld, 2006). Transcriptional silencing has been 
implicated in a shift to replication at late S-phase of the cell cycle (Gilbert, 2002). 
Replicators are sequences which have been shown to influence the initiation of 
replication, and can prevent the replication delay and instability associated with 
long-term transgene expression (Fu et al., 2006). By utilising both of these elements 
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in our reprogramming vectors, we aimed to achieve efficient induction of 
reprogramming factors after generating differentiated cells as well as throughout 
the process of reprogramming. iPS cell lines generated from Rosa26M2rtTA/+ MEFs 
were screened by Southern blot to determine the number of integrations of the 
reprogramming cassette (data not shown), and a number of low copy (1-3) clones 
were identified and expanded for further use. 
In order to carry out preliminary investigation of the usefulness of the 
identified novel cell surface markers, it was determined that generation of chimeras 
from these iPS clones would be both costly and time inefficient. Thus a system by 
which clones were differentiated in RA and low concentration-leukaemia inhibitory 
factor (LIF) media was used (Figure 3.2b). Clones were plated in at a density of 
1X104 cells/well of a 6 well dish in the presence of RA (10-6M) and LIF (10U) and 
cultured for a period of five days (Smith, 1991). Changes in morphology became 
most obvious after three days of culture, and by day 5 the cells acquired a 
fibroblastic-like morphology, with very few undifferentiated cells (Figure 3.2c, Day 
5+RA). Adding media containing higher levels of LIF (1000U mL-1) and dox (1.5ug 
mL-1) to these cultures resulted in gradual mOrange expression, morphology 
changes and later the appearance of colonies indistinguishable from the original iPS 
cells from which they were derived (Fig 3.2c). One clone, IRI1 showed efficient 
reprogramming and was used for further study under these conditions. Some cells 
were found to maintain the ability to generate colonies in the presence of high 
(1000U mL-1) LIF-containing media in the absence of dox even after five days of 
differentiation, however ensuring the absence of clumps of iPS cells at the initial 
seeding prevented this from occurring at a high frequency (Figure 3.2d). It was also 
found that extending differentiation beyond five days resulted in a dramatic 
decrease in the number of alkaline phosphatase (AP) positive colonies that could be 
generated in the presence of dox (Figure 3.2e), thus five days of differentiation was 







Figure 3.2 A retinoic acid based efficient secondary reprogramming system. a. 
Schematic of pBTAP IRI 2LMKOSimO and generation of iPSC lines. b. Schematic 
of retinoic acid based differentiation and reprogramming system. c. Images of typical 
morphology of RA differentiated cells undergoing reprogramming. BF = Bright Field. 
mOr = mOrange. d. Number of alkaline positive colonies obtained in the presence 
and absence of dox after 5 days of RA differentiation. e. Number of AP+ colonies 
obtained at day 10 of reprogramming after differentiation of ES cells in RA for 




3.1.1.4 Marker expression during secondary reprogramming 
  During 2˚ reprogramming of RA-differentiated IRI1, in order to 
establish how the novel cell surface markers identified from the 6c microarray 
behaved during reprogramming, a time-course of flow cytometric analysis was 
carried out (Figure 3.3). 
CD44 expression was found to be at a moderate level in the RA 
differentiated iPS cells, in contrast to the high transcript levels detected in the 
microarray (Figure 3.3, top panels). However, upon initiation of reprogramming it 
was observed that CD44 levels increased somewhat, with more than 50% of total 
cells highly positive for this marker by day 2. Expression was gradually lost 
however, and by day 12 the reprogramming profile appeared dramatically different 
with a loss of nearly all CD44+ cells. 
SCA1 expression was initially slightly lower than CD44 in the 
majority of differentiated cells (Figure 3.3, middle panels). However, unlike CD44, 
at day 5 SCA1 expression was almost homogeneously high. A gradual loss of 
expression was subsequently observed, however unlike CD44, by day 12 had not 
quite reached low, ES cell-like, levels of expression. 
ICAM-1 expression appeared to be quite broad in the RA 
differentiated iPS cells, with both high and low expressing populations (Figure 3.3, 
bottom panels). Expression of this marker appeared to be quite static with no clear 
emergence of separate populations until day 9 cells appeared to gain ICAM-1 






Figure 3.3 Expression of cell surface markers during secondary 
reprogramming of RA differentiated IRI1 iPS cells. Cells were differentiated in 
the presence of retinoic acid (RA) for five days and cultured in the presence of dox. 
Cells were harvested at the indicated days (d) and used for FACS analysis of the 
expression of cell surface markers CD44 (top), SCA-1 (middle) and ICAM1 (bottom). 
The expression of these markers was compared to reprogramming factor 





3.1.2 Aims of this chapter 
The aim of this chapter is to outline the identification of novel cell surface-
markers which displayed dynamic expression patterns during iPS cell generation. 
Based on this work, a series of validation experiments were carried out to identify 
their robustness and usefulness in marking distinct intermediates of 
reprogramming, and how these populations behave upon isolation. Furthermore, 
the use of a transgene expression reporter led to preliminary observations regarding 
the requirement of reprogramming factor expression during iPS cell generation. 
Finally, expression of the novel surface-markers was compared to expression of a 






3.2.1 Comparison of novel cell surface markers to SSEA-1 during reprogramming 
 During 2˚ reprogramming of IRI1, cells were harvested and stained for 
expression of the ES cell marker SSEA1 (Figure 3.4a). As expected, SSEA1 
expression increased with prolonged reprogramming factor expression, with more 
than 80% of cells expressing this marker by day 11 of dox administration. To 
investigate the correlation of SSEA1 expression and cell behaviour during 
reprogramming, cells were re-plated at clonal density in the absence of dox at 
different time-points and stained for AP+ colony formation after five days. From this 
data it was found that even at day 9, when >60% of cells were SSEA1+ only 40% of 
cells were capable of successfully generating AP+ colonies (Figure 3.4b). This 
supported the idea that SSEA1 was not an appropriate marker of fully 
reprogrammed cells, and indeed there appeared to be no clear correlation between 
SSEA1 expression and successful completion of reprogramming. A time-course of 
flow cytometric analysis was carried out with expression compared to that of SSEA1 
which acted as a reference for the usefulness of the novel markers (Figure 3.4c). 
CD44 expression was found to be at a moderate level in the RA 
differentiated iPS cells, in contrast to the high transcript levels detected in the 
microarray (Figure 3.4c, top panel). However, upon initiation of reprogramming it 
was observed that CD44 levels rapidly increased with more than 50% of total cells 
highly positive for this marker by day 8. This increase in CD44 expression was 
mirrored by an increase in SSEA1, and four populations of cells could be observed 
by day 8, with both CD44 expressing and non-expressing cells containing both 
SSEA1 positive and negative fractions. However by day 11 the reprogramming 
profile appeared dramatically different with a loss of all CD44+ cells. This 
population remained absent for the remainder of the reprogramming process, while 
SSEA1 expression gradually increased. 
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 ICAM-1 expression appeared to be quite broad in the RA differentiated iPS 
cells, with both high and low expressing populations (Figure 3.4c, middle panel). 
Upon initial transgene expression this marker was relatively static with no clear 
emergence of separate populations until day 11 when the majority of cells became 
ICAM-1+. Similarly to CD44 staining at day 8, there appeared to be both positive 
and negative populations expressing SSEA1. By day 14 a very minor ICAM-1 
negative population was observed with most cells expressing an iPS cell-like 
phenotype. 
 SCA1 expression was initially very low if not absent in the majority of 
differentiated cells (Figure 3.4c, bottom panel). However, unlike the other novel 
markers, it appeared to show a rapid response to transgene induction with a large 
up-regulation in expression even after 2 days. Expression appeared to increase 
further in the SSEA1- cells by day 8, however it was apparent that SSEA1+ cells had 
reduced expression of this marker. This pattern became much more apparent by day 
11 when there was a clear profile of SCA1+SSEA1- versus SCA1-SSEA1+ cells. By day 












Figure 3.4. SSEA1 expression compared to novel reprogramming markers. a. 
Total number of colonies generated after dox treatment for the indicated days and 
AP stained after a five further days of culture in the presence of dox (+dox) or after 
dox washout (-dox). b. SSEA1 expression measure by flow cytometry during 
secondary reprogramming. c. Flow cytometry profiles of novel cell surface markers 
compared to SSEA1 during time-course analysis of 2˚ reprogramming.  
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3.2.2 Reprogramming factor expression during iPS cell generation. 
 During reprogramming using the RA based 2˚ reprogramming system, not 
only could the expression pattern of cell surface markers be identified, but also the 
expression level of the reprogramming factors themselves due to the presence of the 
ires-mOrange cassette contained within the vector. One startling observation 
however, was that transgene expression levels did not appear to remain constant in 
the cells undergoing reprogramming, despite maintenance of dox at an identical 
concentration throughout the entire culture period (Figure 3.5a). In fact, while the 
majority of cells displayed high levels of mOrange at the mid-point of 
reprogramming (day 8) the later stages (day 11) reduced expression to an identical 
level to that of cells at earlier time-points (day 5).  
This finding was further explored in cells undergoing reprogramming 
stained for SSEA1 (figure 3.5b). In these cells it was found that there appeared to be 
a negative correlation between expression of this marker and the mOrange reporter, 
with the SSEA1high cells (green) displaying lower reporter expression than their 
SSEA1neg/low counterparts (red). However, as described previously, SSEA1 expression 
may not correlate well with the reprogramming process, thus CD44 expression was 
compared to that of mOrange in order to further understand this observation 
(Figure 3.5c). At the early stages of reprogramming (day 5) there did not appear to 
be a difference in mOrange expression between CD44high and CD44low cells. A more 
significant difference became apparent at day 8 when the expression of CD44 
appeared to correlate well with mOrange expression. By day 11 the majority of cells 
had decreased CD44 expression as previously described, and similarly, expressed 
low levels of mOrange. However it was observed that the minor population which 
maintained high levels of CD44 continued to express higher levels of the 
reprogramming factors. This result provided evidence that there may be some form 
of reprogramming factor down-regulation required for the completion of 
reprogramming, irrespective of attempts to drive further expression e.g. 




 Figure 3.5. Down-regulation of reprogramming factor expression during 
secondary reprogramming. a. mOrange expression level of total population 
undergoing reprogramming. b. SSEA1 expression identifies differences in mOrange 
expression. Cells were analysed at day 8 post reprogramming factor induction. c. 





3.2.3 CD44 expression predicts differences in reprogramming ability 
In order to assess the functional significance of the observed differences in 
CD44, SSEA1 and mOrange expression, cells were isolated from each of the 
observed populations previously described at day 8 of reprogramming (Figure 
3.6a). Sorting purity (typical for all experiments) was more than 80% (Figure 3.6b). 
Sorted cells were plated on gelatine in the absence of dox in order to assess their 
ability to form iPS cell-like colonies (Figure 3.6c). Strikingly, differences among the 
populations could be observed even after only three further days of culture. The 
CD44 positive populations were unable to give rise to any colonies; rather all cells 
appeared to differentiate and give rise to a fibroblastic-like culture. In contrast, the 
CD44 negative sorted populations were capable of producing a number of iPS cell-
like colonies capable of maintaining an undifferentiated state, however some 
differentiated cells could also be observed in these cultures. 
 The significance of SSEA1 expression could also be examined, and it was 
observed that in the case of the differentiated cultures produced by the CD44 
positive sorted cells, cell survival appeared to be slightly poorer in cells also positive 
for SSEA1 compared to their negative counterparts. In the CD44 negative 
populations, there appeared to be fewer differentiated background cells in the 
SSEA1 positive sorted cells. These results suggested that CD44 expression is a more 
useful marker in terms of predicting which cells are closer to an iPS cell-like state 
compared to the commonly used marker SSEA1. In addition, the presence of a 
population expressing both a marker negatively correlated with reprogramming 
success (CD44) at the same time as an ES cell marker (SSEA1) suggested there may 
be more than one route to the fully reprogrammed state, and further reinforced the 
requirement for a system which can accurately untangle the heterogeneity of cell 
cultures undergoing reprogramming. 
 It was observed, as previously described (Figure 3.5), that at the time of 
sorting both of the CD44 negative populations were found to be expressing lower 
levels of the reprogramming factors as measured by mOrange expression, compared 
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to the CD44 positive populations (Figure 3.6d). Coupled with the result that the 
CD44 positive populations were unable to generate iPS colonies, and therefore were 
delayed in the reprogramming process compared to the CD44 negative cells, this 
indicated that some form of transgene down-regulation is indeed required for 
successful reprogramming. However, this appeared to be an intrinsically 
determined process requiring some key change/s to occur within the cells 
themselves before transgene expression can be down-regulated, as these cells did 
not complete reprogramming when dox (and therefore transgene expression) was 
removed. 
 
3.2.4 Comparison of novel cell surface marker and Nanog-GFP expression 
 In order to enhance analysis of the reprogramming process of the novel 
markers, and investigate correlation with pluripotency gene expression, iPS cell 
lines were generated by Dr. Kaji using pBTAP IRI 2LMKOSimO from RosartTA/rtTA 
MEF carrying a Nanog-GFP reporter (Chambers et al., 2007). A single integration 
clone, D6s4B5 was identified, expanded and used for further experiments. 
 After RA differentiation, the D6s4B5 line efficiently underwent 
reprogramming in the presence of dox (Figure 3.7a). In addition to the previously 
described morphology changes and mOrange up-regulation associated with this 
reprogramming system, a small number of Nanog-GFP+ cells could be identified by 
day 8 of reprogramming. These cells rapidly expanded and large, Nanog-GFP+ iPS 
cell-like colonies could be obtained. In addition it was observed that mOrange 
expression appeared to be down-regulated in the cells which had acquired GFP 
expression. This down-regulation could also be observed by flow cytometry (Figure 
3.7b). Over a time-course of cells undergoing reprogramming it was found that 
GFP+ cells appeared to arise not from the cells expressing the highest levels of 





(Figure 3.7b, Day 5, Day 8+Dox). Also of note was that the cells expressing the 
highest levels of GFP appeared to eventually down-regulate expression of mOrange 
to an even lower level (Figure 3.7b, Day 11+Dox). This again supported the idea that 
reprogramming factor down-regulation was required for successful iPS cell 
Figure 3.6: CD44 expression as a marker 
of reprogrammed cells. a. Populations 
sorted at day 8 of reprogramming. b. Purity of 
sorted populations. c. Typical appearance of 
sorted cells cultured in the absence of dox. d. 
mOrange expression of sorted populations at 




generation. Flow cytometry was also used to investigate the correlation of 
pluripotency gene expression and the novel cell surface markers identified from the 
microarray data. 
CD44 expression was found to have a negative correlation with Nanog-GFP 
expression (Figure 3.7c). There was almost a complete absence of CD44+GFP+ cells 
during the time-course, with GFP+ cells only appearing once CD44 expression had 
been almost totally down-regulated. This finding went some way towards 
explaining the previous observation that cells which had lost CD44 expression, but 
not yet gained SSEA1 expression, could give rise to reprogrammed colonies (Figure 
3.6d). 
The more heterogeneous pattern of ICAM-1 expression compared to CD44 
at the later stages of reprogramming was also reflected in the appearance of Nanog-
GFP+ cells at Day 8, a significant minority of which were observed in an ICAM- 
population (Figure 3.7d). However, at the later stages of reprogramming the 
majority of the GFP+ cells were also ICAM-1+. Interestingly, this appeared to suggest 
that cells which do not have an iPS cell-like expression profile can express Nanog-
GFP. 
Nanog-GFP+ cells were initially observed in SCA1+ cells at day 8, however as 
time passed they appeared to lose SCA1 expression (Figure 3.7e). This again 
indicated that even cells which have not yet acquired an iPS cell-like phenotype can 
express pluripotency genes. The wide distribution of SCA1 expression among the 
Nanog-GFP+ cells was unique compared to ICAM-1 and CD44 in which it appeared 
only minor populations of Nanog-GFP+ cells did not express an ES cell-like 








Figure 3.7: Nanog-GFP expression correlates with an ICAM-1+CD44- 
phenotype. a. Morphology, mOrange and Nanog-GFP expression of RA 
differentiated iPS cell clone D6s4B5 during 2˚ reprogramming. Time-course analysis 
by flow cytometry of mOrange expression compared to b. Nanog-GFP, c. CD44, d. 
ICAM-1 and e. SCA1 expression during 2˚ reprogramming. 
 
3.2.5 ICAM-1 and CD44 expression defines a stable reprogrammed population 
 The ability to identify a population of cells in a heterogeneous culture which 
behaved similarly to fully reprogrammed iPS cells would be an extremely useful 
tool. However such systems would be required to be reliable and reproducible, and 
as it had previously shown a good correlation with iPS cell colony formation (Figure 
3.6c), the loss of CD44 expression was further investigated. Similarly, the close 
correlation between ICAM-1 expression and a gain of Nanog-GFP expression was 
also of interest. 
 Time-course analysis during reprogramming of RA differentiated cells was 
carried out and highlighted a pathway to an iPS cell-like profile of gradual CD44 
loss followed by a gain of ICAM-1 expression (Figure 3.8a). Loss of CD44 expression 
was strongly correlated with gain of Nanog-GFP expression, although a significant 
number of Nanog-GFP-ICAM-1-CD44- cells could still be observed. 
 Cells expressing the iPS cell phenotype of ICAM-1+CD44- were isolated from 
a culture undergoing reprogramming (Figure 3.8b). iPS cell-like colonies which 
expressed Nanog-GFP arose from this sorted population both in the presence and 
absence of dox, with low levels of background differentiation (Figure 3.8c). This 
indicated that this profile may correctly identify cells that are either fully 
reprogrammed or at least in the latter stages of reprogramming displaying 








Figure 3.8: ICAM-1 and CD44 expression identifies an end point of 
reprogramming. a. Reprogramming time-course of RA differentiated cells stained 
for ICAM-1 and CD44 expression. b. Sorting strategy 5 days post dox addition of 
ICAM-1+CD44- cells (white box) and profile of sorted populations cultured +/-dox as 
indicated. c. Colony formation observed in sorted population +/-dox after 7 days. d. 
Sorting strategy for cells not expressing an iPS cell profile. e. Profile of sorted 
populations 2, 4 and 7 days post sort. 
  
To further dissect the relevance of ICAM-1 and CD44 expression before the 
acquisition of an iPS cell-like profile, the GFP+ and GFP- populations outside of this 
gate were isolated and re-plated (Figure 3.8d). Flow cytometric analysis of the 
isolated populations revealed a conserved pattern of changes in cell surface marker 
expression (Figure 3.8e). 
After 2 days of further culture in the presence of dox, the majority of the 
Nanog-GFP+ sorted cells were found to be CD44-, and the majority of cells had 
acquired ICAM-1 expression. By day 4 post sort most cells had up-regulated ICAM-
1 expression and cells maintained this profile after a further 3 days. Some Nanog-
GFP- cells could be observed, however the vast majority of cells maintained GFP 
expression. 
 The Nanog-GFP- cells appeared to maintain a similar profile post sort, with a 
minority of GFP+ cells expressing an iPS cell profile after 2 days of culture. This 
population appeared to increase over the following four days, with a gradual loss of 
CD44+GFP- cells and a gain in ICAM-1-CD44- cells, of which 1/3 expressed Nanog-
GFP. By day 7 there was a loss of the ICAM-1+CD44+ population with most GFP- 
cells ICAM-1-. Interestingly, a significant number of Nanog-GFP- cells could be 
observed to display an ICAM-1+CD44- iPS cell profile by day 7 post sort.  
 These results indicated that cells reproducibly acquire an ICAM-1+CD44- 
phenotype during reprogramming, irrespective of the initial starting expression 
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profile. Nanog-GFP expressing cells appeared to behave in a more homogeneous 
manner with down-regulation of CD44 rapidly followed by up-regulation of ICAM-
1. The GFP- cells behaved in a more heterogeneous manner, and it was not clear 
from which population ICAM-1+CD44- cells arose: either being derived in a similar 
manner to the GFP+ cells from cells which lost CD44 expression; from the double 
positive cells; or indeed from both. In addition, the gain of Nanog-GFP expression 
did not occur homogeneously, which indicated there may be more than one 
pathway towards the reprogrammed state in cells which had not yet acquired 
Nanog-GFP expression. 
 
3.2.6 Defined populations to identify reprogramming pathway 
 The heterogeneity of the Nanog-GFP- cells indicated that further subdivision 
of the non-reprogrammed cells was required to further dissect the reprogramming 
process. In both the GFP+ and GFP- sorted cells, it was clear that CD44 down-
regulation was conserved thus this marker was used to further define sub-
populations. Cells which did not display an iPS cell profile of ICAM-1+CD44- were 
isolated from a culture undergoing reprogramming, and were separated based on 
differences in CD44 expression alone (Nanog-GFP+ cells), or on CD44 and ICAM-1 
(Nanog-GFP- cells) (Figure 3.9a). Cells in each population were isolated and re-
plated in the presence of dox, and all populations gave rise to Nanog-GFP+ iPS cell 
colonies after 4 days of culture in the presence of dox (Figure 3.9b). 
 The non-reprogrammed Nanog-GFP+ cells which did not express CD44 
(Figure 3.9c 2NG+) were found to rapidly up-regulate ICAM-1 expression as 
expected. These cells maintained an iPS cell phenotype with low levels of Nanog-
GFP- cells arising. The CD44 expressing cells (1NG+) appeared to have poorer 
growth (data not shown) and after two days a small number of cells were observed 
to express an iPS cell profile. The remaining cells appeared to lose GFP expression, 
and surprisingly, after a further 2 days of culture an ICAM-1-CD44- population was 
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apparent, the majority of which expressed Nanog-GFP. These cells appeared to 
behave similarly to the 2NG+ population and rapidly acquired ICAM-1 expression 
after a further two days. 
 The Nanog-GFP- populations which had been divided into ICAM-1-CD44- 
(3NG-), ICAM-1-CD44+ (2NG-) and ICAM-1+CD44+ (1NG-) were similarly analysed 
in order to determine if the heterogeneity of this population had been reduced 
(Figure 3.9c). Similarly to 2NG+, the 3NG- population dramatically up-regulated 
ICAM-1 expression after 2 days of culture, with GFP+ cells identified in both ICAM-
1+/- cells. Longer culture continued this trend, with increasing numbers of GFP+ cells 
and an increase in ICAM-1 expression. Population 2NG+ had been identified as 
being of interest, as unlike the Nanog-GFP+ cells, of which the CD44+ population 
was very minor, in GFP- cells it was unclear if loss of ICAM-1 expression was 
required for the CD44+ cells to undergo reprogramming (Figure 3.8e, Nanog-GFP-). 
It was observed that after two days of culture roughly 1/3 of cells had down-
regulated CD44 expression and about half of these had acquired an ICAM-1+CD44- 
profile. Few cells appeared to express Nanog-GFP outside of this iPS cell-like 
phenotype. This loss of CD44 expression continued and by day 6 post sort the 
majority of cells were CD44-/Nanog-GFP+. Surprisingly, the 1NG- population 
appeared to behave in a similar manner to 2NG-, and there was a clear loss of the 
ICAM-1+CD44+ cells after 4 days while the ICAM-1- population appeared to be 
maintained, while this result did not preclude the possibility that double positive 
cells contribute to reprogramming, they may represent a more minor, non-sustained 





Figure 3.9: Identifying a route to the reprogrammed state using ICAM-1 and 
CD44. a. Sorting strategy 5 days post dox addition of ICAM-1+CD44- cells 
subdivided into Nanog-GFP+/- populations (white boxes). Nanog-GFP+: 2 = ICAM-1-
CD44-; 1 = ICAM-1-CD44+. Nanog-GFP-: 3 = ICAM-1-CD44-; 2 = ICAM-1-CD44+; 1 = 
ICAM-1+CD44+. b. Colonies formed from each sorted sub-population after 4days 
culture in the presence of dox. c. Analysis of ICAM-1 and CD44 expression profile 
2,4 and 6 days post sorting of sub-populations. NG+, NG- refers to Nanog-GFP 




3.3.1 Novel cell surface markers for reprogramming intermediates. 
 The microarray analysis based on reprogramming of the 6c cell line was 
found to accurately provide an insight into the dynamics of cell surface marker 
expression. SSEA1 expression had previously been identified as an early marker of 
reprogramming intermediates (Stadtfeld et al., 2008a). However, my data indicated 
that further discrimination of cells within the SSEA1+ fraction is required, with one 
population of cells found to be expressing ES cell-like levels of this marker 
completely failing to generate reprogrammed colonies. This finding suggests that 
during reprogramming alongside successful intermediates, populations arise which 
may not be capable of generating iPS cells. This highlights the importance of 
understanding the mechanism of reprogramming and using the correct markers to 
do so. 
 Unlike SSEA-1 expression, the novel markers ICAM-1, CD44 and SCA1 were 
found to show differences in their expression pattern later in reprogramming time-
course experiments. SCA1 expression displayed a pattern of early up-regulation 
followed by rapid down-regulation. A recent study attempted to use SCA1 
expression to discriminate between populations in a starting culture of MEF 
(Nemajerova et al., 2012). It was found that cells negative for the MEF cell-surface 
marker THY-1and either positive or negative for SCA1 were capable of undergoing 
reprogramming more efficiently; suggesting THY-1 is a better marker of the 
reprogramming state of MEF then SCA1. In addition, also among their findings it 
was indicated that expression of this marker can be driven by the reprogramming 
factor KLF4. Therefore the initially high level and subsequent down-regulation of 
Klf4/reprogramming factor expression, may be responsible for inducing the similar 
pattern of SCA1 detected during reprogramming in the ICAM-1/CD44 system.  
 ICAM-1 and CD44 expression, in contrast to SCA1, displayed a more simple 
gain and loss pattern respectively which proved useful for identification of 
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reprogramming intermediates. ICAM-1 expression appeared to be up-regulated 
almost exclusively at the latter stages of reprogramming. Some slight down-
regulation of ICAM-1 was observed when sorted cells were plated in the absence of 
dox, however these cells still generated iPS cell-like colonies and maintained 
Nanog-GFP expression. The down-regulation of CD44 appeared to be a key event 
during reprogramming, as evidenced by the fact that cells positive for this marker 
could not efficiently generate iPS cell colonies in short term culture. Although a 
minor double positive population was observed, it was unclear if these cells lost 
ICAM-1 expression, and in general CD44 down-regulation appeared to be a 
prerequisite for ICAM-1 up-regulation. Combined staining of cells with ICAM-1 
and CD44 highlighted an apparent route to a fully reprogrammed ICAM-1+CD44-
Nanog-GFP+ state as evidenced by the stable, transgene independent nature of this 
sorted population. This retinoic acid based differentiation system may not accurate 
represent changes that occur during reprogramming from more differentiated cell 
types however, and further work was required to confirm these observations in 
somatic cell reprogramming (see Chapter 4). 
 
3.3.2 Down-regulation transgene expression during reprogramming 
While the commonly used marker SSEA1 failed to accurately identify cells at 
different stages of the reprogramming process, down-regulation of the mOrange 
transgene reporter appeared to correlate with reprogramming success. Similarly, 
cells expressing low levels of ICAM-1 or high levels of CD44 were found to have 
high levels of mOrange. This further supports the use of these markers to untangle 
the process of reprogramming, and indicates that continued high-level 
reprogramming factor expression is incompatible with successful reprogramming. 
This is similar to the observations of many viral reprogramming studies which 
reported incomplete reprogramming associated with continued viral transgene 
expression, and more recently a secondary reprogramming system which 
demonstrated that continued transgene expression may suppress full acquisition of 
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the reprogrammed state (Hotta and Ellis, 2008; Stadtfeld et al., 2008a; Golipour et al., 
2012).  This suggests another advantage of using a polycistronic vector for delivery 
of reprogramming factors is the ability to couple their expression to a reporter 
which itself can be used as an indicator of the progression of reprogramming. It 
should be noted that complete down-regulation of the reprogramming factors was 
not required to generate iPS cells using pBTAP IRI 2LMKOSimO. This has also been 
observed in viral mediated reprogramming of human cells with a polycistronic 
vector (Papapetrou et al., 2009). However, high transgene expression does appear to 
be required for successful reprogramming, as at least some portion of sorted CD44+ 
cells were capable of generating Nanog-GFP+ colonies. 
 
3.3.3 Nanog-GFP expression during RA differentiated cell reprogramming 
During reprogramming, populations of Nanog-GFP+ cells could be detected 
outside of the iPS cell-like profile of ICAM-1+CD44-. Isolation of these cells 
highlighted that they achieved a reprogrammed profile more rapidly than their 
Nanog-GFP- counterparts; however, these cells also appeared to follow the process 
of CD44 down-regulation followed by ICAM-1 up-regulation. Further experiments 
were required to establish the relevance, if any, of these changes in cell surface 
marker expression (see Chapter 4). Also of note was the observation that while GFP- 
sorted cells appeared capable of giving rise to a minor population of ICAM-1-CD44-
GFP+ cells, CD44+GFP+ cells were almost undetectable. This indicated that these cell 
surface markers may be capable of dissecting the latter stages of reprogramming in 
detail, even after the expression of key pluripotency genes, and suggested the 
potential for heterogeneity in the state or behaviour of Nanog expressing cells 
during reprogramming, as observed in live cell imaging of the reprogramming of 
human cells (Chan et al., 2009). In addition, how cells achieve a fully reprogrammed 
state could be inferred, with some, rarer cells activating Nanog-GFP expression 
early (CD44+) and rapidly completing the reprogramming process compared to the 
apparent majority of cells that only up-regulate GFP after CD44 expression is lost in 
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a process that is slightly delayed. One caveat of these results however, is the 
possibility that the in vitro differentiation model used to obtain the above results 
may not accurately reflect the kinetics of Nanog-GFP expression and up-regulation 
during reprogramming, and as with all of the optimisation experiments described in 
this chapter, required re-examination in a more practical, biologically relevant 





CHAPTER 4 - Identification of a route to iPS cells from MEF 
 
4.1 Introduction 
 Mouse embryonic fibroblast (MEF) cultures are among the most commonly 
used cell types to generate iPS cells, due to their use in the original study of 
reprogramming and ease of preparation (Takahashi and Yamanaka, 2006). The vast 
majority of subsequent work using this cell type has identified a number of key 
features of reprogramming, some of which have been successfully observed in the 
reprogramming of other cell types or cells from other species (Takahashi et al., 2007; 
Hanna et al., 2008; Li et al., 2009b; Ye et al., 2009). MEF have also been widely used 
in the screening and identification of small molecules which have been shown to 
increase the reprogramming efficiency, in terms of either increasing the total 
number of iPS cell colonies produced or accelerating the appearance of iPS cell 
colonies (reviewed in Feng et al., 2009b). For the majority of compounds identified, 
for example the use of “2i” (GSK3 and FGFR inhibitor) conditions to generate fully 
reprogrammed cells from pre-iPS cells, it is unclear as to whether their use enhances 
the process (i.e. more cells successfully complete reprogramming) or rather their use 
simply selects for those cells which are most capable of adapting in drug-
supplemented culture (Silva et al., 2008). In addition, it may be possible that cells 
achieve a fully reprogrammed state by a variety of pathways, with small molecules 
enhancing one route over another. This may be especially relevant in the case of 
reprogramming MEF cultures which are typically heterogeneous in nature, and 
therefore an accurate system to monitor changes in cells undergoing 





 4.1.1 Aims of this chapter 
 The aim of this chapter is to assess the use of the identified novel cell surface 
markers ICAM-1 and CD44 in reprogramming from MEF. In addition, other 
reprogramming systems were utilised to examine the reproducibility of this marker 
system. Changes in reprogramming efficiency and how this related to expression of 
these markers was also carried out. Finally, based on observations from these 
experiments a number of intermediate reprogramming populations were identified, 
isolated and scrutinised in order to determine how reprogramming progresses and 





4.2.1 Efficient generation of iPS cells from transgenic MEFs 
 The iPS cell line D6s4B5 was used to generate chimeric embryos from which 
secondary (2°) MEF were isolated (Figure 4.1a). Varying concentrations of dox 
(1.5ug mL-1 to 60ng mL-1) were tested to determine what concentration was optimal 
for 2˚ MEF reprogramming, with 300ng mL-1 found to generate the greatest number 
of colonies (data not shown). During reprogramming cells were observed to up-
regulate reprogramming factor expression, undergo morphological changes, 
generate large iPSC-like colonies and eventually express Nanog-GFP (Figure 4.1b). 
In order to investigate if the reprogramming efficiency of this secondary 
system could be further increased, 2˚ MEF were cultured in the presence of vitamin 
C (VitC, 10ug mL-1) and/or A83-01, an inhibitor of the activin receptor-like kinase 
receptor 4,5,7 (ALKi, 500nM) which is involved in the TGF-β signalling pathway, 
both of which have been shown to have a positive effect on reprogramming 
efficiency (Esteban et al., 2010; Li et al., 2010). Both VitC and ALKi dramatically 
increased the total number of AP+ colonies generated compared to dox alone (~8 
fold), and surprisingly, an even greater increase (~25 fold) was observed when these 
small molecules were used in combination (Figure 4.1c). This culture condition 
(dox/VitC/ALKi) was used for all further experiments with the D6s4B5 iPS cell line, 
unless otherwise stated. 
Colony formation was closely monitored in order to understand the nature 
of reprogramming in this secondary system (Figure 4.1d). After initial up-regulation 
of reprogramming factor expression it was observed that cells rapidly clustered in 
small groups. Shortly thereafter cell death was observed among certain cells in the 
colonies. Cells which survived this period then rapidly expanded and eventually 
up-regulated Nanog-GFP expression. A direct correlation could be made between 
the time at which colonies reached this minimum size and the subsequent up-
regulation of the Nanog-GFP reporter, suggesting that not all cells are capable of 
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successfully completing reprogramming even after successful transgene up-
regulation and clustering, and that a type of “selection” occurs during the 
reprogramming process with only successful cells surviving (Figure 4.1e). 
Figure 4.1: Efficient reprogramming system to generate iPS cells. a. Overview 
of secondary reprogramming system from MEF. b. Colony formation in the presence 
of dox. c. Colony formation was greatly enhanced in the presence of VitC and ALKi. 
d. Monitoring of colony formation during reprogramming revealed clustering of 
transgene expressing cells with only some cells capable of completing successful 
reprogramming (Nanog-GFP up-regulation). e. The timing of minimum colony 
appearance was correlated with subsequent Nanog-GFP expression. 
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4.2.2 Previously reported cell surface markers are not closely correlated with                           
Nanog-GFP expression 
 MEFs undergoing reprogramming were initially examined via FACS 
analysis for the dynamics of mOrange and Nanog-GFP expression (Figure 4.2a). It 
was observed that mOrange expression was rapidly up-regulated and maintained 
for about 7 days before Nanog-GFP expressing cells were observed. Interestingly 
Nanog-GFP+ cells did not appear to arise from cells expressing the highest level of 
the reprogramming factors; rather they appeared from a population of cells 
expressing slightly lower levels of mOrange (Day 8). This underlines the importance 
of establishing the correct level of reprogramming factor expression for successful 
reprogramming. As the Nanog-GFP+ population matured and expanded, these cells 
displayed a further gradual down-regulation of mOrange (reprogramming factor) 
expression. This is similar to the loss of transgene expression widely associated with 
completed reprogramming in retroviral reprogramming systems (Maherali et al., 
2007; Okita et al., 2007; Wernig et al., 2007). Next, reprogramming cells were 
examined for their expression of the widely used, previously reported MEF 
associated marker THY-1, as well as the ES cell-associated cell surface markers E-
CADHERIN and SSEA-1. 
THY-1 expression in the transgenic MEF was found to be quite broad, with 
both THY-1high and THY-1low populations (Figure 4.2b). After 4 days of dox addition 
and reprogramming factor expression, a loss of the THY-1high population could be 
observed. By day 6 of reprogramming almost all cells had lost THY-1 expression, 
and no further THY-1 expression could be detected during the reprogramming 
process. As expected, all Nanog-GFP+ cells arising during reprogramming were 
THY-1-. 
It has been widely reported that during reprogramming cells undergo a 
mesenchymal-to-epithelial (MET) transition (Li et al., 2010; Samavarchi-Tehrani et 
al., 2010). E-CADHERIN is a marker of cells which have successfully undergone 
this transition (Figure 4.2c). As expected, MEF, as a mesenchymal cell type, were 
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negative for this marker. However, 2 days of transgene expression was sufficient to 
generate E-CADHERIN expressing cells, resulting in almost 100% of cells positive 
for this marker by day 6 of reprogramming. Some residual cells failed to up-regulate 
E-CADHERIN expression, however Nanog-GFP+ cells were observed to only arise 
from the E-CADHERIN+ population. 
SSEA-1 is a classical marker of undifferentiated ES cells (Solter and 
Knowles, 1978). After four days of transgene expression a minor population of 
SSEA-1+ cells were observed. By day 6 about 50% of the cells expressed SSEA-1, and 
this proportion was maintained throughout the remainder of the reprogramming 
process and in fully reprogrammed iPS cells. Interestingly, unlike the markers THY-
1 and E-CADHERIN, it appeared that Nanog-GFP+ cells arose from both SSEA-1 
negative and positive populations (Day 8, Day 10), consistent with broad SSEA-1 
expression levels in undifferentiated ES/iPS cells (Figure 4.2d). In order to determine 
the source of SSEA-1-/Nanog-GFP+ cells, we isolated cells at day 5 of 
reprogramming, before the appearance of Nanog-GFP+ cells (Figure 4.3a). These 
cells were sorted based SSEA-1 expression and re-plated in reprogramming 
conditions (Figure 4.3b). SSEA-1 expression was observed to fluctuate in both sorted 
populations, indicating that SSEA-1 expression is not stable in the latter stages of 
reprogramming. In addition, Nanog-GFP+ cells arose from both sorted populations 
by day 2 after sorting, indicating SSEA-1 expression does not predict the appearance 








































































































































































































































































































































































































































































































































































































4.2.3 CD44, ICAM-1 and Nanog-GFP expression dynamics during reprogramming 
reveal distinct population changes 
MEF undergoing reprogramming were examined for CD44 and ICAM-1 
expression in order to confirm the previous observations made using the in vitro 
retinoic acid differentiation system (Chapter 3). 
CD44 expression was found to be relatively high and homogeneous in the 
undifferentiated MEF (Figure 4.4a). Expression of this marker was found to be 
maintained at this high level until at least day 6 of reprogramming. At day 8, a 
population of CD44- cells could be observed. Nanog-GFP+ cells were found almost 
exclusively in this CD44- population. This trend was confirmed upon continued 
reprogramming, with the vast majority of Nanog-GFP+ cells found in the CD44- 
population. 
The pattern of ICAM-1 expression in MEF was observed to be relatively 
broad (Figure 4.4b). Upon initiation of reprogramming factor expression this broad 
expression is maintained. However, around day 6 there is a marked decrease in the 
ICAM-1high population. This was followed, at day 8, by an increase of the ICAM-1high 
population, concurrent with a gain in Nanog-GFP expression. By day 12 of 
reprogramming the majority of Nanog-GFP+ cells were ICAM-1+, similar to fully 
reprogrammed iPS cells. 
Unlike the previously described markers (Section 4.2.2), the changes in both 
the loss of CD44 and gain of ICAM-1 expression appeared to be closely correlated 
with a gain in Nanog-GFP expression. This suggested that these markers may be 
more suitable to identify intermediate stages of the reprogramming process by 
providing an insight to events occurring between the gain of E-CADHERIN 
expression and up-regulation of pluripotency genes. Also of note is that the 
expression pattern of both CD44 and ICAM-1 closely matched that observed in the 
retinoic acid differentiation system, suggesting that this in vitro method is suitable 




Figure 4.4: FACS analysis of CD44 and ICAM-1 expression during secondary 
reprogramming from MEF. a. Expression of CD44 was monitored upon transgene 
induction. Note correlation of CD44 down-regulation and Nanog-GFP appearance at 
Day 8. b. ICAM-1 expression during reprogramming. c. CD44/ICAM-1 double 
staining was carried out during secondary reprogramming. Percentages indicate 
proportion of cells in each gate. Red; Nanog-GFP- cells, Green; Nanog-GFP+ cells. 
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In order to further investigate the significance of CD44 and ICAM-1 
expression changes, cells undergoing reprogramming were double-stained for these 
markers (Figure 4.4c). As expected MEF displayed high CD44 and broad ICAM-1 
expression. By day 4 more than 50% of cells had down-regulated ICAM-1 
expression. At day 6 a small proportion (~6%) of cells had also down-regulated 
CD44 expression, giving rise to a double negative population. At this stage, a small 
proportion of ICAM-1 single positive cells were also observed (~2%). This 
population, which displayed an iPS cell-like CD44-/ICAM-1+ phenotype, appeared 
more prominent at day 8, with almost a quarter of cells found within this gate. 
FACS analysis at subsequent time-points (Day 10, 12) revealed an increase in this 
ICAM-1 single positive population concurrent with a decrease in the CD44-/ICAM-1- 
population. 
Interestingly, we identified cells expressing the Nanog-GFP reporter before 
the acquisition of a CD44-/ICAM-1+ surface marker profile. A small proportion (<1%) 
of CD44+/-/ICAM-1- cells at day 6 were found to Nanog-GFP+. While the Nanog-
GFP+/ CD44+ population remained minute, at days 8, 10 and 12 a significant 
population of Nanog-GFP+/CD44-/ICAM-1- cells could be observed. At day 8 a 
similar proportion of Nanog-GFP+/CD44-/ICAM-1+ cells were detected however, 
unlike their ICAM-1- counterparts, cells in this gate appeared to readily expand, and 
at later stages represented the largest population present in the reprogramming 
cultures (Day 10, 12). Significantly however, despite the appearance of GFP+ cells, 
GFP- cells could always be detected in the same gates, usually in greater proportion, 
and even at the later stages of reprogramming (e.g. Day 8, 10, 12). 
CD44+/ICAM-1+ cells appeared to rapidly disappear from cultures 
undergoing reprogramming. In order to investigate if the heterogeneity of ICAM-1 
expression in the starting population of MEF influenced the dynamics of the 
reprogramming process, cells were sorted based on ICAM-1 expression and re-
plated in reprogramming conditions (Figure 4.5). FACS analysis indicated that both 
ICAM-1+ and ICAM-1- MEF followed a similar pattern of cell surface marker 
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changes. The kinetics of the reprogramming process were also largely identical with 
a very slight delay in ICAM-1+ sorted MEF in CD44 down-regulation. This data 
indicated that ICAM-1 expression does not distinguish the reprogramming potential 






















































































































































































































These results suggested that during reprogramming from MEF, cells follow 
a distinct series of changes in CD44 and ICAM-1 marker expression, with ICAM-1 
down-regulation followed by gradual CD44 down-regulation which in turn is 
followed by a rapid up-regulation in ICAM-1 expression. The dynamics of Nanog-
GFP reporter activation in relation to these markers did not appear to be as 
straightforward however, with the appearance of both Nanog-GFP+ and –GFP- cells 
in populations with identical ICAM-1/CD44 expression profiles. Therefore more 
accurate analysis in order to determine how these markers correlated with the 
reprogrammed state was required. 
 
4.2.4 Identification of intermediate populations of the reprogramming process 
The previous results indicated that during reprogramming from MEF, 
ICAM-1 and CD44 expression could potentially be used to identify different stages 
in the reprogramming process. However, FACS analysis reveals only the total 
number of cells within each gate at the time of analysis. This means that it is not 
possible to accurately determine if the observed changes in population dynamics are 
the result of one population arising from another, or is simply the rapid expansion 
of one population over another. This may in fact be a common issue with many 
reprogramming studies, and the idea that “more” reprogrammed cells may grow 
more favourably in stem cell conditions is plausible. To this end, we attempted to 
isolate the individual populations identified using CD44 and ICAM-1 and closely 
monitor their behaviour. In addition, in order to identify the expression dynamics of 
the Nanog-GFP reporter, cells in Nanog-GFP+ and GFP- sub-populations were 
isolated.  
Day 10 of reprogramming was selected as this time-point consistantly 
displayed enrichment for all identified populations of interest (Figure 4.6a). Nanog-
GFP+ (NG+) or Nanog-GFP- (NG-) cells were further subdivided based on their 
expression of CD44 and ICAM-1: CD44+ICAM-1+ (Gate 1 with 1NG-, 1NG+ 
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populations); CD44-ICAM-1- (Gate 2 with 2NG-, 2NG+ populations); and CD44-
ICAM-1+ (Gate 3 with 3NG-, 3NG+ populations.) The CD44+/ICAM-1+ populations 
were not isolated due to their very low numbers and later experiments indicated 
these cells do not represent a significant reprogramming pathway (see Figure 4.6b).  
 
 
Figure 4.6. CD44/ICAM-1 sub-populations represent distinct stages of 
reprogramming. a. Nanog-GFP+ (NG+) and Nanog-GFP- (NG-) cells were 
subdivided into CD44+ ICAM-1- (Gate1), CD44- ICAM-1- (Gate 2) and CD44- ICAM-
1+ (Gate 3) populations at day 10 of reprogramming. b. FACS analysis of sorted 
sub-populations after 3 day culture in the presence of dox. Red; Nanog-GFP- cells, 
Green; Nanog-GFP+ cells. 
 
Cells were sorted from 1NG+/- and 2NG+/- in order to monitor their 
progression during the reprogramming process. 3NG+/- populations were not 
sorted as they already expressed the iPS cell CD44-ICAM-1+ phenotype and 
represented a stable end point with regard to the novel cell surface markers’ profile. 
The sorted populations were re-plated in reprogramming conditions and re-
analysed for CD44, ICAM-1 and Nanog-GFP expression after a further 3 days of 
culture (Figure 4.6b). 2NG+ cells were found to maintain Nanog-GFP expression  
and rapidly gained ICAM-1 expression, entering Gate 3. Their Nanog-GFP- 
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counterparts (2NG-) also gained ICAM-1 with apparent ease, however, in contrast 
to the 2NG+ population where around 1% of cells retained a double negative profile 
(ICAM-1-/CD44-), 8.5% of 2NG- cells maintained this phenotype. Surprisingly, 1NG+ 
cells, which represented the smallest population at day 10, showed down-regulation 
of CD44 expression and produced a large 3NG+ population. Interestingly, unlike the 
2NG+ populations not all cells appeared to maintain Nanog-GFP expression, most 
notably those cells which did not downregulate CD44 expression, although GFP- 
cells could be found in all three gates. Finally, analysis of the 1NG- population 
revealed that although the majority  (69%) of cells were CD44-, few of these cells had 
also gained ICAM-1 expression (18%), and fewer still Nanog-GFP expression (~5%). 
In addition, the reprogramming kinetics of the 1NG- population are delayed, with 
greater numbers of 1NG- and 2NG- cells observed compared to the 1NG+ sub-
population. 
Taken together, these results suggested that reprogramming proceeded in 
the order of Gate 1Gate 2Gate 3. However, it was also clear that expression of 
the Nanog-GFP reporter had an effect on the kinetics of the movement from each 
gate/stage to the next. In order to determine if these kinetic differences reflect the 
probability of each sub-population to successfully undergo reprogramming, cells 
were again isolated at day 10, including 3NG+/- populations, and plated at clonal 
density (Figure 4.7). Cells were cultured for an additional ten days after 
reprogramming and Nanog-GFP positive colonies were quantified and compared to 
a sorted, fully reprogrammed iPS cell line. From this analysis we identified the 
3NG+ population as having a similar colony forming potential (cfp) as fully 
reprogrammed iPS cells, suggesting this population was close to a completely 
reprogrammed state. The other isolated populations displayed a range in their cfp 
which appeared to be correlated to how distant each population was from attaining 
a 3NG+ profile. Interestingly, 3NG- cells, although bearing an iPS cell-like CD44 and 
ICAM-1 profile, had a much reduced cfp compared to 3NG+. Similarly, among 
populations with the same CD44/ICAM-1 cell surface marker profile, in all cases the 
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Nanog-GFP+ cells displayed a greater ability to generate colonies, consistant with 




Figure 4.7: Relative probability to generate Nanog-GFP+ iPS cell colonies. Day 
10 sorted sub-populations were plated and GFP+ colonies counted after 10 days of 
culture in reprogramming conditions and compared to fully reprogrammed iPS cells. 
Error bars represent standard deviation, n=3. 
 
4.2.5 Behaviour of sorted sub-populations reveals distinct characteristics of 
reprogramming 
While analysis at 72 hours revealed the macro-behaviour of the sorted populations, 
this time period was sufficient to allow more rapid proliferation of one population 
over another. This obscured the actual transition rate of each individual sub-
population. Therefore, a greater level of accuracy was required to understand the 
mechanism of reprogramming. This was achieved by sorting all populations at day 
10 and carrying out re-analysis after just 24 hours of continued culture in 
reprogramming conditions (Figure 4.8). Surprisingly, the overall result of this 
experiment did not vary greatly from that carried out at 72 hours, thus confirming 
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the original analysis on the characteristics of each sub-population. Of note however, 
is the sorting of the 3N populations. While 3NG+ barely changed after 24 hours, 
supporting the idea that this is a stable and reliable marker set with which to define 





This analysis also enabled the identification and quantification of the total 
number of cells arising from each sub-population and their tendency to move to the 
next stages of reprogramming as defined by the CD44/ICAM-1/Nanog-GFP marker 
system (Figure 4.9). Further supporting the identification of the 3NG+ population as 
being very similar to fully reprogrammed iPS cells, we discovered that this 
population maintains its phenotype and rapidly expands in culture. In contrast, 
3NG- cells have a lower capacity to proliferate, and a small number of cells can 
successfully transition to a 3NG+ state. 2NG+ cells rapidly gain 3NG+ status and a 
minor number of cells remain 2NG+ or lose GFP expression to become 2NG-. 2NG- 
cells tend to transition rapidly to 3NG-, with low Nanog-GFP activation. This  
Figure 4.8: CD44/ICAM-1/Nanog-GFP expression re-analysed 24 hours 
after sorting. Sub-populations were sorted at day 10 and underwent FACS 
analysis after 24 hours of culture in reprogramming conditions. Red; Nanog-







Figure 4.9: Total number of cells in each gate after 24 hours for day 10 sorted 
populations. Each reprogramming population was sorted at day 10 and cells 
cultured in reprogramming conditions for 24 hours. Cells were then harvested and 
CD44/ICAM-1/Nanog-GFP expression was re-analysed. Total cell numbers found in 




population also shows a higher level of proliferation than 2NG+ cells. As observed, 
the 1NG+ cells have the potential to transition rapidly to the final 3NG+ state, 
however, they appear to be somewhat heterogeneous in their behaviour, generating 
similar numbers also of 2NG- and 3NG- cells. Finally, 1NG- cells display a more 
predictable pattern, with approximately half the total cells in a 2NG- state, with the 
remainder maintaining their sorted phenotype. 
In order to investigate if the observed transition trend was a conserved 
characteristic of the cells in each identified gate, and was not specific to day 10 sub-
populations, similar 24 hour analysis was carried out at day 8 of reprogramming 
(Figure 4.10). This revealed that although the proportions of each of the identified 








Figure 4.10: Behaviour of Day 8 sorted sub-populations are similar to that of 
day 10 sub-populations. a. Sorting strategy at day 8 of reprogramming. b. Each 
sub-population sorted at day 8 was re-plated in reprogramming conditions, and 
reanalyzed after 24 hours. c. Total cell numbers in each gate after 24 hour analysis 
for each sorted population. The error bars represent the standard deviation. n=3. 
Red; Nanog-GFP- cells, Green; Nanog-GFP+ cells. 
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4.2.6 Validation and application of CD44/ICAM-1 reprogramming marker system. 
 Before progressing with further analysis using the CD44/ICAM-1 marker 
system and its associated sub-populations, it was important to validate the 
usefulness of these markers in other contexts. This would ensure that these 
observations were reproducible and not context specific. 
 The 6c cell line was generated using 4 separate piggyBac vectors to deliver 
the dox inducible reprogramming factors c-Myc, Klf4, Oct4 and Sox2 (Woltjen et al., 
2009). Using secondary MEF isolated from 6c generated chimera, secondary 
reprogramming and FACS analysis was carried out (Figure 4.11a). Despite the 
absence of a pluripotency reporter, CD44 and ICAM-1 expression could be used to 
identify cell surface marker changes during the reprogramming process. It was 
observed that the changes in CD44/ICAM-1 expression recapitulated the 
observations made using the D6s4B5 cell line. The majority of cells were ICAM-1low 
by day 6 of reprogramming, and by day 10 some cells had lost CD44 expression. 
Some cells expressed an ES cell-like ICAM-1+/CD44- profile, and this population was 
larger at a later time-point (day 14). This indicated that even in systems containing 
multiple, random insertions of the reprogramming factors these novel markers 
could be used to trace the fate of cells undergoing reprogramming.  
Another potential issue identified with this marker system is its potential for 
use in lower efficiency, but vastly more common, primary reprogramming contexts. 
Primary reprogramming was carried out using the same vector used to generate the 
D6s4B5 cell line, pB TAP IRI MKOSimO (MKOS), and a modified version in which 
the polycistronic reprogramming cassette was replaced with factors in the order of 
Oct4, Sox2, Klf4 and c-Myc (OSKM, prepared by Dr. Eleni Chantzoura)(Carey et al., 




Figure 4.11: The reprogramming pathway is conserved in different 
reprogramming systems. a. Non-polycistronic PB 2o reprogramming with the 6c 
cell line. b. Primary PB reprogramming using both MKOS and OSKM polycistronic 
cassettes. c. Typical colonies arising from MKOS, OKMS primary PB 
reprogramming. Red; Nanog-GFP- cells, Green; Nanog-GFP+ cells. 
 
It had been observed that the colonies generated using the MKOS and 
OSKM vectors differed somewhat, with some OSKM-derived colonies failing to 
down-regulate mOrange expression and similarly fail to acquire Nanog-GFP 
expression (Figure 4.11c). Further differences became apparent in the course of the 
primary reprogramming experiments; OSKM cultures appeared to down-regulate 
ICAM-1 expression more rapidly than MKOS cells (Day 6), however this apparent 
advantage was lost at later stages of reprogramming with MKOS cultures reaching 
3NG+ more quickly and in greater numbers (Day 10). This experiment highlighted 
how differences observed in the kinetics of reprogramming using this marker 




Figure 4.12: Secondary reprogramming in the presence of dox, ALKi either 
with or without VitaminC (+ or -VitC). a. Both total and Nanog-GFP+ colony 
numbers decreased in the absence of VitC. b. Cells reprogrammed in the absence 
of VitC displayed delayed reprogramming kinetics. Red; Nanog-GFP- cells, Green; 
Nanog-GFP+ cells. 
 
As previously described, secondary reprogramming from MEF in the 
presence of both ALKi and VitC greatly increased colony number (Figure 4.1c). In 
order to investigate if this marker system could respond to changes in 
reprogramming efficiency mediated by small molecules, cells were reprogrammed 
in the absence of VitC, but in the presence of dox and ALKi (Figure 4.12). As 
expected, there was a decrease both in total colony number, and also in the number 
of Nanog-GFP+ colonies generated in the absence of VitC (Figure 4.12a). FACS 
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analysis of cells undergoing reprogramming in these conditions revealed a delay in 
down-regulation of CD44 expression at day 6 compared to the +VitC cultures 
(Figure 4.12b). At day 8, cells also appeared to be stalled at the 2NG- stage (CD44-
/ICAM-1-/Nanog-GFP-), with this population seemingly delayed in its ability to 
increase ICAM-1 expression (Day 10). In addition, the transition to 3NG+ appeared 
to be somewhat hindered, with an accumulation of cells in the 3NG- stage (Day 12). 
These results confirmed that this marker system could be used to identify those 
populations of cells which were specifically affected by the action of small 





4.3.1 Efficient reprogramming from secondary MEF 
 In order to accurately study the intermediate stages of reprogramming, a 
highly efficient reprogramming system was required. In the identification of the 
single integration D6s4B5 clone and subsequent cell line, much of the variability of 
reprogramming factor expression was addressed as the reprogramming factors 
were expressed in all cells simultaneously from an identical locus. The presence of 
insulator and replicator sequences in the reprogramming construct served two 
purposes; to help maintain high expression of the reprogramming factors during 
initial primary and subsequent secondary reprogramming, and to prevent in vivo 
differentiation-mediated modifications to the transgene-containing locus which may 
prevent re-expression of the reprogramming factors (Fu et al., 2006; Gaszner and 
Felsenfeld, 2006). While the presence of these genetic elements slightly reduced the 
average number of transgene insertions compared to constructs without (data not 
shown), it is unclear what effect they had upon transgene expression during 
secondary reprogramming. 
The D6s4B5 reprogramming system displayed a reprogramming efficiency 
of ~3%, which is comparable to that described for MEF in the original secondary 
reprogramming system established in Rudolf Jaenisch’s lab, (Wernig et al., 2008). 
This study posited insufficient transgene expression as a potential reason for this 
lower than expected efficiency, however, as illustrated in Figure 4.1d, many cells 
which do not successfully complete the reprogramming process appear to express 
high levels of the reprogramming factors. More likely is the inherent heterogeneity 
of the starting MEF population which can be observed at the cell surface-marker 
level (Figure 4.2b, 4.4b), and probably also at the epigenetic level, as outlined in 
another study from the Jaenisch lab (Meissner et al., 2007). Indeed, many small 
molecules which modulate histone-modifying enzymes have been reported to 
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positively influence reprogramming from MEF, given appropriate reprogramming 
conditions (see section 1.4.2). 
While retrovirus silencing has long been associated with pluripotent cells, 
the down-regulation of reprogramming factors in this study’s non-viral piggyBac 
transposon system suggests that this event may be important in ensuring successful 
reprogramming, and not simply a consequence of virus-mediate delivery of 
reprogramming factors (Hotta and Ellis, 2008). Supporting this, a recent report 
identified that continued dox-mediated expression of reprogramming factors at 
later stages (day 17) of reprogramming actually prevented up-regulation of a 
number of genes associated with the pluripotency network including endogenous 
Sox2, Utf1 and Dppa4 (Golipour et al., 2012). 
 
4.3.2 Conventional markers are limited in their use during reprogramming 
 One of the most important findings from these experiments was the 
discovery that many commonly used markers of reprogramming were simply 
unsuitable for discriminating between cells which can successfully complete 
reprogramming and those which fail. Identification of ICAM-1 and CD44 enabled 
isolation of defined populations of cells which appeared to display specific 
reprogramming potentials and could be used to trace the progress of the MEF to iPS 
cell process. 
 THY-1 expression was rapidly down-regulated, as previously reported 
(Stadtfeld et al., 2008a). This confirms that the use of such early markers is not 
suitable to investigate the latter events of reprogramming such as pluripotency gene 
up-regulation.  
 It has previously been reported that SSEA-1 expression is 
heterogeneous in ES cells, and sorting experiments have indicated that purified 
SSEA-1+ and SSEA-1- sorted populations recreate pre-sort heterogeneity in an 
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identical manner within three days of re-plating (Cui et al., 2004). This is similar to 
my finding that expression of SSEA-1 remains relatively heterogeneous and 
constant after only 6 days of reprogramming (Figure 4.2d). This data along with the 
other findings outlined above suggests that SSEA-1 is not a reliable marker with 
which to isolate cells undergoing reprogramming, as at later stages SSEA-1- 
populations are just as likely to be undergoing successful reprogramming (Figure 
4.3).  
The E-CADHERIN expression data generated in this reprogramming system 
also casts doubt on another “cornerstone” of reprogramming (Figure 4.2c). This 
marker was found to display rapid kinetics, with almost all cells positive for this 
marker after 4 days of reprogramming factor expression in this reprogramming 
system. This finding questions the importance of the MET which has been the focus 
of much interest since it was first implicated in reprogramming (Li et al., 2010). That 
cells undergo this transition so readily suggests that it does not actually represent a 
major barrier to the reprogramming process in this system. Further to this, data 
from our lab has shown that even in the absence of ALKi, cells undergo MET just as 
efficiently as their inhibitor-treated counterparts (Tyson Ruetz, in preparation). 
Further study of this mechanism in the context of iPS cell generation may not 
actually yield useful information about the molecular requirements of successful 
reprogramming. 
 
4.3.3 ICAM-1 and CD44 are superior markers for tracing the reprogramming 
process 
Murine ICAM-1 was first isolated using the rat monoclonal antibody YN1/1 
and identified to have high similarity to the human Icam-1 (Horley et al., 1989). A 
member of the immunoglobulin (Ig) supergene family, it is one of 5 intercellular 
adhesion molecules identified, so named due to their Ig-like domains expressed on 
the extracellular portion of the cellular membrane (Hayflick et al., 1998). ICAM-1 is 
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expressed on vascular endothelial cells, lymphocytes and monocytes, but typically 
expressed only at low levels (Rothlein et al., 1986). ICAM-1 has been reported to be 
the ligand for the β2 integrin molecules LFA-1 (CD11a/CD18 = α1β2 integrin) and 
MAC1 (CD11b/CD18 = αMβ2 integrin) present on leucocytes (Staunton et al., 1990). 
Elevated levels of ICAM-1 are induced upon stimulation of cells with inflammatory 
cytokines (Dustin et al., 1986). This was abolished in ICAM-1 homozygous mutant 
mice, which, despite displaying retarded lymphocyte migration and decreased 
inflammatory response, were otherwise viable (Sligh et al., 1993).  
ICAM-1 was reported to be expressed at homogeneously high levels in 
mouse ES cells, however its specific receptors (LFA-1 and MAC1) were found to be 
absent, suggesting this marker does not play a functional role in these cells, despite 
maintaining lymphocyte-binding ability, and upon differentiation, a response to 
IFN-γ stimulation (Tian et al., 1997). Up-regulation of Icam-1 expression has been 
associated with activation of the LIF signalling target Stat3 in glioblastoma cells 
treated with ionising radiation, suggesting a potential link between these factors 
(Kesanakurti et al., 2012) However, this up-regulation was dependent on the 
presence of activated nuclear factor-κВ (NF-κВ), and Tian et al. (1997) reported that 
treatment of ES cells with the NF-κВ-activator tumour necrosis factor alpha (TNFα), 
failed to increase ICAM-1 expression levels. These results indicate that knockdown 
or blocking of ICAM-1 would more than likely not be detrimental to the 
reprogramming process, and as shown in Figure 4.5, the initial ICAM-1 expression 
in the starting MEF population appeared to have little influence over the 
reprogramming pathway. 
 CD44 was identified in the early 1980s as a cell-surface molecule on 
lymphocytes (Gallatin et al., 1983). It was soon linked to cancer-initiating cells 
(CICs) isolated from many different tissues, and discovered to be a member of the 
cartilage link protein family (Goldstein et al., 1989; Stamenkovic et al., 1989; Naor et 
al., 2008). Encoded by a single gene, many variants of CD44 have been described 
which arise through differences in N-glycosylation and O-Glycosylation patterns 
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and from various splicing products found in the extracellular domain of the protein 
(Screaton et al., 1992). Expression of CD44 is dependant of the specific variant, with 
the most common or standard being CD44s which is expressed on most vertebrate 
cells (Naor et al., 2008). The isoform found on epithelial cells, CD44v, is also found 
during early embryonic development and is associated with lymphocyte maturation 
and activation (Ruiz et al., 1995). Oligomerization of CD44 proteins at the cellular 
membrane can occur mediated via the transmembrane region, and results in the 
formation of glycolipid-enriched domains which can play an important role in 
mediating signal transduction (Oliferenko et al., 1999). Finally, the cytoplasmic tail 
of the CD44 proteins can interact with cytoskeletal proteins which can influence cell 
migration and shape (Fehon et al., 2010). 
CD44 has been reported to be associated with certain signalling pathways 
found in both stem cells and transformed cancerous cells. For example, over-
expression of CD44 in colorectal adenoma-carcinoma appears to be a direct result of 
aberrant Wnt signalling associated with the cancerous state (Wielenga et al., 1999). 
In addition, hyaluronan (HA) binding to CD44 has been described to result in 
protein kinase Cε (PKCε) activation in breast, head and neck tumour cells, which 
results in NANOG phosphorylation and translocation to the nucleus (Bourguignon 
et al., 2009; Bourguignon et al., 2012). However as CD44 is absent in ES cells, this 
function is probably highly context dependent. Intriguingly there appear to be 
numerous associations between the expression of CD44 and the epithelial-to-
mesenchymal transition (EMT), which is in direct opposition to the required MET 
during reprogramming (see section 1.3.4 for a fuller discussion of MET and iPS cell 
generation). In breast cancer cells, over-expression of SLUG, a key protein required 
for EMT, appears to result in a shift to a CD44+ phenotype (Bhat-Nakshatri et al., 
2010). The TGF signalling pathway is responsible for driving EMT during 
development and there is evidence that TGFβ-receptor I can be activated by 
HA/CD44 interaction which leads to EMT-associated cellular reorganization 
(Bourguignon et al., 2002; Takahashi et al., 2010). The Takahashi study also utilised 
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CD44 knockout mice and found that EMT failed to occur. While this suggests that 
CD44/HA signalling in MEF may actually function to maintain the mesenchymal 
phenotype and interference with this signalling pathway may positively influence 
reprogramming, my results clearly showed CD44 expression was maintained after a 
gain in E-CADHERIN expression (Figures 4.2b, 4.4a). This suggests CD44 has little 
control over the progression of MET during reprogramming. 
The above data suggests the functional activity of CD44 and ICAM-1 is most 
likely unimportant for iPS cell generation, and bears little impact on interpretation 
of results obtained using this reprogramming system. Combined staining for ICAM-
1 and CD44 expression during the reprogramming process was capable, however, of 
tracing the movement of cells from one stage of reprogramming to the next. In 
addition, the ability to monitor, via mOrange expression, only those cells expressing 
the reprogramming factors greatly increased the accuracy of this study’s analysis. 
Loss of ICAM-1 expression appears to be the first major transition using this marker 
system. The subsequent down-regulation of CD44 may indicate a significant change 
in cellular character, as observed in the in vitro reprogramming system when loss of 
its expression appeared more indicative of successful reprogramming compared to 
SSEA-1 (Chapter 3, Figure 3.5). The subsequent gain of ICAM-1 expression and 
acquisition of an ES cell-like phenotype provides, for the first time, an accurate 
profile with which iPS and iPS-like cells can be isolated from MEF undergoing 
reprogramming. 
These markers also highlighted the heterogeneity of MEF cultures 
undergoing reprogramming. This heterogeneity was actually found to occur within 
the cells that comprise individual colonies, as illustrated by immunofluorescence 
staining (Figure 4.13). This further emphasises the requirement of suitable markers 
during reprogramming in order to isolate and group together cells from different 




Figure 4.13: Immunofluorescence for CD44 and ICAM-1 at day 6, 8 and 10 after 
reprogramming initiation. Cells in a single colony have distinct CD44, ICAM-1, 
Nanog-eGFP expression, indicating clonal analysis is not sufficient to isolate cells in 
similar stages. Note expression of mOrange tends to be low in colonies with Nanog-
eGFP+ cells consistent with this study’s flow cytometry data. (Image provided by 
Tyson Ruetz). 
 
4.3.4 Nanog has a key influence on reprogramming from MEF 
 Investigation of the three ICAM-1/CD44 identified populations was further 
enhanced through the use of the Nanog-GFP reporter. Interestingly, Nanog-GFP 
expression was observed in all sub-populations, even those not displaying an ES 
cell-like profile (Figure 4.4c, GFP+ panels). It should be noted however, that Nanog-
GFP expression appeared to still be closely linked to completion of reprogramming 
as the overall representation of these cells was correlated with a movement towards 
ES cell-like ICAM-1/CD44 profile, reflecting the importance of this molecule in 
establishing pluripotency (Silva et al., 2009). In the past, reporters of Nanog 
expression have been used as strict indicators of completed reprogramming 
(Maherali et al., 2007; Okita et al., 2007; Wernig et al., 2007). Probably due to the 
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consistent use of selective agents for Nanog in all three cases, these studies reported 
homogenous Nanog expression in iPS cells generated from MEF. This approach does 
not take into account the possibility that Nanog expression may occur 
asynchronously during reprogramming, and indeed in all cases, delayed 
administration of the selective agent resulted in an increase in Nanog positive iPS 
cell colonies. As illustrated in Figure 4.13, the D6s4B5 secondary reprogramming 
system generated colonies that displayed heterogeneous activation of the Nanog-
GFP reporter during reprogramming. This suggests that selective approaches may 
aberrantly target cells which are in fact undergoing successful reprogramming, but 
have not yet activated the Nanog promoter. This therefore decreases the quality and 
quantity of data obtained from these studies regarding the reprogramming process. 
In addition, the use of egfp cDNA in the original cell line from which D6s4B5 was 
derived may have resulted in a more sensitive reporter than the gfp used in the 
previous studies, which could have influenced the selection of lines for 
expansion/further study etc (Hatano et al., 2005; Maherali et al., 2007).  
 Isolation of the ICAM-1/CD44 populations and their further subdivision 
based on Nanog-GFP expression highlighted the importance of using a reporter of 
pluripotent gene activity, as this marker was capable of identifying distinct sub-
populations of cells undergoing reprogramming (Figure 4.6). For each sorted sub-
population, the presence of the Nanog-GFP reporter appeared to benefit the 
reprogramming process. The three day analysis of the sorted populations (Figure 
4.6b) revealed two interesting aspects of this reprogramming system; 1) Sorted 
Nanog-GFP- cells, despite progressing through ICAM-1/CD44 profile changes, did 
not readily up-regulate Nanog-GFP, and 2) in contrast to this, a significant 
population of 1NG+ cells appeared to lose GFP expression but still showed 
enhanced progression of the reprogramming process compared to 1NG- cells. In 
contrast, 2NG+ cells did not lose GFP expression, suggesting a possible stabilisation 
of Nanog-GFP expression, which may also go some way towards explaining the 
proportional increase of GFP+ cells observed (1NG+<2NG+<3NG+) at the time of 
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sorting (Figure 4.6a). This may be associated with increased expression of accessory, 
complementary pluripotency factors, or an epigenetic-mediated modification of the 
locus enabling enhanced Nanog promoter activity as cells progress towards a more 
reprogrammed cell-state (Buganim et al., 2012; Fidalgo et al., 2012). 
The apparent differences in 1NG+/- reprogramming kinetics were also 
observed to influence their cfp (Figure 4.6). However, in contrast, 2NG+ cells 
produced a higher cfp than 2NG-, despite the similar rapid gain in ICAM-1 
expression displayed by both populations. Interestingly, despite the heterogeneous 
nature of Nanog expression in ES cells and fully reprogrammed iPS cells, 3NG- 
produced fewer Nanog-GFP colonies than 3NG+ even though both populations 
displayed an iPS cell-like ICAM-1/CD44 profile. These results highlight the 
limitations of using these cell-surface markers in isolation, and the importance of 
integrating the Nanog-GFP reporter into this reprogramming strategy. 
 
4.3.5 Reprogramming from MEF occurs in a step-wise, reproducible pattern 
 Analysis of the isolated sub-populations after 24 hours provided some of the 
most clear information about the possible routes available to cells undergoing 
reprogramming in this system (Figure 4.8). The differences observed between this 
data and the 72 hour analysis highlight one of the major issues with many 
reprogramming studies; the expansion of more/fully reprogrammed populations 
over others present in the culture. It is clear from the cell counting data that the 
sorted 3NG+ population rapidly expands, even within the two ES cell-cycles 
theoretically possible in 24 hours. All of the other sorted populations show 
generation of some 3NG+ cells, and it is the expansion of this population that is 
detected in the 72 hour analysis.   
Closer examination of the subsequent transitions of each of the sorted 
populations revealed that Nanog-GFP- populations appeared to prefer a direct 
transition to the next NG- population, with a low number of cells acquiring GFP 
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expression after 24 hours. While 3NG- cells were more similar in terms of ICAM-1 
expression, the transition to 3NG+ was relatively low. (Note: Nanog-GFP expression 
has been reported to fluctuate in ES cells, however after 24 hours only 6% of Nanog-
GFP- cells become Nanog-GFP+. This is in contrast to the ~25% of 3NG- cells which 
transition to 3NG+ after 24 hours in this study. This suggests the 3NG- population 
does not simply represent the Nanog low cells found in LIF/serum ES cell culture, 
but is in fact a distinct reprogramming intermediate (Chambers et al., 2007)). Many 
of the NG- populations also showed some propensity to maintain their sorted 
profile, a feature most pronounced with 1NG- cells. This suggests that some of these 
populations may act as sinks or reservoirs for cells whose transition to the next stage 
of reprogramming is prevented by as yet unknown hurdles which must be 
overcome for efficient iPS cell generation. 
In contrast, apart from 3NG+, which appeared to represent a population 
similar to fully reprogrammed iPS cells, the NG+ populations did not display much, 
if any, self-renewal. The contrast between the rapid, almost homogenous transition 
of 2NG+ cells to 3NG+ and the very heterogeneous behaviour of the 1NG+ 
population, despite its Nanog-GFP expression, is striking. I speculate that at the 
single cell level, while both 1NG+ and 2NG+ cells have short lives in culture, the 
actual cellular characteristics of the 2NG+ group is more stably defined. As cells 
approach a more reprogrammed state, as with 2NG+ cells, it is conceivable that ES 
cell-associated factors, including pluripotency genes and epigenetic regulators, 
become increasingly active and regulated, with alternative behaviour, i.e. 
intermediate characteristics, becoming less favourable (Buganim et al., 2012; 
Golipour et al., 2012). On the other hand, 1NG+ cells may be the result of fortunate, 
but rare and temporal activation of reprogramming associated factors, the 
expression of which can neither be sustained nor is sufficient to establish a stable 
pluripotency network centred on the activation of the core factors Nanog, Oct-4 and 
Sox2 (Chambers and Tomlinson, 2009). In addition, as previously illustrated (Figure 
4.1d), in comparison to cells at the later stages, early stage reprogramming 
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populations appear to express much higher levels of the reprogramming factors. 
These transcription factors have numerous targets and their very use in 
reprogramming is due to their ability to drive cells towards a pluripotent state by 
aberrantly activating their targets in non-physiological contexts, therefore these 
factors may also contribute to the premature appearance of the 1NG Nanog-GFP+ 
population (Soufi et al., 2012). 
The observation that each of the sub-populations displayed distinct, 
reproducible behaviour has enabled the construction of a “route map” from MEF to 
iPS cells (Figure 4.14). This analysis focused on the major transitions that cells 
undergo from one stage of the reprogramming process to the next. This 
visualization of the data attempts to highlight that in the case of this secondary 
reprogramming system, cells appear to have more than one option in order to 
achieve successful reprogramming: 1) Cells that fail to up-regulate Nanog-GFP 
expression at the early stages of reprogramming (1NG-) continue on a relatively low 
efficiency route with late stage activation of Nanog-GFP (1NG-  2NG-  3NG-  
3NG+); and 2) Those few cells which both activate and maintain Nanog-GFP 
expression early in the reprogramming process (1NG+) appear to use a more 
efficient route, transitioning to the final reprogrammed state with some ease (1NG+  




This data indicates that although reprogramming is a stepwise event with 
cells passing through distinct stages, there is more than one route via which this 
process can occur. These findings also highlight the strength of using an accurate 
marker and reporter system. As shown in Figure 4.11b and 4.12, this system is 
robust enough for use even in lower efficiency primary reprogramming and in the 
context of altered reprogramming conditions, as the intermediate stages of 
reprogramming as identified by ICAM-1, CD44 and Nanog-GFP expression were 
largely conserved, even if the reprogramming kinetics may be altered. This data also 
shows that cells within individual colonies undergo reprogramming in a 
heterogeneous manner, and highlights the importance of identifying these different 
populations of cells. This enables much more accurate and thorough understanding 
of how reprogramming truly happens as different culture conditions, 
reprogramming systems and combinations of reprogramming factors can be 
compared to each other. For example, it has recently been shown that VitC acts to 
enhance reprogramming by reducing the levels of H3K9 methylation (Chen et al., 
2013). Using this marker system VitC treated and untreated populations could be 
Figure 4.14: Major transitions (>500 cells) of each population within 24 
hours at day 10 of secondary reprogramming. Y axis indicates relative colony 






isolated, their behaviour monitored, and individual populations analysed via 
H3K9me3 ChIP-seq to identify the most important sites of methylation loss. This 
type of approach is currently being applied in our lab to investigate the role of ALKi 
in reprogramming, and to compare the differences that appear during 
reprogramming with MKOS and OSKM reprogramming polycistronic cassettes. 
However, in all cases, identification of the different population dynamics represents 
merely the first step in understanding how a gene or molecule acts to affect 
reprogramming. RNA-sequencing analysis of the different stages of reprogramming 





CHAPTER 5 - High resolution analysis of sub-
populations provides novel insights into the molecular 
mechanisms of reprogramming 
 
5.1 Introduction 
Many studies of cells undergoing the reprogramming process utilise next-
generation sequencing technologies in order to probe the mechanism of iPS cell 
generation (Samavarchi-Tehrani et al., 2010; Golipour et al., 2012; Soufi et al., 2012). 
While these methods can provide information on the general progression of the 
reprogramming process there are a number of issues with regards the resulting data 
from these studies. The resolution of the resulting data is low as most strategies 
utilise bulk cultures of cells, a minority of which will successfully complete 
reprogramming. In addition, as demonstrated by the data in Chapter 4, even in 
secondary systems, cells undergoing reprogramming do not behave 
homogeneously, with different sub-populations and expansion of more-/fully-
reprogrammed cells in culture. This means that sampling in bulk gives the average 
of cells at different stages of reprogramming rather than reflecting the different 
discrete stages of the reprogramming process. 
Reduction in the background “contaminating” signal of cells which fail to 
become iPS cells is crucial, and this can only be achieved through the use of high-
efficiency reprogramming systems. However, these systems have yet to be 
combined with accurate population analysis due to a lack of suitable markers to 
identify intermediate stages of the reprogramming process. In addition, many 
methods require some pre-existing knowledge or expectation regarding the analysis 
output, for example the selection of primers and probes to detect known factors in 
single-cell QPCR analysis, which limits discovery of novel mediators of the 
reprogramming process (Buganim et al., 2012). These technical limitations have 
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obscured correct analysis and understanding of the reprogramming process and 
must be addressed for the best use of these technologies.  
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5.1.1 Aims of this chapter 
 The aim of this chapter is to outline the results of the RNA sequencing 
(RNAseq) analysis carried out on the identified reprogramming sub-populations. 
Analysis of this data identified differentially expressed genes between each sub-
population which identified five distinct gene expression patterns occurring during 
reprogramming from MEF. This analysis revealed that pluripotency gene up-
regulation was identified to occur in two waves, which were classified as “Early” 
and “Late” relative to each-other. In addition, more un-expected patterns of gene 
expression were identified with transient up- and down-regulation of certain factors 
found to occur during reprogramming, providing a unique insight into the 
mechanism of iPS cell generation. Further investigation of transiently up-regulated 
genes revealed that during reprogramming from MEF, cells express epidermis-
associated genes, and this was confirmed by immunofluorescence and single cell 
QPCR analysis. Finally, another reprogramming system which displayed lower 
reprogramming efficiency compared to the D6s4B5 cell line was also subjected to 
RNA-sequencing of the same sub-populations. Comparison of the gene expression 
profile of this cell line to D6s4B5 was used to identify novel transcription factors 
which enhanced the efficiency of primary reprogramming. 
Note 1: All bioinformatic processing of data, including GeneProf processing of raw 
data, identification of differentially expressed genes (DEGs), clustering analysis, 
principal component analysis (PCA), gene ontology (GO) enrichment, and other 
applications of R were carried out by Dr. Stavroula Skylaki . Interpretation of some 
of this data was carried out by Dr. Keisuke Kaji. 
Note 2: All single-cell QPCR experiments and data processing was carried out by 




5.2.1 Sample collection for RNA sequencing analysis 
 In order to more fully investigate the nature of the identified reprogramming 
sub-populations, RNAseq analysis was carried out in collaboration with the 
Linnarsson group, which has developed a multiplexed RNA sequencing system as 
outlined in section 2.3.3 (Islam et al., 2011; Islam et al., 2012). Briefly, day 10 sorted 
sub-populations were FACS-sorted from three different experiments and RNA 
isolated. RNA quality was measured and at least two samples from each population 
were used for analysis. Control samples included the D6s4B5 iPS cell and E14 ES 
cell lines, as well as both wild-type MEF and D6s4B5 transgenic MEF isolated at 
E12.5. In addition, it had been observed that while the 3NG+ population at day 10 
had a similar colony forming potential (cfp) as fully reprogrammed iPS cells, this 
was only in the continued culture of dox-containing media. 3NG+ cells isolated at 
day 10 of reprogramming were cultured at clonal density in the absence of dox, and 
it was observed that the cfp of this population was roughly 60% that of D6s4B5 iPS 
cells (Figure 5.1, 3NG+). However, when 3NG+ cells isolated at day 15 of 
reprogramming were cultured in the absence of dox, the cfp was now found to be 
similar to D6s4B5 iPS cells (Figure 5.1, 3NG+ D15). This indicated that a further five 
days of culture in reprogramming conditions was sufficient to enable all 3NG+ cells 
to reach a dox-independent state. This population was also included for analysis as 
comparison of this population to 3NG+ at day 10 could yield important information 
about the stabilisation of the exogenous-factor-independent reprogrammed state. 
However, it may be the case that this event does not represent a major barrier for 
successful reprogramming in this system, as all 3NG+ cells appeared to undergo this 






Figure 5.1: Nanog-GFP Colony formation potential of 3NG+ cells in the 
absence of dox. 3NG+ cells sorted at day 10 (3NG+) and day 15 (3NG+D15) of 
reprogramming were plated at clonal density in the absence of dox. The number of 








5.2.2 Identification of differentially expressed genes 
The raw data obtained from the RNAseq analysis was processed using 
GeneProf which allowed quality control and alignment of the obtained reads to the 
genome (Figure 5.2, see section 2.3.4 for methods used) (Halbritter et al., 2012).  
 
 
Figure 5.3: Hierarchical clustering of sub-populations based on DEG 
expression. a. Number of DEGs between samples identified via both edgeR and 
DESeq are indicated with arrows as shown. b. Agglomerative hierarchical clustering 
based on Pearson’s Correlation Coefficient with complete linkage. P-values were 
adjusted using a threshold for false discovery rate (FDR) ≤ 0.05. Green and red 




The total number of reads per sample, per gene, was quantified, and this 
allowed identification of the differentially expressed genes (DEGs, FDR ≤ 0.05) 
between each of the sub-populations (Figure 5.3a). This list of genes was then used 
to carry out hierarchical clustering of the sub-populations and revealed four major 
branches: [MEF], [1NG-/+], [2NG-/+ and 3NG-/+], and [3NG+D15, iPSCs and ESCs] 
(Figure 5.3b). 
This data highlighted the relatively high reproducibility among the three 
experiments used to collect the RNA for this analysis. In addition, 3NG+D15 cells 
were identified to be more similar to iPS and ES cells than to day 10 3NG+ cells 
(Figure 5.4a). PCA analysis of the DEGs identified a distinct difference between 
2NG+ and 3NG- sub-populations (Figure 5.4b). 
 
 
Figure 5.4: Analysis of reprogramming intermediates and fully reprogrammed 
iPS cells. a. Comparison of gene expression profiles between iPSCs and 3NG+, 
3NG+D15 and ES cells. b. PCA analysis of sub-populations using DEGs. Green and 




This appeared to reflect the two previously identified routes to the fully 
reprogrammed state, as observed from FACS analysis of the sub-populations, 
reflecting their different probabilities to successfully transition to the 3NG+ state 
(Figure 5.4b, red and green paths). 
 
5.2.3 DEG expression patterns reveal processes of reprogramming 
 The DEGs could be further categorized based on their expression pattern 
across the clustered sub-populations (Figure 5.5). This analysis revealed 5 major 
gene expression patterns among the DEGs during reprogramming (A-E). Some of 
the expression patterns were expected, such as Group A which indicated genes 
expressed in MEF but down-regulated in reprogramming intermediates and 
pluripotent cells, Group D which showed late-reprogramming-stage up-regulation 
of genes expressed in pluripotent cells but not in MEF, and Group C contained 
genes up-regulated early in, and maintained throughout, the reprogramming 
process and in iPS/ES cells. More unexpected was the identification of genes 
expressed at a similar level in both MEF and iPS/ES cells, but which showed 
transient up- (Group B) or down-regulation (Group E) exclusively in the 
reprogramming intermediate populations.  
 Gene ontology (GO) analysis was carried out using DAVID (see 
Supplementary Table 3 in Appendix)(Huang da et al., 2009). Group A was enriched 
for genes associated with diverse functions, but especially enriched for cell 
adhesion, extracellular matrix organisation and signal transduction-associated 
factors, as previously reported from microarray analysis of MEF (Tanaka et al., 
2002). Group D contained genes associated with pluripotency. Interestingly, 
pluripotency genes were also found in Group C, suggesting that there may be a 
number of genes important for establishing iPS cells that are more easily re-
activated than others (Buganim et al., 2012; Golipour et al., 2012). 
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Further investigation of this data was carried out via comparison to other 
published datasets. A recent report identified genes down-regulated in MEF very 
rapidly (within 3 cell-cycles) after reprogramming factor expression (Koche et al., 
2011). In my data, a number of these genes were similarly down-regulated in all day 
10 sub-populations and ES/iPS cells compared to MEF, indicating that Group A 
most likely contained genes down-regulated at the early stages of reprogramming 
(Figure 5.6a). Similarly, the expression pattern of 22 pluripotency-related genes in 
my data set was examined (Kim et al., 2008a; Xu et al., 2010). Including endogenous 
Oct4 (Pou5f1), 8 pluripotency genes were already up-regulated at the 1NG+/2NG- 
stages to the level found in 3NG+ cells (Figure 5.6b, Group C), while 14 pluripotency 
genes were more gradually up-regulated in the later stage reprogramming 





Figure 5.5: Global gene expression changes during stage transitions. 
Hierarchical clustering of samples with DEGs and expression heat map. Groups 




Figure 5.6: Gene expression changes during reprogramming. a. Down-
regulation of genes expressed in reprogramming factor-un-induced MEF 
populations. b. Early and late up-regulation of pluripotency-related genes. 
 
 
Figure 5.7: Epidermis gene expression during secondary reprogramming. 
Transient up-regulation of epidermis and keratinocyte genes is rapidly lost in 2NG+ 
and 3NG+/- populations. 
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5.2.4 Epidermis genes are up-regulated during reprogramming  
While a loss of fibroblast character and gain of pluripotent cell properties is 
consistent with previous findings (Brambrink et al., 2008; Stadtfeld et al., 2008a; Li et 
al., 2010; Samavarchi-Tehrani et al., 2010), the identification of Groups B and E, with 
their transient expression pattern found exclusively in the intermediate stages of 
reprogramming, warranted further investigation, as this finding suggested that 
reprogramming from MEFs to iPSCs was not simply the loss of MEF genes and gain 
of ES cell genes. 
GO analysis of Group E produced a small number of terms, with heart and 
tube development comprising the majority of hits. The significance of the transient 
down-regulation of these developmental processes is unclear, however this finding 
suggested that the transition from MEF to iPS cells may involve unexpected factors 
and processes. 
 Genes related to ectoderm/epidermis development and keratinocyte 
differentiation were highly enriched (P≤0.000274) in Group B. Down-regulation of 
those epidermis genes appeared to coincide with the second, later wave of 
pluripotency gene up-regulation, suggesting MEFs expressed multiple epidermis-
related genes before reaching a pluripotent state (Figure 5.7). In addition, analysis of 
expressed sequence tag (EST) data of different developmental stages and tissues in 
the mouse failed to identify co-expression of these epidermis genes in any one single 
tissue, and significantly nor at any stage of embryonic development (Supplementary 
Table 5, Appendix). This suggested that during reprogramming cells do not simply 
reverse developmental processes.  
The RNAseq analysis was carried out on populations of cells which 
displayed heterogeneous behaviour (Figure 4.7, 4.8). Therefore the observed 
transient up-regulation of epidermis associated genes may be the result of a minor 
population expressing high levels of these genes. Epidermis gene expression was 
identified by single-cell qPCR for Ehf and Ovol1, detected in ~65% and 70% of 1NG- 
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cells (Figure 5.8d). This analysis also confirmed the co-expression of epidermis 
genes with the earlier up-regulated pluripotency genes, but not the later set.  
Single cell qPCR is limited by the number of cells used for analysis, and in 
order to investigate how the RNAseq analysis correlated with protein expression, 
immunofluorescence staining was carried out for two epidermis markers, SFN and 
KRT17 (Figure 5.8). These proteins were barely detectable in MEFs and iPSCs, while 
transient up-regulation was observed in the intermediate stages of reprogramming 
(Figure 5.8a,b). By day 9 of dox treatment both SFN and KRT17 were expressed 
throughout colonies undergoing reprogramming. SFN protein appeared to be 
down-regulated before the onset of Nanog-GFP expression. KRT17 protein was 
detectable in some Nanog-GFP+ cells, however KRT17 staining was highest in 
mOrangehigh, Nanog-GFP- cells (Figure 5.8c). In summary this data, in addition to 
the RNAseq single cell QPCR analysis, indicated that during reprogramming from 
MEF most cells express epidermis-associated genes. This expression pattern was 
greatest at the earlier stages of reprogramming, during an initial wave of 
pluripotency gene expression, but was down-regulated concurrent with a second 




































































































































































































































































































































































5.2.5 Identification of candidate genes to improve reprogramming efficiency 
 Splinkerette PCR was used to identify the site containing the reprogramming 
vector in D6s4B5 iPS cells (data not shown, carried out by Laurence Lemier). The 
vector was found to be integrated into the Sp3 locus, and the suitability of this locus 
for efficient reprogramming was investigated. Nanog+/GFP, Rosa+/rtTA (RTANG) ES 
cells were targeted with PB-TAP IRI 2LMKOSimO at the Sp3 locus to produce 
Sp3+/PB-TAP IRI 2LMKOSimO ES cells (TANGO ES cells, all work carried out by Dr. Eleni 
Chantzoura and Dr. Keisuke Kaji). This ES cell line was used to generate chimera 
from which MEF were isolated for secondary reprogramming (TANGO MEF). 
Despite expressing the reprogramming factors from the same locus as 
D6s4B5 MEF, TANGO cells appeared to be somewhat hindered in undergoing the 
reprogramming process (Figure 5.9a). While 3NG+ cells could eventually be 
detected, this appeared to be due to the expansion of a small number of cells, with 
the majority failing to undergo reprogramming. Cells were sorted in each of the six 
NG populations at day 10 of reprogramming (Figure 5.9b). The cfp of each of the 
sorted TANGO populations was almost 50% lower than that of the corresponding 
D6s4B5 populations (Figure 5.9c). Surprisingly, the 3NG+ TANGO population had a 
similar cfp as D6s4B5 cells. This suggested that although reprogramming was 
hindered at earlier stages, the few cells that successfully completed this process 





Figure 5.9: TANGO undergoes reprogramming less efficiently than D6s4B5. a. 
FACS analysis of secondary MEF undergoing reprogramming. b. TANGO MEF 
sorting at day 10 of reprogramming. c. Nanog-GFP cfp of sorted TANGO 
populations compared to D6s4B5 cells from the same time-point. 
 
In order to identify factors which may increase the efficiency of 
reprogramming, a number of screening steps were carried out to compare the 
RNAseq analysis of D6s4B5 and TANGO sub-populations. Sufficient numbers of 
TANGO 3NG+ cells could not be isolated at day 10 and these were not included in 
the analysis. Briefly, DNA binding factors were identified from the D6s4B5 dataset 
using the MGI GO database (Hill et al., 2001),  within this group genes identified to 
increase expression proportionally to their cfp were filtered, and those whose 
expression differed greatly in TANGO were selected for further study (Figure 
5.10a). Genes not previously described in reprogramming from somatic cells were 
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identified using these criteria (Figure 5.11). Five genes from this analysis were 
cloned from cDNA isolated from E14 ES cells using primers which introduced SalI 
and BstZ17I sites. After a TOPO vector intermediate stage, these sites were used to 
ligate the cDNA of interest into a site in a pENTR vector upstream of an ires-linked 
human CD2 (hCD2) gene which was to be used as a reporter for future isolation of 
novel cDNA-containing cells if desired. Gateway cloning was then used to 
introduce the cDNA sequence to the dox-inducible piggyBac vector pB TAP IRI to 
generate PB TAP IRI cDNA-ires-hCD2. Restriction sites introduced were selected 
based on their low frequency of occurrence in the mouse genome 
(www.tools.neb.com), and alternative cloning sites BstBI and AgeI could also be 
used to subsequently introduce newly cloned cDNA directly into the pB TAP IRI 
vector after the introduction of the CD2 reporter to the vector (Figure 5.10b). Each 
over-expression vector was introduced alongside the PB-TAP IRI 2LMKOSimO 
construct in primary reprogramming of Nanog+/GFP, Rosa+/rtTA (RTANG) MEF, and 
total Nanog-GFP+ colonies were quantified on day 15 of reprogramming (Figure 
5.12). In order to maximise potential differences in reprogramming efficiency 
induced by the novel factors, cells were reprogrammed in the absence of ALKi 
which increased the efficiency of reprogramming from MEF in the secondary 
system (Figure 4.1c). Eras, one of the top hits in the comparative analysis between 
D6s4B5 and TANGO cell lines, has been reported to increase the efficiency of 
reprogramming, and was included as a positive control(Polo et al., 2012). However, 
this factor was not found to enhance reprogramming compared to the empty vector 
control. Of the tested genes, the helicase component Mcm3 and primordial germ cell 
specification-factor Prdm14 displayed a five- and six-fold increase in Nanog-GFP+ 










Figure 5.10: Identification and over-expression of novel reprogramming 
factors. a. Overview of method to identify novel factors differentially expressed 
between D6s4B5 and TANGO. b. Cloning strategy used to introduce cDNA of 








Figure 5.11: RNAseq analysis comparison of TANGO and D6s4B5 





Figure 5.12: Over-expression of novel factors increases the colony formation 
potential in primary reprogramming. Values are fold increase over PB TET empty 
vector. Error bars represent standard deviation (n = 2). 
 
This data indicated that the reprogramming system identified using ICAM-1 
and CD44 markers and the Nanog-GFP reporter was suitable for not only 
identification of novel routes to reprogramming, but also factors which greatly 





5.3.1 RNAseq analysis reveals distinct properties of reprogramming populations 
 The functional differences evident between the identified reprogramming 
intermediate populations appeared to be reflected at the transcriptional level. 
Importantly, all the populations analysed were from the same time-point, and the 
data generated using this approach enables accurate transcriptional analysis of the 
reprogramming process independent of expansion of different reprogramming 
intermediates, and holds the potential to identify genes crucial for the success of 
reprogramming. This is unique among other marker-based approaches which have 
simply compared one reprogramming time-point against another (Polo et al., 2012).  
This system also enables investigation of the stabilisation of the 
reprogrammed state via comparison of the gene expression differences of the 3NG+ 
sub-population which is transgene-dependent at day 10 and independent at day 15 
(Figure 5.13). A number of the factors up-regulated at day 15 are expressed during 
embryonic development and in the inner cell mass, including the 
glycosphingolipid-associated enzyme β1,3gnt5 (B3gnt5), which has been shown to 
be essential for blastocyst formation (Biellmann et al., 2008). The functional 
relevance of these factors remains to be examined, but remains a source of further 
information about the establishment and maintenance of the reprogrammed state. 
 
Figure 5.13: Genes up-
regulated between day 
10 and day 15 in 3NG+ 
cells. A number of 
factors are activated in 
this population to a level 
similar to that in fully 
reprogrammed iPS cells 
and ES cells. 
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Other differences between the reprogramming intermediates were revealed 
through the DEG analysis. This highlighted the series of transcriptional changes 
undertaken at each stage of the reprogramming process, and unsupervised 
clustering of the populations based on the total DEGs identified during 
reprogramming largely reflected the shifts in population behaviour, indicating a 
major phase of reprogramming requires the transition from the 1NG+/- and 2NG- 
populations, and subsequently the apparent differences in 2NG+ and 3NG- 
populations between each-other and the 3NG+ population. Another important 
transition appears to be the acquisition of a reprogramming factor-free, stably 
reprogrammed state, with day 15 3NG+ cells clustering with fully reprogrammed 
iPS cells and ES cells. These transitions could be observed at a high resolution, with 
the PCA analysis supporting the idea that cells have the potential to utilise different 
pathways to reach an iPS cell-state during reprogramming. This highlights the 
requirement for accurate identification of different sub-populations which arise, 
apparently even during the later stages of reprogramming; identification of 
pathways and processes which result in more efficient generation of iPS cells could 
potentially not only improve reprogramming technology, but also lend insights into 
the plasticity of cellular behaviour and how this is modulated at different stages of 
reprogramming thus resulting in the heterogeneity of this process. 
 
5.3.2 Pluripotency gene up-regulation is a two-stage process during 
reprogramming 
 The unexpected identification of early- and late-stage up-regulation of 
pluripotency genes further supports the idea that reprogramming occurs, at least to 
some extent, in a step-by-step, predictable process, and requires appropriate 
conditions for successful progression. The presence of Pou5f1 among the group of 
“early” genes is striking, considering the key role of OCT4 in ES cell maintenance 
(Niwa et al., 2000). Similarly, Sall4, a regulator of Pou5f1, was also identified as 
being up-regulated to an iPS/ES cell-level in all populations (Zhang et al., 2006). The 
155 
 
later set of genes included many factors with roles are important for successful 
reprogramming including Klf2 and Esrrb (Jiang et al., 2008; Festuccia et al., 2012). 
A recent study also reported identification of two distinct groups of 
pluripotency-associated genes during reprogramming (Golipour et al., 2012). 
Factors were separately classified based on their contribution towards either the 
“maturation” or stabilisation of cells, based on changes in their expression upon 
exogenous reprogramming factor down-regulation during reprogramming. While 
the authors carried out a siRNA screen in ES cells and cells undergoing 
reprogramming to validate these classifications, the data was somewhat dubious as 
neither validation of gene knock-down nor rescue of knock-down phenotype were 
demonstrated, and therefore it is unclear if their separation of pluripotency factors is 
accurate. Another study also identified a two-phase pattern of pluripotency gene 
expression, and concluded that up-regulation of “early” wave genes, including Oct4 
and Sall4 does not identify cells which will undergo successful reprogramming, 
however the “late” wave of genes can be markers of the fully reprogrammed state 
(Buganim et al., 2012). These findings have been extended by the RNAseq analysis 
carried out in my study. Buganim et al. (2012) puts forward a model where re-
activation of endogenous SOX2 activity is important during reprogramming, with 
SOX2-activated factors in turn activating their targets, and thus leading to the 
establishment of a stabilised pluripotency network. The authors claim that therefore 
the latter stages of reprogramming occur in a hierarchical, ordered manner, 
however, this is described as occurring after a more stochastic phase in which 
chance activation of factors enables progression of reprogramming. However, this 
study was limited by the use of single cell qPCR analysis which is dependent on the 
selection of known, or expected factors, and it may be the case that the earlier 
“stochastic” phase also occurs in a similarly ordered manner as the later 
“hierarchical” phase, but that at present our understanding of the events of early 
reprogramming are poorly understood. Gene expression at earlier stages of 
reprogramming was examined in a study which sampled THY-1 and SSEA-1 sorted 
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cells at early time-points (Polo et al., 2012). This study also reported earlier up-
regulation of Sall4 and Pou5f1 and later activation of Sox2, suggesting a conserved 
phenomenon, at least in MEF undergoing reprogramming, however as previously 
discussed, THY-1 and SSEA-1 are not highly accurate markers with which to 
identify populations of cells undergoing successful reprogramming (see Section 
4.3.2). 
As outlined previously (see Section 4.3.4), there appeared to be stabilisation 
of Nanog-GFP expression as cells progressed from one stage of reprogramming to 
the next (1NG2NG/3NG), which correlated with an increase in cfp among the 
Nanog-GFP+ sorted populations themselves. I speculated that this increased stability 
of Nanog promoter activity in 2NG+ and 3NG+ is due to the presence of a 
pluripotency transcription factor network, or epigenetic changes which enabled 
greater access to this locus. The RNAseq analysis revealed Nanog was also expressed 
among the Nanog-GFP- sorted populations, being detected at higher levels than the 
preceding NG- sub-population, but at lower levels than their NG+ equivalent (1NG-
<2NG-≈1NG+<3NG-<2NG+<3NG+). Notably, Nanog was detected among the second 
wave of pluripotency genes. Importantly, a recent report claimed Nanog mRNA is 
expressed in a mono-allelic fashion in ES cells cultured in serum and LIF, with bi-
allelic expression only occurring when cells were cultured in their naïve state in 2i 
conditions or on feeders (Miyanari and Torres-Padilla, 2012). While this could have 
explained the inconsistency observed between Nanog-GFP and Nanog transcription, 
a report recently demonstrated detection of NANOG protein as a result of 
transcription from both alleles in ES cells, and suggested poor reporter choice, 
genetic background or transcriptional bursting as reasons for the original findings 
(Faddah et al., 2013; Filipczyk et al., 2013). However, a further study also identified 
a few, rare cells which expressed Nanog in a mono-allelic manner in both serum/LIF 
and 2i conditions, and ruled out transcriptional bursting as an explanation for this 
observation (Hansen and van Oudenaarden, 2013). Why 3NG- cells, which express 
higher levels of Nanog than 1NG+ do not activate expression of the reporter is 
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unclear, however this discrepancy does not lessen the importance of the functional 
and transcriptional characteristics of the sub-populations identified by Nanog-GFP 
expression. 
 
5.3.3 Epidermis gene expression occurs during reprogramming from MEF 
 The most striking finding from the RNAseq analysis of the intermediate 
populations was the identification of the transient gene expression patterns, in 
particular the transiently up-regulated group of epidermis-associated genes (Group 
B). Expression of epidermis genes in partially reprogrammed cells from B-cells had 
previously been noted, and was thought to be a result of the off-target effects of 
Sox2 and Klf4 activity (Mikkelsen et al., 2008). Consistent with my data, analysis of 
three published microarray data sets incorporating partially reprogrammed iPS cells 
(piPSCs), a time course experiment and a sub-population analysis confirmed 
transient epidermal gene expression during reprogramming (Sridharan et al., 2009; 
Samavarchi-Tehrani et al., 2010; Polo et al., 2012) (Figure 5.14). This data indicates 
this pattern of gene expression is conserved during reprogramming, indicating cells 
undergoing reprogramming experience apparently more complex gene expression 
changes than the simple down-regulation of MEF genes followed by up-regulation 
of ES cell genes. Notably, it has also been shown that pre-iPS cells derived from 
different starting materials and by different laboratories have similar characteristics, 
and the observed maintenance of epidermis gene expression in the study by 
Sridharan et al. (2009) confirms these genes are found in other pre-iPS cell lines, 
suggesting this may be a conserved feature of reprogramming from other cell-types, 
not just MEF (Polo et al., 2012). The timing of up-regulation and down-regulation of 
each individual epidermis gene is not synchronized in the time course and 
THY1/SSEA1/Oct4-GFP datasets (Figure 5.14). Interestingly, the RNAseq data 
generated from the ICAM-1/CD44/Nanog-GFP sub-population analysis indicated 
that this wave of transient gene expression is down-regulated at a point when the 
later phase of pluripotent gene expression is activated, which is only apparent in 
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sufficiently homogeneous systems, and therefore suggests why it may have been 




 While there is an apparent inverse correlation between epidermis and late 
stage pluripotency genes, it remains unclear if the former group play a functional 
role during reprogramming. Further to this, epidermis gene up-regulation was 
detected during Klf4 and Oct4, but not Sox2 and Oct4, based reprogramming of 
MEF (Nemajerova et al., 2012). This may suggest the observed up-regulation of 
epidermis genes may simply be a by-product of Klf4 over-expression during 
reprogramming. Reprogramming human fibroblasts in the absence of exogenous 
Klf4 has been demonstrated, and also in MEFs, both in cells lacking p53 activity and 
Figure 5.14: Up-regulation of 
epidermis gene expression in 
a variety of reprogramming 
systems. Expression pattern of 
epidermis-related genes, from 
Sub-population Group B, 
common to piPSCs, bulk time-




by the inclusion of the kinase inhibitor Kenpaullone, with the latter strategy also 
shown to be effective in reprogramming mouse neural stem (NS) cells (Huangfu et 
al., 2008b; Kawamura et al., 2009; Lyssiotis et al., 2009). However, in all the above 
studies, the efficiency of reprogramming in the absence of Klf4 was severely affected 
and was not totally restored in any instance, indicating additional, as yet unknown 
functions for this factor during reprogramming. In addition, this suggests that even 
if the transient expression of these genes is the result of Klf4 activity, this is an 
important stage in efficient reprogramming. 
 
5.3.4 RNAseq analysis reveals genes which improve reprogramming efficiency 
 As a proof of principle, preliminary results suggest that this reprogramming 
system can be used to identify factors which improve reprogramming from MEF. 
Prdm14 showed the greatest effect on colony formation, and recent reports have 
highlighted its important roles both in reprogramming epiblast stem cells to a more 
naïve state and in ES cell maintenance (Gillich et al., 2012; Grabole et al., 2013). 
Interestingly, Prdm14 activity in ES cells involves the repression of lineage specifiers 
in part by mediating PRC2-complex-member Jarid2 target binding, and was shown 
to co-localize with Nanog and Esrrb, all three of which are up-regulated as part of 
the second wave of pluripotency genes in the RNAseq dataset (Yamaji et al., 2013) 
(Figure 5.6b).  
 Mcm3 is a member of the minichromosome maintenance proteins (Mcm2-7) 
which constitute the core of the replicative DNA helicase complex which is recruited 
to origins of replication in early G1, in a process termed “origin licensing” (Sclafani 
and Holzen, 2007). Abrogation of Mcm2 and Mcm4 activity in mice has previously 
been linked to chromosomal instability and an increased disposition to developing 
cancer (Pruitt et al., 2007; Shima et al., 2007). The complex relationship between 
members of the Mcm family was demonstrated by the finding that the efficiency of 
reprogramming from Mcm4-/-, and Mcm4-/- Mcm2-/+ MEF could be increased by 
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decreasing levels of Mcm3 expression (Chuang et al., 2010). This data indicated the 
levels of these family members relative to each other are important in 
reprogramming. However, it is unclear why altering the levels of individual 
members of a hetero-hexameric complex such as the one formed by the Mcm family 
members should have a rescue effect as described by this study. This may indicate 
theses proteins can function in other processes. Interestingly, in D6s4B5 cells, 
similarly to Mcm3, other members of the Mcm2-7 complex also increase during 
reprogramming (Figure 5.15, D-Mcm). Expression of these factors was largely 
similar in TANGO with the exception of Mcm3 and Mcm2 which were expressed at 
substantially lower levels than in D6s4B5 reprogramming (Figure 5.15, T-Mcm). 
Knockdown of Mcm3 and Mcm2 in human cells was found to result in 
hypersensitivity to replication stress with cells accumulating aberrant chromosome 
rearrangements, breaks and gaps (Ibarra et al., 2008). Similarly, reprogramming has 
been shown to induce expression of the tumour suppressor protein p53 which 
greatly decreases the efficiency of iPS cell generation, while inhibition of its activity 
generates iPS cells which carry DNA damage and chromosomal aberrations (Marion 
et al., 2009). It may be the case that during reprogramming expression of the Mcm 
complex members, especially Mcm3 and Mcm2, helps to maintain chromosomal 
integrity, thus reducing p53 activation and therefore overcoming this barrier to 
reprogramming.  
 Future investigation of factors identified through comparison with 
other cell lines, other reprogramming methods, different reprogramming culture 
conditions and using additional or alternative reprogramming factors can be carried 
out accurately using this reprogramming system, thus allowing further dissection of 




Figure 5.15: Mcm complex member expression during reprogramming. Sub-
population expression levels for D6s4B5 (D-Mcm, solid lines) and TANGO (T-Mcm, 





CHAPTER 6 - General discussion and summary 
 
6.1 Overview of results from this study 
 Starting with Gurdon’s work in the 1960’s, it had been shown that 
“resetting” of a differentiated cell to a pluripotent-like state was possible through 
cell-fusion or nuclear transfer, the exact factors required for this process to occur 
remained largely a mystery. Therefore the discovery that pluripotency could be 
induced in differentiated cells by over-expression of a defined set of transcription 
factors revolutionised the field of stem cell research. While this technology appeared 
to herald an era of huge potential for both investigation of pluripotency, 
differentiation and therapeutic applications of this knowledge, there were a number 
of obstacles to be overcome before these ideas would become reality. 
This first set of induced pluripotent stem (iPS) cells was unable to contribute 
to viable chimeric mice, despite displaying many of the attributes of embryonic stem 
(ES) cells. It was later discovered that in cells undergoing the reprogramming 
process, more stringent selection for the expression of key pluripotency genes, such 
as Nanog and Oct4, produced iPS cells which could contribute to chimeric mice. 
These iPS cells were found to display an epigenetic profile which was much more 
similar to ES cells than those originally isolated by Takahashi and Yamanaka. 
Further advances were made through identification of additional factors, small 
molecules and culture conditions which were found to enhance the reprogramming 
process. However, despite these advances, the efficiency and heterogeneous of 
generating iPS cells in the vast majority of reprogramming systems prevented 
accurate high-resolution analysis of the requirements of successful reprogramming. 
 The aim of my project was to identify novel markers that could be used to 
isolate defined populations of cells undergoing reprogramming which could be 
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used to investigate the molecular mechanism of iPS cell generation from MEFs. By 
using a relatively efficient secondary reprogramming system, I discovered that 
markers widely used in reprogramming studies such as SSEA-1, THY-1 and E-CAD 
were insufficient to accurately identify the diverse populations of cells that arise 
during the reprogramming process. In contrast, I discovered that during 
reprogramming the dynamic expression patterns of novel markers ICAM-1 and 
CD44, when coupled with a Nanog-GFP reporter, could be used to isolate 
populations of cells which displayed distinct potentials to generate iPS cells. 
Uniquely, this demonstrated that even at a single time-point cultures and colonies of 
cells undergoing reprogramming are heterogeneous, highlighting the importance of 
this marker system’s ability to isolate each of these sub-populations. 
Further profiling of these populations by FACS analysis revealed distinct 
and reproducible kinetics during the transition from one population to the next. 
This demonstrated that the heterogeneity that arises during reprogramming can be 
attributed not only to differences in the timing of the reprogramming process but 
also to differences in the routes cells take to achieve a reprogrammed state. This was 
illustrated by the identification, for the first time, of two major routes available to 
cells undergoing reprogramming from MEF; one activating Nanog-GFP expression 
before loss of CD44, and gain of ICAM-1 expression, and the other doing so only 
after achieving an ES cell-like ICAM-1+/CD44- phenotype. Interestingly, while one 
route appeared to generate iPS cells more efficiently than the other, the ability of 
cells to take this “better” route was low. 
In order to further investigate this observation and dissect the key 
characteristics of each of the sub-populations, RNAseq analysis was carried out. 
This method revealed that although isolated from a single time-point, each sub-
population did indeed represent a distinct population of cells, with distinct 
transcriptional profiles, and each of the differentially expressed genes (DEGs) 
expressed in each were identified. A number of important results were obtained by 
using RNAseq analysis, including the identification of additional factors involved in 
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each of two waves of pluripotency gene up-regulation which had previously been 
reported in a study limited by single cell qPCR (sc-qPCR). In addition, analysis of 
DEGs between the sub-populations revealed two unexpected expression patterns; 
the transient up- and also down-regulation of genes during reprogramming. Gene 
ontology (GO) analysis identified a number of genes associated with epidermis 
development among the set of transiently up-regulated genes, and expression of 
these genes was confirmed by sc-qPCR of cells in each of the sub-populations and 
immunofluorescence staining of colonies undergoing reprogramming. This clearly 
demonstrated that during reprogramming from MEF cells enter an intermediate 
stage associated with the expression of epidermis-related genes. In addition, this 
transient gene expression pattern was identified in other reprogramming studies 
and in pre-iPS cells generated from B-cells, suggesting it may be a conserved 
characteristic of the reprogramming process (Sridharan et al., 2009; Samavarchi-
Tehrani et al., 2010; Polo et al., 2012). 
 
Finally, it was demonstrated that by applying this marker and high-
resolution analysis other, less efficient, reprogramming systems could be 
investigated to identify novel factors that enhance the reprogramming process. 
Using this technique, two novel genes, Prdm14 and Mcm3, were identified to 
increase the efficiency of generating Nanog-GFP+ iPS cell during primary 
reprogramming. 
These results demonstrated the ability of this system to accurately 






Figure 6.1: Overview of study findings. This study identified novel reprogramming 
cell surface markers ICAM-1 and CD44 which, in association with a Nanog-GFP 
reporter, illuminated the pathway(s) to the fully reprogrammed state through a 
number of distinct intermediate subpopulations. Transcriptional profiling revealed 
gene expression patterns during reprogramming including previously un-identified 






6.2 Future directions 
6.2.1 Other novel markers of the reprogramming process 
 While ICAM-1 and CD44 were sufficient to identify populations at the latter 
stages of reprogramming, other markers could be integrated in order to further 
increase the range and resolution of this system. For example, at earlier stages these 
markers may be unsuitable to correctly discriminate between the potential of 
populations to undergo reprogramming as illustrated by the almost identical 
reprogramming profile and kinetics illustrated by ICAM-1 sorted MEF cells (Figure 
4.5). However, one caveat of this type of analysis however, is the heterogeneity of 
the reprogramming process at early stages of reprogramming, with a large number 
of genes responding to reprogramming factor expression, the majority of which may 
not play a role in promoting iPS cell generation (Soufi et al., 2012). One approach 
could be to sort CD44+ cells at various time-points after reprogramming factor 
expression and determine a change in iPS cell potential. Changes in gene expression 
between this and earlier populations may reveal factors important for successful 
reprogramming, with the ultimate aim being identification of a very early up-
regulated factor or factors which can be used to identify cells correlated with 
reprogramming success, for example a marker of a day 10 1NG+ precursor. 
However, as outlined in this study, even at the latter stages of reprogramming more 
than one route is available for cells to undergo reprogramming, and identification of 
such a marker may be difficult. 
It may be more appropriate to apply the type of analysis carried out with 
ICAM-1 and CD44 to non-MEF reprogramming systems. While these exact markers 
may not be suitable, other differentiated cell types have well characterised cell 
surface markers, and the dynamics of their expression changes during 
reprogramming may enable similar analysis as carried out in this study. It has been 
reported that pre-iPS cells cluster separately from SSEA-1 cells undergoing 
reprogramming from MEF, suggesting they may take a different route to the 
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reprogrammed state (Polo et al., 2012). Interestingly, pre-iPS cells demonstrate an 
ICAM-1-/CD44+ profile (see Appendix, Supplementary Figure 15), suggesting these 
markers could be used to investigate the mechanism of reprogramming from these 
intermediates. 
 
6.2.2 Investigation of the epigenetic state of identified sub-populations 
 While the RNAseq analysis carried out in this study provides a wealth of 
information regarding the transcriptional capability of each of the sub-populations, 
the epigenetic state of these cells remains unknown. A large number of studies have 
emphasised the importance of epigenetic regulators in ensuring successful 
reprogramming, and the system generated in my study provides a unique 
opportunity to investigate the dynamics of epigenetic change during 
reprogramming. A factor which may prove difficult to overcome is the quantity of 
cells required for thorough analysis of epigenetic features such as Chromatin-
immunoprecipitation coupled with high-throughput DNA sequencing (ChIP-seq), 
which may not be possible for the lesser-occurring sub-populations such as 1NG+ 
and 2NG+. Of course, this technical obstacle may be overcome by either increasing 
the starting numbers of MEFs used for analysis, or by sampling at different time-
points which may be more enriched for the sub-population required, and this 
would require functional validation, as carried out for the day 10 and day 8 sorted 
cells (Figure 4.9, 4.10). In addition, ChIP-seq protocols using relatively low (1X105) 
number of cells have been recently been reported, although this reduction in cell 
number was correlated to an increase in unmapped sequencing reads (~30% of 
total), and the quality of the antibody used for immunoprecipitation introduces 
another potentially detrimental variable (Gilfillan et al., 2012). 
Another approach to epigenetic investigation of the reprogramming process 
is to analyses the effect of specific factors. For example, one molecule associated 
with regulation of epigenetic factors, and shown to drastically affect the 
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reprogramming process in this study is VitaminC (VitC, Figure 4.12). As illustrated, 
the removal of this molecule reduced the efficiency of reprogramming and altered 
the transition kinetics of each sub-population. It would be interesting to investigate 
if the activity of reported VitC-dependent factors, and their associated epigenetic 
modifications (see Section 1.4.3) are altered compared to control sub-populations. 
This type of analysis could reveal the individual contribution of individual 
epigenetic factors to the series of events required to re-establish an ES cell-like 
epigenetic state during reprogramming. 
 
6.2.3 The role of transient epidermis gene up-regulation during reprogramming 
 While it appears from the results of this study that transient up-regulation of 
epidermis-associated genes during reprogramming of MEF is conserved across 
different systems, the functional role of these genes, if any, was not investigated. 
Introduction of siRNA knock-down vectors against these epidermis genes during 
reprogramming could reveal the importance of these factors during 
reprogramming. Cultures could be monitored for differences in the kinetics of iPS 
cell colony formation and changes in the dynamic of ICAM-1/CD44 expression 
during reprogramming compared to control cells. This could illuminate if this 
transient state is required for, or hinders efficient reprogramming. 
As previously discussed (see Section 5.3.3), a number of studies suggest that 
Klf4 plays a role in the up-regulation of these genes during reprogramming, and 
reprogramming in the absence of Klf4 could also address this question. 
 
6.2.4 Further characterisation and identification of novel enhancers of the 
reprogramming process 
 In this study I demonstrated the identification of two novel factors which 
could increase the efficiency of primary reprogramming in co-operation with the 
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widely-used Yamanaka factors (Figure 5.12). Further investigation of these factors 
could lend further insights into their role in reprogramming. As discussed it would 
be interesting to monitor if Prdm14-associated targets are similarly up-regulated at 
earlier stages in reprogramming and are responsible for the observed increase in 
reprogramming efficiency upon over-expression of this factor. Similarly, 
investigation of factors associated with senescence and DNA damage such as 
activated p53 may lead to greater understanding of the role of Mcm3 in enhancing 
reprogramming. 
 In addition to these factors, a number of other factors differentially 
expressed between D6s4B5 and TANGO reprogramming systems remain to be 
investigated, in a similar manner to the genes above and these may also provide 




6.3 Future perspectives for iPS cell technology 
Although understanding of the mechanism of reprogramming is far from 
complete, and the system developed in this study can help to further our knowledge 
of this process, iPS cells have already been applied in therapeutic contexts. Recently, 
the Japanese Ministry of Health approved a plan to carry out the world’s first 
clinical trial involving transplantation of retinal pigment epithelial cells generated 
from iPS cells derived from patients with age-related macular degeneration. This is 
a tremendously exciting development and is the product of intensive research in 
this field, and although it remains to be seen if this trial will be successful, it is likely 
that the promise of iPS cells is finally coming to fruition.  
Much debate has focused on attempting to understand if the mechanism of 
reprogramming is a stochastic or deterministic process (Hanna et al., 2009b; 
Yamanaka, 2009; Buganim et al., 2012). In 2009, Hanna and colleagues reported that 
if given enough time (i.e. number of cell divisions) almost all clonally derived B-
cells can undergo reprogramming (Hanna et al., 2009b). This indicated that 
reprogramming was a stochastic process, with the acquisition of the fully 
reprogrammed state varying from cell to cell (variable latency). More recently 
however, Hanna and colleagues (Rais et al., 2013) reported knock-down of a 
component of the nucleosome remodelling and deacetylation (NuRD) complex, 
methyl-CpG binding domain protein 3 (Mbd3), was sufficient to abolish the 
stochastic nature of reprogramming. Dramatically, this report demonstrated that in 
a secondary reprogramming system driven by dox-mediated expression of a 
polycistronic reprogramming vector in single-cell sorted Mbd3-/- MEF, 100% of cells 
expressed an Oct4-GFP reporter by day 8 of reprogramming. Unusually, cells 
underwent reprogramming in 2i/LIF under physiological oxygen (5% O2) 
conditions. In addition to MEF, a number of other cell types were reprogrammed at 
a similar efficiency including pro- and mature B-cells, adult tail tip fibroblasts, 
hematopoietic stem cells and neural precursors. ChIP-seq and sc-qPCR analysis 
revealed Mbd3-/- cells lost DNA methylation and up-regulated pluripotency genes 
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between days 4 and 8 of reprogramming. In contrast to another report investigating 
Mbd3 in reprogramming, this report did not observe up-regulation of endogenous 
pluripotency-associated genes in the absence of Mbd3 in MEF, and rather reported a 
direct physical interaction between the reprogramming factors and Mbd3 itself (Luo 
et al., 2013). In wt cells, this interaction was found to recruit Mbd3 and another 
NuRD complex component, Chd4, to common target genes which displayed higher 
expression in Mbd3-/- cells. This lead to the conclusion that in the absence of Mbd3, 
reprogramming is a deterministic process, with a loss of the variable latency of 
individual cells achieving a reprogrammed state. Interestingly, it was reported in 
human fibroblasts that while the Yamanaka factors demonstrate quite promiscuous 
binding upon over-expression during reprogramming, large regions which contain 
reprogramming factor-bound targets in ES cells remain unbound and methylated, 
and it would be interesting to determine if there is a correlation between these two 
observations, especially as Hanna et al. also demonstrated Mbd3-/- enhanced 
reprogramming of differentiated human cells (Soufi et al., 2012). The 6 days 
required for reprogramming in Mbd3-/- cells was only reported in 2i/LIF medium 
which is not commonly used throughout the whole reprogramming time-course, 
and lower reprogramming efficiencies were reported for more usual 
reprogramming medium. This discrepancy could be investigated to understand the 
role of the 2i components in reprogramming, and indeed, the addition of other 
factors which may further accelerate the onset of reprogramming.  
The fact that the previous report which demonstrated Mbd3 knockdown did 
not observe such a dramatic increase in reprogramming efficiency is surprising (Luo 
et al., 2013). In addition, it had previously been reported that in reprogramming 
from primary human cells Mbd3 knockdown negatively affected colony formation, 
in contrast to the reported increase in reprogramming efficiency observed in Hanna 
and colleague’s report, although this could only be achieved by the addition of 
LIN28 to the reprogramming cocktail (Onder et al., 2012). Of course, these 
experiments were carried out under different culture conditions, and the exact 
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experiments carried out by Hannah and colleagues must be repeated by other 
groups. Assuming these results can be independently verified, the study of 
reprogramming may not remain a mystery for much longer if totally homogeneous, 
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High-resolution analysis with novel cell-surface
markers identifies routes to iPS cells
James O’Malley1, Stavroula Skylaki2, Kumiko A. Iwabuchi1, Eleni Chantzoura1, Tyson Ruetz1, Anna Johnsson3,
Simon R. Tomlinson1, Sten Linnarsson3 & Keisuke Kaji1
The generation of induced pluripotent stem (iPS) cells presents a
challenge to normal developmental processes. The low efficiency
and heterogeneity of most methods have hindered understanding
of the precise molecular mechanisms promoting, and roadblocks
preventing, efficient reprogramming. Although several intermedi-
ate populations have been described1–7, it has proved difficult to
characterize the rare, asynchronous transition from these inter-
mediate stages to iPS cells. The rapid expansion of minor repro-
grammed cells in the heterogeneous population can also obscure
investigation of relevant transition processes. Understanding the
biological mechanisms essential for successful iPS cell generation
requires both accurate capture of cells undergoing the reprogram-
ming process and identification of the associated global gene
expression changes. Here we demonstrate that in mouse embryonic
fibroblasts, reprogramming follows an orderly sequence of stage
transitions, marked by changes in the cell-surface markers CD44
and ICAM1, and a Nanog–enhanced green fluorescent protein
(Nanog–eGFP) reporter. RNA-sequencing analysis of these popu-
lations demonstrates two waves of pluripotency gene upregulation,
and unexpectedly, transient upregulation of several epidermis-
related genes, demonstrating that reprogramming is not simply
the reversal of the normal developmental processes. This novel
high-resolution analysis enables the construction of a detailed repro-
gramming route map, and the improved understanding of the repro-
gramming process will lead to new reprogramming strategies.
Several reports have suggested that reprogramming progresses in an
ordered manner3,5,6,8–10. To identify markers whose expression chan-
ged concurrent with pluripotency gene expression, we performed time
course microarray analysis using a piggyBac transposon-based secon-
dary reprogramming system3,11 (Supplementary Fig. 2a). Of a number
of candidate cell-surface markers, Cd44 and Icam1 (also known as
CD54) demonstrated the most dynamic expression changes through-
out secondary mouse embryonic fibroblast (MEF) reprogramming
(Supplementary Fig. 2b). For further investigation, we generated an
efficient secondary reprogramming system in which doxycycline-
mediated induction of the reprogramming factors could be monitored
by an mOrange reporter placed after the 2A-peptide-linked repro-
gramming cassette c-Myc-Klf4-Oct4-Sox2 (MKOS)12, and endogen-
ous Nanog promoter activation could be followed by expression of
enhanced green fluorescent protein (eGFP)13 (Supplementary Fig 3).
Reprogramming cultures were supplemented with vitamin C and an
Alk inhibitor, both of which enhance reprogramming efficiency10,14,15.
In this secondary reprogramming system, Nanog–eGFP1 cells appeared
as early as day 6, and .60% of mOrange1 transgene-expressing cells
were found to be Nanog–eGFP1 by day 12 (Supplementary Figs 4
and 5a). Most mOrange1 transgene-expressing cells lost expression of
Thy1 (also known as CD90) and gained E-cadherin (also known as
Cdh1) expression by day 4 (Supplementary Fig. 5b, c). Expression of
stage-specific embryonic antigen 1 (SSEA-1, also known as Fut4) barely
changed after day 8, with a gradual gain of Nanog–eGFP1 cells in both
SSEA-11 and SSEA-12 cell populations (Supplementary Fig. 5d).
Consistent with heterogeneous expression of SSEA1 in iPS and embry-
onic stem (ES) cells, it was not possible to delineate the reprogramming
process accurately using SSEA-1 (Supplementary Fig. 6). By contrast, the
appearance of CD442 and ICAM11 cells at later time points closely
correlated with Nanog–eGFP expression (Supplementary Fig. 5e, f).
Double staining for CD44 and ICAM1 revealed that a distinct series
of population changes occur during reprogramming (Fig. 1). Initially,
MEFs displayed high CD44 and broad ICAM1 expression, with most
becoming ICAM12 by day 6, along with the appearance of a minor
CD442 ICAM12 cell population. By day 8, CD442 populations
appeared enriched, and at day 12 almost all cells displayed an iPS/ES-
cell-like CD442 ICAM11 profile, of which more than 60% expressed
Nanog–eGFP. Consistent with the observation that Nanog expression is
not necessarily a sign of completed reprogramming16, Nanog–eGFP1
cells were observed even before cells obtained this iPS/ES-cell-like
phenotype (CD442 ICAM11). Both ICAM11- and ICAM12-sorted
MEFs demonstrated similar fluorescence-activated cell sorting (FACS)
profile changes during reprogramming (Supplementary Fig. 7).
Immunofluorescence for CD44 and ICAM1 revealed that reprogram-
ming is not synchronized even within individual colonies (Supplemen-
tary Fig. 8). Secondary reprogramming of the non-polycistronic iPS
cell line 6c (refs 3, 11) and primary reprogramming using MKOS and
Oct4-P2A-Sox2-T2A-Klf4-E2A-cMyc (OSKM)17 piggyBac transposons
resulted in similar ICAM1 and CD44 profile changes, indicating their
suitability for use in other systems and contexts (Supplementary Fig. 9).
These findings demonstrated the asynchronous but stepwise manner of
reprogramming, and highlighted the potential usefulness of CD44 and
ICAM1 to isolate intermediate reprogramming subpopulations.
Next, we aimed to confirm that the observed CD44/ICAM1 profile
changes reflected the transition of individual cells from one stage to the
next, and not merely the loss of one major population and expansion
of another minor population. CD441 ICAM12 (gate 1), CD442
ICAM12 (gate 2) and CD442 ICAM11 (gate 3) cell populations, either
Nanog–eGFP1 (that is, 1NG1, 2 NG1 and 3NG1) or Nanog–eGFP2
(1NG2, 2NG2 and 3NG2), were isolated by cell-sorting at day 10 of
reprogramming and re-plated in reprogramming conditions (Fig. 2a).
After 3 days, both NG1 and NG2 cells progressed in the order of gates
1 to 2 to 3 (Fig. 2b). This progression correlated well with increased
Nanog–eGFP1 colony-forming potential (c.f.p.), with 3NG1 cells dis-
playing similar clonogenicity to fully reprogrammed iPS cells (Fig. 2c).
Of cells with the same CD44/ICAM1 profile, Nanog–eGFP expression
correlated with a higher c.f.p. (for example, 1NG2 versus 1NG1).
To examine the progression of the reprogramming process more accur-
ately, cells from each gate were sorted, and their expression of CD44/
ICAM1/Nanog–eGFP was re-analysed after 24 h (Fig. 2d). On the basis
of total cell numbers in each gate after 24 h (Supplementary Fig. 10), we
generated a reprogramming route map representing differences in the
1MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh BioQuarter, 5 Little France Drive, Edinburgh EH16 4UU, UK. 2Stem Cell Dynamics Research Unit, Helmholtz Center Munich,
Ingolstädter Landstraße 1, 85764 Neuherberg, Germany. 3Laboratory for Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Scheeles väg 1, SE-171 77
Stockholm, Sweden.
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efficiency of these stage transitions and in Nanog–eGFP1 c.f.p. (Fig. 2e).
Similar results were obtained when each subpopulation was sorted at
day 8 (Supplementary Fig. 11). This analysis revealed that reaching a
Nanog–eGFP1 state is a rate-limiting step—as few cells overcame this
barrier in the 24 h assay—and those that do so reprogram more efficiently
than their Nanog–eGFP2 counterparts, consistent with the role of Nanog
as an accelerator of reprogramming and the gateway to pluripotency18,19.
To determine global gene expression changes during these stage
transitions, we carried out RNA-sequencing analysis using a highly
multiplexed sample bar-coding system20–26 (see Methods and Sup-
plementary Table 1). Hierarchical clustering using the complete list
of differentially expressed genes (DEGs) revealed four major branches:
(1) MEFs; (2) 1NG2/1 and 2NG2; (3) 2NG2/1 and 3NG2/1; and (4)
3NG1 sorted at day 15 (3NG1D15), iPS and ES cells (Fig. 3a). There
was a prominent gene expression difference between 3NG1 and
3NG1D15 cells, with the latter being more similar to iPS and ES cells
(Fig. 3a and Supplementary Fig. 12), possibly reflecting the observed
difference in the c.f.p. in the absence of doxycycline (Supplementary
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Figure 1 | FACS analysis during secondary reprogramming of MEFs with
CD44/ICAM1 double staining. Loss of CD44 expression was rapidly followed
by ICAM1 upregulation and Nanog–eGFP expression. By day 12, most cells
displayed an ICAM1/CD442 ES-cell-like profile. Red denotes Nanog–eGFP2
cells; green denotes Nanog–eGFP1 cells.
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Figure 2 | CD44/ICAM1 subpopulations represent distinct stages of
reprogramming. a, Nanog–eGFP1 (NG1) and Nanog–eGFP2 (NG2) cells
were subdivided into CD441 ICAM12 (gate 1), CD442 ICAM12 (gate 2) and
CD442 ICAM11 (gate 3) populations at day 10 of reprogramming. b, FACS
analysis of sorted subpopulations after a 3-day culture in the presence of
doxycycline (dox). c, Relative probability to generate Nanog–eGFP1 iPS cell
colonies from each subpopulation compared to fully reprogrammed iPS cells.
Error bars represent s.d., n 5 3. d, Expression of CD44, ICAM1 and Nanog–
eGFP was re-analysed 24 h after sorting. e, Major transitions (.500 cells) of
each population within 24 h. The y axis indicates relative c.f.p. after a further
10 days. Arrow size reflects relative cell numbers.
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Fig. 13). The DEGs between these two populations may be involved in
the establishment of an exogenous-factor-independent self-renewal
state. Principal component analysis clearly distinguished 2NG1 from
3NG2 cells, consistent with the higher probability of the former to
reach the 3NG1 state within 24 h (Supplementary Figs 10 and 12b).
DEGs could be classified into five distinct expression pattern groups
(A–E) (Fig. 3a and Supplementary Tables 2 and 3). Group A contained
readily downregulated fibroblast-related genes. Group D comprised
factors gradually upregulated towards iPS cells, in which ES cell genes
were highly enriched (P # 0.000367) (Fig. 3c). However group C,
which contained genes upregulated at early stages and maintained
throughout reprogramming, also included some pluripotency-related
factors. To extend this finding, we examined the expression pattern of
22 pluripotency-related genes in our data set27,28. Interestingly, 8 pluri-
potency genes, including endogenous Oct4 (also known as Pou5f1),
were already upregulated at the 1NG1/2NG2 stages to the level found
in 3NG1 cells (Fig. 3b, left), whereas 14 pluripotency genes were more
gradually upregulated in the later stage reprogramming populations
(Fig. 3b, right, and Supplementary Table 4). This early and late pluripo-
tency gene upregulation was confirmed at the single cell level5 (Fig. 3e),
highlighting the high resolution of the CD44/ICAM1 sorting system.
We also identified two additional gene expression patterns display-
ing transient upregulation (group B) or downregulation (group E)
exclusively in the intermediate stages of reprogramming. This finding
indicates that reprogramming from MEFs to iPS cells is not simply the
loss of MEF genes and gain of ES cell genes. Gene Ontology analysis
revealed that genes related to ectoderm/epidermis development and
keratinocyte differentiation were highly enriched in group B
(P # 0.000274) (Fig. 3c, d and Supplementary Tables 3–5). Although
SFN and KRT17 were barely detectable by immunofluorescence in
MEFs and iPS cells, transient upregulation was observed in the inter-
mediate stages of reprogramming (Supplementary Fig. 14). Single-cell
PCR confirmed the co-expression of epidermis genes (Ehf and
Ovol1) with early pluripotency genes in the 1NG2/1 stage (Fig. 3e).
Consistent with our data, analysis of three published microarray data
sets incorporating partially reprogrammed iPS cells1, a time course
experiment3 and a subpopulation analysis with Thy1, SSEA-1 and
Oct4–eGFP (ref. 6) confirmed transient epidermal gene expression
during reprogramming (Supplementary Figs 15–17 and Sup-
plementary Tables 6–8). Partially reprogrammed cells from B cells also
displayed similar epidermis gene expression4, whereas two factor-
reprogramming (Oct4 and Sox2) of MEFs did not29. Therefore, this
intermediate state could be a consequence of the use of Klf4 that is
important for efficient reprogramming, and demonstrates that the
reprogramming process is not simply a reversion of normal differenti-
ation (summarized in Supplementary Fig. 1). It would be intriguing to
investigate whether similar transient gene expression changes can be
seen in reprogramming of ectoderm or endoderm lineages. Down-
regulation of these epidermis genes coincided with upregulation of
‘late’ pluripotency genes. Future examination of this rapid switch in































































































































































































































































































Ectoderm development 2.14 × 10–6
Epidermis development 4.18 × 10–6





Stem-cell development 8.31 × 10–5
Stem-cell differentiation 3.67 × 10–4
Epidermal cell differentiation 4.26 × 10–5
Epithelial cell differentiation 2.41 × 10–4



































































































Figure 3 | Global gene expression changes during the stage transition.
a, Hierarchical clustering of samples with DEGs and expression heat map.
Groups A–E represent different expression patterns. b, Early (left) and late
(right) upregulation of pluripotency-related genes. Black and red asterisks
indicate early and late pluripotency genes, respectively, previously identified by
single-cell quantitative PCR (qPCR)5. c, Epidermal and stem-cell gene
enrichment in gene list B and D, respectively. d, Transient upregulation of 18
epidermis/keratinocyte-related genes during reprogramming. e, Single-cell
gene expression analysis. Each square represents one reaction chamber from
one cell. Colour corresponds to DCt value, as shown in the legend.
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The integrative data analysis described above demonstrated that this
CD44/ICAM1/Nanog–eGFP marker system could uniquely provide
high-resolution information during late pluripotency gene upregula-
tion, enabling the discrimination of ‘reprogramming’ from ‘expansion
of reprogrammed cells’ (Fig. 3b and Supplementary Figs 16b and 17f).
This system also refines investigation of the kinetics of reprogram-
ming. It has recently been shown that vitamin C increases reprogram-
ming efficiency by facilitating histone 3 Lys 9 (H3K9) demethylation7,
and that reprogramming factors fail to bind trimethylated H3K9-rich
regions in the initial stages of reprogramming30. We carried out repro-
gramming in the absence of vitamin C and observed not only a
decrease in the iPS cell colony number, but also a marked delay in
the transition from one stage of reprogramming to the next (Sup-
plementary Fig. 18). Similar analyses can be performed using our
marker system to investigate the mechanism of action of other factors
that alter reprogramming efficiency. Isolation and analysis of sub-
populations affected by these factors could reveal the downstream
genes specifically involved in, and required for, successful reprogram-
ming. Further studies using this high-resolution analysis system have
the potential to make a considerable contribution towards revealing
the molecular mechanisms of reprogramming.
METHODS SUMMARY
The vector PB-TAP IRI 2LMKOSimO, a modified version of polycistronic repro-
gramming vector pCAG2LMKOSimO (ref. 12), containing insulator and replica-
tor sequences and driven by the tetO2 promoter, was constructed as described in
the Methods. This vector was used to generate iPS cell line D6s4B5 from reverse
tetracycline transactivator (rtTA)-expressing MEFs carrying a Nanog–eGFP
reporter13. D6s4B5 iPS cells were used to generate chimaeric embryos from which
MEFs were isolated at embryonic day 12.5. Transgenic MEFs were cultured in
doxycycline (300 ng ml21), vitamin C (10mg ml21) and Alk inhibitor (500 nM),
and collected for flow cytometry analysis (BD Fortessa), carried out using
antibodies for CD44 and ICAM1 every 2–3 days. Cells were sorted (BD FACS
Aria II) at day 10 or 15, and replated on gelatin for analysis at 24 h, or at clonal
density on irradiated MEFs for Nanog–eGFP1 c.f.p. 10 days after cell sorting. All
flow cytometry data were analysed using FlowJo (Tree Star). Immunofluorescence
was carried out using confocal microscopy (Leica TSC SP2). RNA from sorted
samples was extracted using Trizol (Invitrogen), and 10 ng total RNA was used for
multiplexed RNA-sequencing20,21. Data were analysed using GeneProf22, and
DEGs were identified using edgeR and DESeq Bioconductor libraries23–25. Gene
Ontology enrichment was calculated using DAVID26.
Full Methods and any associated references are available in the online version of
the paper.
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METHODS
Vector construction. The piggyBac transposon PB-TAP containing the tetO2
promoter, an attR1R2 Gateway cloning cassette (Invitrogen) and rabbit b-globin
poly A signal, was provided by A. Nagy. To minimize silencing of the reprogram-
ming vector, a chicken b-globin insulator31 was inserted into the PacI site between
the piggyBac 39-terminal repeat (39-TR) and the tetO2 promoter, and a human
lamin B2 (LMB2) replicator32 plus another chicken b-globin insulator were
inserted into the EcoRV site between the rabbit b-globin poly A signal and the
piggyBac 59-TR, to generate PB-TAP IRI. The BamHI fragment containing
loxP-flanked MKOS reprogramming cassette followed by ires-mOrange
(2LMKOSimO) from pCAG2LMKOSimO (ref. 12) was inserted into a Gateway
entry vector pENTR 2B (Life Technologies), to generate attP2LMKOSimO
pENTR. Finally the attP2LMKOSimO cassette was Gateway-cloned into the
PB-TAP IRI to yield reprogramming piggyBac transposon PB-TAP IRI
attP2LMKOSimO. Similarly, reprogramming piggyBac transposon PB-TAP IRI
2LOSKMimO was generated after transferring the OSKM reprogramming
cassette17 into attP2LMKOSimO pENTR replacing the MKOS cassette. Plasmid
sequences are available on request.
Generation of a primary iPS cell line D6s4B5. Embryos at 12.5 days post coitum
(d.p.c.) were obtained from RosartTA/rtTA, NanogeGFP/1, Col1a11/1 mice, which
were derived by crossing TNG mice13 and B6;129-Gt(ROSA)26Sortm1(rtTA*M2)Jae
Col1a1tm2(tetO-Pou5f1)Jae/J (Jackson Laboratory). The embryos were decapitated,
eviscerated, dissociated with 0.25% trypsin and 0.1% EDTA, and plated in MEF
medium (GMEM, 10% FBS, penicillin–streptomycin, 13 non-essential amino
acids (Invitrogen), 1 mM sodium pyruvate and 0.05 mM 2-mercaptoethanol).
The PB-TAP IRI attP2LMKOSimO (500 ng) and pCyL43 piggyBac transposase
expression vector33 (2mg) were introduced into the MEFs by nucleofection
(Amaxa) as before12, and cells were cultured in ES cell medium (MEF medium
supplemented with 1,000 U ml21 leukaemia inhibiting factor (LIF)) in the pres-
ence of 1.0mg ml21 doxycycline (Sigma) for an initial 8 days, and thereafter 0.5mg
ml21 doxycycline. Pluripotency of a clonal iPS cell line D6 was confirmed by
teratoma formation, and a subclone D6s4B5 was used for secondary reprogram-
ming. To compare CD44 and ICAM1 profiles of primary reprogramming with
PB-TAP IRI attP2LMKOSimO and PB-TAP IRI 2LOSKMimO vectors, MEFs
were nucleofected as above and cultured in the presence of 1.0 mg ml21 doxycy-
cline, 10mg ml21 vitamin C (Sigma) and 500 nM Alk inhibitor A 83-01 (TOCRIS
Bioscience).
Secondary reprogramming. Each chimaeric embryo was collected at 12.5 d.p.c.,
dissociated and cultured in MEF medium. One-twentieth of the dissociated cells
were exposed to doxycycline (300 ng ml21) for 2 days, and the proportion of
transgenic MEFs was measured by FACS analysis of mOrange expression. For
FACS time course and colony counting experiments, secondary transgenic MEFs
were diluted to 5% and 30% by addition of 129 wild-type MEFs and plated in a
gelatinized 6-well-plate at 1 3 105 cells per well (5,000 and 30,000 transgenic MEFs
per well, respectively). For sorting experiments, MEFs were plated at 2 3 105 cells
per gelatinized 100 mm plate (1 3 104 transgenic MEFs per plate). Cells were
cultured in reprogramming medium, which is ES cell medium supplemented with
300 ng ml21 doxycycline, 10mg ml21 vitamin C and 500 nM Alk inhibitor.
Medium was changed every 2 days.
Flow cytometry and cell sorting. Cell-surface marker analysis was performed
with the following eBioscience antibodies: ICAM-1-biotin (13-0541; 1/100),
CD44-biotin (17-0441; 1/100), CD44- allophycocyanin (APC) (17-0441; 1/300),
streptavidin-phycoerythrin (PE)-Cy7 (25-4317-82; 1/1500), SSEA-1-647 (51-
8813; 1/50), E-cadherin-biotin (13-3249; 1/100), Thy1-APC (17-0902, 1/300)
and CD2-biotin (13-0029; 1/100). For sorting experiments, dead cells were
excluded using 49,6-diamidino-2-phenylindole (DAPI) nucleic acid stain
(Invitrogen) (0.5 ng ml21). Cells were incubated in 0.25% trypsin and 1 mM
EDTA (Life Technologies) for 1–2 min at 37 uC, collected in GMEM media con-
taining 10% FCS and counted. Staining was carried out in FACS buffer (2% FCS in
PBS) at ,1 3 106 cells ml21 for 15–30 min at 4 uC, and followed by washing with
FACS buffer, sorting and/or analysis with FACSAriaII and LSRFortessa (both BD
Biosciences), respectively. Excitation laser lines and filters used for each fluoro-
phore are summarized in Supplementary Table 9. Data were analysed using
FlowJo software (Tree Star). Intact cells were identified based on forward and side
light scatter, and subsequently analysed for fluorescence intensity. Additional
gating was carried out as outlined in Supplementary Fig. 2. For colony formation
assays, sorted cells were plated on c-irradiated MEFs in 12-well plates at 3.5 3 103
cells per well. Nanog–eGFP1 colonies were quantified 10 days after sorting. For
24 h or time-course analysis, sorted cells were plated in gelatinized 48-well plate at
1 3 104 cells per well. In both cases, cells were cultured in reprogramming medium
after sorting.
Immunofluorescenceand confocal microscopy imaging. Images of cells stained
with ICAM-1-biotin (1/100), CD44-APC (1/300) and streptavidin-PE-Cy7 (1/
1,500) antibodies described above were captured with a confocal microscope
(Leica TSC SP2) and Leica confocal software. Cells stained with anti-Krt17
(LifeSpan BioSciences) and anti-Sfn (Sigma) antibodies and anti-Rabbit IgG
CF633 secondary antibody (Sigma) were imaged with a fluorescence microscopy
(Olympus).
Multiplexed RNA sequencing and data analysis. RNA was isolated with TRI
reagent (Sigma) following the manufacturer’s instructions. RNA quality and
concentration was determined using the Agilent 2100 Bioanalyzer (Agilent
Technologies). Using 10 ng RNA, reverse transcription with bar-coded primers,
complementary DNA amplification, and sequencing with Illumina HiSeq 2000
were performed as previously described20,21. Quality control of the obtained reads
and alignment to the mouse reference genome (NCBI37/mm9) were performed
using the GeneProf web-based analysis suite with default parameters22. Gene
expression read counts were exported and analysed in R to identify DEGs, using
the edgeR and DESeq Bioconductor libraries23–25. For both methods, low express-
ion transcripts (less than 13 reads in all samples) were filtered out, and P values
were adjusted using a threshold for false discovery rate (FDR) # 0.05. Genes listed
as DEGs by both methods in any two subpopulation comparison indicated in
Supplementary Table 1 and Supplementary Fig. 12a (total 3,171) were used for
further analysis. Hierarchical clustering and K-means clustering (K 5 5) was per-
formed using Cluster 3.0, and Java Treeview was used for visualization34,35. This
multiplexed RNA-sequencing technology reads only the 59 end of transcript, thus
detecting only endogenous Oct4 and Sox2. Nanog expression was detectable in
Nanog–eGFP2 populations owing to the reporter system. Principal components
analysis was performed in R and plotted with the scatterplot3d library36. Gene
Ontology enrichment was calculated using the DAVID functional annotation
bioinformatics tool26. Gene Ontology term enrichment analysis was carried out
with a modified Fisher exact P value. The three additional published studies1,3,6
(GEO accession numbers GSE21757, GSE14012 and GSE42379) were analysed in
a similar way. For the time course data, the analysis was performed as following:
data were robust multi-array average (RMA)37 normalized using the expression
console from Affymetrix and, because no replicates were provided, fold changes
between two samples were calculated in Excel. Genes with more than 1.5-fold
changes were classified as DEGs. For the Plath and Polo data set, data were RMA-
normalized using the ‘affy’ package38 in R, and DEGs were identified using the
‘limma’ package38 in R with fold change $ 1.5 and FDR # 0.05, or fold change
$ 1.5 where no replicates were available. Subsequently, K-means clustering of the
identified DEGs was performed for all studies. Selected gene expression data are
shown as the relative expression against the highest signal among the samples
using an averaged signal value (reads per million) of duplicates/triplicates.
Single-cell gene expression analysis. Single-cell qPCR was performed as
described previously5 with slight modifications. In brief, 22 sets of TaqMan gene
expression assays (Applied Biosystems; Supplementary Table 9) were pooled at a
final concentration of 180 nM per primer set and 50mM per probe. Individual cells
were sorted directly into 10ml RT-PreAmp Master Mix (5ml of CellsDirect reac-
tion mix (Invitrogen), 2.5ml of pooled assays, 0.2ml of SuperScript III (Invitrogen),
1.3ml of water) using FACSAria II. Cell lysis and sequence-specific reverse trans-
cription were performed at 50 uC for 15 min. Reverse transcriptase was inactivated
by heating to 95 uC for 2 min. Subsequently, in the same tube, cDNA went through
sequence-specific amplification by denaturing at 95 uC for 15 s, and annealing and
amplification at 60 uC for 4 min for 22 cycles. Preamplified products were diluted
fivefold with water and analysed in 48.48 dynamic arrays on a biomark system
(Fluidigm) following the Fluidigm protocol. Ct values were calculated and visua-
lized using BioMark real-time PCR analysis software (Fluidigm). Each assay was
performed in replicate.
31. Gaszner, M. & Felsenfeld, G. Insulators: exploiting transcriptional and epigenetic
mechanisms. Nature Rev. Genet. 7, 703–713 (2006).
32. Fu, H. et al. Preventing gene silencing with human replicators. Nature Biotechnol.
24, 572–576 (2006).
33. Wang, W. et al. Chromosomal transposition of PiggyBac in mouse embryonic
stem cells. Proc. Natl Acad. Sci. USA 105, 9290–9295 (2008).
34. Saldanha, A. J. Java Treeview–extensible visualization of microarray data.
Bioinformatics 20, 3246–3248 (2004).
35. de Hoon, M. J., Imoto, S., Nolan, J. & Miyano, S. Open source clustering software.
Bioinformatics 20, 1453–1454 (2004).
36. Ligges, U. & Maechler, M. scatterplot3d — an R package for visualizing
multivariate data. J. Stat. Softw. 8, 1–20 (2003).
37. Irizarry, R. A. et al. Summaries of Affymetrix GeneChip probe level data. Nucleic
Acids Res. 31, e15 (2003).
38. Gautier, L., Cope, L., Bolstad, B. M. & Irizarry, R. A. affy–analysis of Affymetrix
GeneChip data at the probe level. Bioinformatics 20, 307–315 (2004).
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Supplementary Figure 1. A Route map to iPSCs defined by CD44 and ICAM1 expression change. Sequential 
changes of CD44 and ICAM1 expression allowed isolation of subpopulations at different stages of reprogramming, 
the progression of which was accompanied by a gradual increase of iPSC colony formation efficiency. Differences 
in the transition rate of each subpopulation from one stage to the next revealed preferential routes to iPSCs. Global 
gene expression profiling highlighted transient up-regulation of multiple epidermis genes. There were two groups of 
pluripotency genes; those displaying early initiation of expression which overlapped with epidermis gene 
























Supplementary Figure 2. Identification of novel reprogramming cell surface markers, Cd44 and Icam1. a. 
Secondary (2o) reprogramming was carried out using the 6c cell line generated by 4 piggyBac (PB) transposons 
carrying reprogramming factors c-Myc, Klf4, Oct4 and Sox2. Subsequently RNA was extracted from SSEA-1+ cells 
at day5, 8, 11, 14, 17 as well as from 2o iPSCs for microarray analysis to identify novel reprogramming cell surface 
markers. This experiment was performed in the absence of VitC and Alki. b. Microarray analysis of 6c 2o 
reprogramming identified Cd44 and Icam1 as potential cell surface markers to dissect the reprogramming process. 
Thy1 expression is already down-regulated in SSEA1+ cells at day5 and E-cadherin expression plateaus at day8, 
suggesting previously identified markers are not suitable for investigation of the later stages of reprogramming. 





















Supplementary Figure 3. A piggyBac (PB) secondary (2°) reprogramming system with 2A peptide-linked 
reprogramming cassette MKOS followed by ires mOrange. a. The reprogramming PB transposon with 
insulators and replicator introduced into Nanog-eGFP MEFs. b. Upon administration of dox, induction of 
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Supplementary Figure 4. Gating strategy for secondary reprogramming. Intact cells were gated using side and 
forward scatter (Intact cells). Transgenic cells were gated from wild-type cells using mOrange reporter (Transgenic 
cells). Nanog-eGFP+ and Nanog-eGFP- cells were determined based on wild-type MEFs and coloured in green and 
red respectively. 






























Supplementary Figure 5. Expression pattern of previously used and novel markers during 2° 
reprogramming. a. Nanog-eGFP expression during secondary reprogramming. Note appearance of eGFP+ cells at 
day 6 from mOrange expressing cells. b, c. Thy1 negative population (b) and E-cadherin positive population (c) 
plateau by day 4 of 2o reprogramming. d. SSEA-1 expression level in established iPSCs are heterogeneous and 
Nanog-eGFP+ cells appear from both SSEA-1+ and SSEA-1- cells. e. Downregulation of CD44 occurs later than that 
of Thy1, more closely correlating with the appearance of Nanog-eGFP+ cells. f. ICAM1 expression is 
heterogeneous in MEFs, but the majority of cells become ICAM1- by around day 6. Re-upregulation 





























Supplementary Figure 5. Expression pattern of previously used and novel markers during 2° 
reprogramming. a. Nanog-eGFP expression during secondary reprogramming. Note appearance of eGFP+ cells at 
day 6 from mOrange expressing cells. b, c. Thy1 negative p pulatio  (b) and E-cadherin positive p pulation (c) 
plateau by day 4 of 2o reprogram ing. d. SSEA-1 expression level in established iPS s are heterog neous and 
Nanog-eGFP+ cells appear from both SSEA-1+ and SSEA-1- cells. e. Downregulation of CD44 occurs later than that 
of Thy1, more closely correlating with the appearance of Nanog-eGFP+ cells. f. ICAM1 expression is 
heterogeneous in MEFs, but the majority of cells become ICAM1- by around day 6. Re-upregulation 
of ICAM1 closely correlates with Nanog-eGFP expression.
SUPPLEMENTARY INFORMATION
















Supplementary Figure 6. SSEA-1 expression does not predict the appearance of Nanog-eGFP+ cells. a. Gating 
strategy for Nanog-eGFP- cells at day 5 of reprogramming. b. Sorting strategy for Nanog-eGFP-, SSEA-1+/- cells at 
day 5 of reprogramming. Cells were isolated, replated in reprogramming conditions and reanalyzed every 48hours. 
Red; Nanog-eGFP- cells, Green; Nanog-eGFP+ cells. 
 
Supplementary Figure 7. Similar reprogramming kinetics with ICAM1+/- MEFs. ICAM1+ and ICAM1- 
secondary MEF were sorted before initiating reprogramming. CD44, ICAM1, Nanog-eGFP expression was 
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Supplementary Figure 8. Immunofluorescence for CD44 and ICAM1 at day 6, 8 and 10 after 
reprogramming initiation. Cells in a single colony have distinct CD44, ICAM1, Nanog-eGFP expression, 
indicating clonal analysis is not sufficient to isolate cells in similar stages. Note expression of mOrange tends 



















Supplementary Figure 9. The reprogramming pathway is conserved in different reprogramming systems. a, 
Non-polycistronic PB 2o reprogramming with the 6c cell line. b. Primary PB reprogramming using both MKOS and 
OSKM polycistronic cassettes. c. Typical colonies arising from MKOS, OKMS primary PB reprogramming.  7 
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Supplementary Figure 8. Immunofluorescence for CD44 and ICAM1 at day 6, 8 and 10 after 
reprogramming initiation. Cells in a single colony have distinct CD44, ICAM1, Nanog-eGFP expression, 
indicating clonal analysis is not sufficient to isolate cells in similar stages. Note expression of mOrange tends 



















Supplementary Figure 9. The reprogramming pathway is conserved in different reprogramming systems. a, 
Non-polycistronic PB 2o reprogramming with the 6c cell line. b. Primary PB reprogramming using both MKOS and 
OSKM polycistronic cassettes. c. Typical colonies arising from MKOS, OKMS primary PB reprogramming.  
SUPPLEMENTARY INFORMATION






Supplementary Figure 10. Total number of cells in each gate after 24 hours for day 10 sorted populations. 
Each reprogramming population was sorted at day 10 and cells cultured in reprogramming conditions for 24 hours. 
Cells were then harvested and CD44/ICAM1/Nanog-eGFP expression was re-analysed. Total cell numbers found in 
each gate were plotted. This data highlighted the rapid expansion of cells once they entered the 3NG+ gate. The 


















































Supplementary Figure 11. Behavior of day8 sorted subpopulations are similar to that of day 10 
subpopulations. a. Sorting strategy at day 8 of reprogramming. b. Each subpopulation sorted at day8 were replated 
in reprogramming conditions, and reanalyzed after 24 hours. c. Total cell numbers in each gate after 24 hour 








































Supplementary Figure 1 . Behavior of ted subpopulations are similar o that of day 10 
subpo ulations. a. Sorting strategy at da    r gramming. b. Each sub opulation sorted t day8 w re r plated 
in reprogram ing conditions, and reanalyzed after 24 hours. c. Total cell numbers in each gate after 24 hour 
analysis for each sorted population. The error bars represent the standard deviation of three independent 
experiments. 
SUPPLEMENTARY INFORMATION





Supplementary Figure 12. Differentially expressed genes (DEGs) and Principal Component Analysis of 
reprogramming intermediates. a. Number of DEGs between samples identified via both edgeR and DESeq are 
indicated with arrows as shown. P-values were adjusted using a threshold for false discovery rate (FDR) ≤ 0.05. b. 
Using these DEGs (total 3,171), Principal Components Analysis (PCA) was performed. The green and red lines 
connecting the samples are based on the result that 3NG- cells were frequently produced by 2NG- and 1NG- cells 
(Figure 3d), while 2NG+ cells eventually appeared from 1NG+ cells (Figure 3b). c. Comparison of gene expression 
profiles between iPSCs and 3NG+, 3NG+D15, ESCs. Green and red color represents up- or down-regulated genes 
identified by both edgeR and DESeq. 
 
 
Supplementary Figure 13. Nanog-eGFP Colony formation 
potential of 3NG+ cells in the absence of dox. 3NG+ cells 
sorted at day10 (3NG+) and day15 (3NG+D15) of 
reprogramming were plated at clonal density on feeders in the 
absence of dox. The number of Nanog-eGFP+ colonies was 
counted after 10 days. 3NG+ cells from day10 post transgene 
induction showed reduced ability (60%) to generate colonies 
compared to established iPSCs, while cells from day15 
generated similar colony numbers to iPSCs. This suggests that 
about 40% of day10 3NG+ cells have not acquired exogenous 
reprogramming factor independent self-renewal capacity, but   
this trait can be acquired within an additional 5 days in the  
presence of dox. The error bars represent the standard deviation 
of three independent experiments. 
 
 










































Supplementary Figure 14. Transient up-regulation of Sfn and Krt17 during reprogramming. The highest 
protein level of both Sfn and Krt17 was observed around day9 post reprogramming (a, b). c. Higher magnification 
images of white squares in b. While Sfn protein was down-regulated before Nanog-eGFP expression (a), Krt protein 
was detectable in Nanog-eGFP expressing cells in the earlier stage, probably due to the protein stability (blue 









































Supplementary Figure 14. Transient up-regulation of Sfn and Krt17 during reprogramming. The highest 
protein level of both Sfn and Krt17 was observed around day9 post reprogramming (a, b). c. Higher magnification 
images of white squares in b. While Sfn protein was down-regulated before Nanog-eGFP expression (a), Krt protein 
was detectable in Nanog-eGFP expressing cells in the earlier sta e, probably due to the protein stability (blue 
asterisk in c). Higher Krt17 expression was observed in mOrangehigh, Nanog-eGFP- cells (red asterisk in c). 
SUPPLEMENTARY INFORMATION
























Supplementary Figure 15. Comparative analysis using published reprogramming time course and partially 
reprogrammed cell data sets. a. Heat maps from time course11 and partially reprogrammed iPSCs (piPSC)27 data 
sets with differentially expressed genes (DEGs) with > 2.0 fold change and FDR ≤ 0.05, respectively. The DEGs 
were classified into 5 categories based on their expression pattern as identified from our dataset. A complete list of 
DEGs in each category is available in Supplementary Table 6 and 7. b. Venn diagram of all DEGs from this 
(Subpopulation), time course and piPSC data sets, highlighting 1461 DEGs common to all analyses. c. These 1461 
genes were used to compare the overlap within each category against our subpopulation data set. Total number of 
genes belonging to each category is indicated in the upper tables, and their percentages against each Subpopulation 
A-E category are shown below. Overlap of more than 30% with Subpopulation A-E genes are highlighted in pink. 
Note that in the time course and piPSC microarrary datasets some genes are represented by multiple probe sets, 
resulting in several genes appearing in more than one category, with the total number of common genes standing 
























Supplementary Figure 15. Comparative analysis using published reprogramming time course and partially 
reprogrammed cell data sets. a. Heat maps from time course11 and partially reprogrammed iPSCs (piPSC)27 data 
sets with differentially expressed genes (DEGs) with > 2.0 fold change and FDR ≤ 0.05, respectively. The DEGs 
were classified into 5 categories based on their expression pattern as identified from our dataset. A complete list of 
DEGs in each category is available in Supplementary Table 6 and 7. b. Venn diagram of all DEGs from this 
(Subpopulation), time c urse and piPSC data sets, highlighting 1461 DEGs c mmon to ll analyses. c. These 1461 
genes w re used to c mpare the verlap within each category agai st ou subpopulation da a set. Total n mber of 
genes belonging to ach category is indicated in the upper tables, and their percentages against eac  Subpopulation 
A-E category are shown below. Overlap of more than 30% with Subpopulation A-E genes are highlighted in pink. 
Note that in the time course and piPSC microarrary datasets some genes are represented by multiple probe sets, 
resulting in several genes appearing in more than one category, with the total number of common genes standing 
at1466 and 1565, respectively. d. Cd44 and Icam1 expression profiles from Subpopulation, time course and piPSC 
data sets. 




Supplementary Figure 16. Conserved transient epidermis gene up-regulation and limited resolution at the 
later stage of reprogramming without the sorting strategy. a. Expression pattern of epidermis-related genes, 
identified in Subpopulation Group B, common to time course and piPSC datasets. Data are shown as relative 
expression against the highest single value among the samples. Signal values are summarized in Supplementary 
Table 4. The data indicated transient up-regulation of epidermis-related genes is a common feature during 
reprogramming. b. Expression pattern of 19 pluripotency-related genes from time course and piPSC datasets. Genes 
are grouped according to their expression pattern from the Subpopulation dataset, Early (up-regulated in 1N 
populations) and Late (gradually up-regulated through later stages of reprogramming). It is notable that there is a 
large increase in the expression level of many pluripotency genes between the last time point (day21) and iPSCs in 
the Timecourse data, suggesting that proportionally there were few reprogrammed cells by day21. In general, such 
bulk population analysis may not be suitable to investigate how pluripotency genes are up-regulated. Consistent 




Supplementary Figure 16. o served transient epidermis gene up-regulation and limited resolution at the 
later stage of reprogramming without the sorting strategy. a. Expression pattern of epidermis-related genes, 
identified in Subpopulation Group B, common to time course and piPSC datasets. Data are shown as relative 
expression against the highest single value among the samples. Signal values are summarized in Supplementary 
Table 4. The data indicated transient up-regulation of epidermis-related genes is a common feature during 
reprogramming. b. Expression pattern of 19 pluripotency-related genes from time course and piPSC datasets. Genes 
are grouped according to their expression pattern from the Subpopulation dataset, Early (up-regulated in 1N 
populations) and Late (gradually up-regulated through later stag s of reprogramming). It is not ble that there is a 
large increase in the expressio  level of many pluripotency g nes between the last time point (day21) and iPSCs in 
the Timeco rse data, suggesting that proportionally there were few r pro rammed cells by day21. In general, such 
bulk population analysis may not be suitable to investigate how pluripotency genes are up-regulated. Consistent 
with the fact that piPSCs have a low potential to generate iPSCs, most pluripotency genes are not expressed in 
piPSCs. 
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Supplementary Figure 17. Comparative analysis of another marker system (Polo et al. Cell, 2012). a. Heat 
maps from Thy1/SSEA1/Oct4-GFP (TSO) subpopulation datasets with differentially expressed genes (DEGs). A 
complete list of DEGs in each category is available in Supplementary Table 8. b. Venn diagram highlighting 1733 
DEGs common to our CD44/ICAM1/Nanog-eGFP subpopulation dataset. c. These 1733 genes were used to 
compare the overlap within each category against our subpopulation dataset. Overlap of more than 30% with our 
A-E genes are highlighted in pink. Almost equal numbers of TSO D genes belong to our C and D groups (red), 
indicating CD44/ICAM1/Nanog-eGFP sorting strategy gives higher resolution at the late stage of reprogramming. 
Note that in the TSO microarrary dataset some genes are represented by multiple probe sets, resulting in several 
genes appearing in more than one category, with the total number of common genes standing at 1884. d, e, f. 
Expression pattern of Cd44 and Icam1, epidermis-related genes, early and late pluripotency genes from TSO 





















Supplementary Figure 17. Comparative analysis of another marker system (Polo et al. Cell, 2012). a. Heat 
maps from Thy1/SSEA1/Oct4-GFP (TSO) subpopulation datasets with differentially expressed genes (DEGs). A 
complete list of DEGs in each category is available in Supplementary Table 8. b. Venn diagram highlighting 1733 
DEGs common to our CD44/ICAM1/Nanog-eGFP subpopulation dataset. c. These 1733 genes were used to 
compare the overlap within each category against our subpopulation dataset. Overlap of more than 30% with our 
A-E genes are highlighted in pink. Almost equal numbers of TSO D genes belong to our C and D groups (red), 
indicating CD44/ICAM1/Nanog-eGFP sorting strategy gives higher resolution at the late stage of reprogramming. 
Note that in the TSO microarrary dataset some genes are represented by multiple probe sets, resulting in several 
genes appearing in more than one category, with the total number of common genes standing at 1884. d, e, f. 
Expressi  p ttern of Cd44 and Icam1, epidermis-related genes, early and late pluripotency genes from TSO 
Subpopulation dataset, respectively.  











Supplementary Figure 18. Secondary reprogramming in the presence of dox, Alki either with or without 
VitaminC (+ or -VitC). a. Both total and Nanog-eGFP+ colony numbers decreased in the absence of VitC. b. Cells 










Supplementary Figure 18. Secondary reprogramming in the presence of dox, Alki either with or without 
VitaminC (+ or -VitC). a. Both total and Nanog-eGFP+ colony numbers decreased in the absence of VitC. b. Cells 
reprogrammed in the absence of VitC displayed delayed reprogramming kinetics. 
Supplementary Table 3
A
Term Pop Hits % PValue
GO:0007155~cell adhesion 561 8.77 2.92.E-13
GO:0022610~biological adhesion 562 8.77 3.13.E-13
GO:0030198~extracellular matrix organization 101 3.51 1.58.E-12
GO:0043062~extracellular structure organization 149 3.95 3.56.E-11
GO:0030029~actin filament-based process 176 4.09 3.14.E-10
GO:0007167~enzyme linked receptor protein signaling pathway 273 5.12 5.09.E-10
GO:0001568~blood vessel development 244 4.68 1.85.E-09
GO:0030036~actin cytoskeleton organization 165 3.80 1.88.E-09
GO:0001944~vasculature development 250 4.68 3.35.E-09
GO:0001558~regulation of cell growth 92 2.78 5.83.E-09
GO:0001501~skeletal system development 285 4.97 5.95.E-09
GO:0035295~tube development 264 4.53 4.54.E-08
GO:0048729~tissue morphogenesis 238 4.24 6.13.E-08
GO:0048514~blood vessel morphogenesis 198 3.80 8.00.E-08
GO:0040008~regulation of growth 256 4.39 8.18.E-08
GO:0010810~regulation of cell-substrate adhesion 40 1.75 1.40.E-07
GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway 192 3.65 1.76.E-07
GO:0030199~collagen fibril organization 21 1.32 4.44.E-07
GO:0007010~cytoskeleton organization 326 4.82 4.85.E-07
GO:0042127~regulation of cell proliferation 538 6.43 1.64.E-06
GO:0001655~urogenital system development 146 2.92 1.84.E-06
GO:0040007~growth 193 3.36 2.76.E-06
GO:0010811~positive regulation of cell-substrate adhesion 27 1.32 3.98.E-06
GO:0030334~regulation of cell migration 92 2.19 6.73.E-06
GO:0001503~ossification 106 2.34 7.94.E-06
GO:0051270~regulation of cell motion 107 2.34 8.93.E-06
GO:0042325~regulation of phosphorylation 290 4.09 1.02.E-05
GO:0060537~muscle tissue development 136 2.63 1.10.E-05
GO:0001763~morphogenesis of a branching structure 125 2.49 1.47.E-05
GO:0006928~cell motion 367 4.68 1.64.E-05
GO:0014706~striated muscle tissue development 127 2.49 1.80.E-05
GO:0051174~regulation of phosphorus metabolic process 301 4.09 2.00.E-05
GO:0019220~regulation of phosphate metabolic process 301 4.09 2.00.E-05
GO:0045785~positive regulation of cell adhesion 43 1.46 2.23.E-05
GO:0007507~heart development 223 3.36 2.77.E-05
GO:0007517~muscle organ development 176 2.92 2.84.E-05
GO:0032535~regulation of cellular component size 161 2.78 2.87.E-05
GO:0060348~bone development 118 2.34 2.95.E-05
GO:0043549~regulation of kinase activity 192 3.07 2.97.E-05
GO:0001525~angiogenesis 133 2.49 3.22.E-05
GO:0048754~branching morphogenesis of a tube 93 2.05 3.63.E-05
GO:0001822~kidney development 107 2.19 3.91.E-05
GO:0030155~regulation of cell adhesion 94 2.05 4.07.E-05
GO:0008038~neuron recognition 12 0.88 4.35.E-05
GO:0032989~cellular component morphogenesis 351 4.39 4.54.E-05
GO:0051338~regulation of transferase activity 199 3.07 4.96.E-05
GO:0040012~regulation of locomotion 110 2.19 5.33.E-05
GO:0022604~regulation of cell morphogenesis 97 2.05 5.70.E-05
GO:0048589~developmental growth 100 2.05 7.86.E-05
GO:0017015~regulation of transforming growth factor beta receptor signaling pathway 30 1.17 8.86.E-05
GO:0048705~skeletal system morphogenesis 130 2.34 9.18.E-05
GO:0042692~muscle cell differentiation 117 2.19 1.05.E-04
GO:0007409~axonogenesis 163 2.63 1.14.E-04
GO:0051216~cartilage development 78 1.75 1.32.E-04
GO:0008361~regulation of cell size 108 2.05 1.74.E-04
GO:0045859~regulation of protein kinase activity 186 2.78 1.89.E-04
GO:0035239~tube morphogenesis 171 2.63 2.05.E-04
GO:0043009~chordate embryonic development 421 4.68 2.13.E-04
GO:0016477~cell migration 240 3.22 2.31.E-04
GO:0031032~actomyosin structure organization 25 1.02 2.43.E-04
GO:0042060~wound healing 112 2.05 2.51.E-04
GO:0009792~embryonic development ending in birth or egg hatching 425 4.68 2.52.E-04
GO:0001656~metanephros development 58 1.46 2.57.E-04
GO:0007411~axon guidance 98 1.90 2.61.E-04
GO:0048812~neuron projection morphogenesis 176 2.63 2.89.E-04
GO:0000904~cell morphogenesis involved in differentiation 212 2.92 3.36.E-04
GO:0030030~cell projection organization 319 3.80 3.41.E-04
GO:0044092~negative regulation of molecular function 132 2.19 3.79.E-04
GO:0048732~gland development 197 2.78 3.84.E-04
GO:0060415~muscle tissue morphogenesis 18 0.88 3.91.E-04
GO:0055008~cardiac muscle tissue morphogenesis 18 0.88 3.91.E-04
GO:0048667~cell morphogenesis involved in neuron differentiation 182 2.63 4.28.E-04
GO:0051146~striated muscle cell differentiation 89 1.75 4.30.E-04
GO:0045185~maintenance of protein location 28 1.02 4.69.E-04
GO:0007229~integrin-mediated signaling pathway 76 1.61 4.70.E-04
GO:0031175~neuron projection development 218 2.92 4.75.E-04
GO:0060429~epithelium development 271 3.36 4.77.E-04
GO:0016192~vesicle-mediated transport 466 4.82 5.73.E-04
GO:0001657~ureteric bud development 42 1.17 8.00.E-04
GO:0048598~embryonic morphogenesis 359 3.95 8.57.E-04
GO:0032990~cell part morphogenesis 212 2.78 9.00.E-04
B
Term Pop Hits % PValue
GO:0007398~ectoderm development 133 2.75 2.14.E-06
GO:0008544~epidermis development 125 2.60 4.18.E-06
GO:0030216~keratinocyte differentiation 48 1.53 2.57.E-05
GO:0009913~epidermal cell differentiation 51 1.53 4.26.E-05
GO:0009611~response to wounding 347 4.27 4.31.E-05
GO:0030855~epithelial cell differentiation 123 2.14 2.41.E-04
GO:0006952~defense response 448 4.73 2.49.E-04
GO:0009266~response to temperature stimulus 51 1.37 2.67.E-04
GO:0031424~keratinization 28 1.07 2.74.E-04
GO:0006954~inflammatory response 225 2.90 5.78.E-04
GO:0050727~regulation of inflammatory response 57 1.37 5.81.E-04
GO:0032101~regulation of response to external stimulus 103 1.83 6.55.E-04
GO:0002478~antigen processing and presentation of exogenous peptide antigen 23 0.92 8.41.E-04
C
Term Pop Hits % PValue
GO:0034660~ncRNA metabolic process 202 2.83 3.66.E-04
GO:0006790~sulfur metabolic process 94 1.83 4.81.E-04
D
Term Pop Hits % PValue
GO:0045934~negative regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 397 6.24 1.49.E-07
GO:0051172~negative regulation of nitrogen compound metabolic process 401 6.24 1.81.E-07
GO:0010558~negative regulation of macromolecule biosynthetic process 418 6.00 1.41.E-06
GO:0010605~negative regulation of macromolecule metabolic process 506 6.70 1.50.E-06
GO:0031327~negative regulation of cellular biosynthetic process 430 6.00 2.34.E-06
GO:0009890~negative regulation of biosynthetic process 434 6.00 2.78.E-06
GO:0010629~negative regulation of gene expression 410 5.77 3.37.E-06
GO:0016481~negative regulation of transcription 372 5.31 7.49.E-06
GO:0045449~regulation of transcription 2227 17.09 1.25.E-05
GO:0045892~negative regulation of transcription, DNA-dependent 308 4.62 1.76.E-05
GO:0051253~negative regulation of RNA metabolic process 310 4.62 1.93.E-05
GO:0019827~stem cell maintenance 22 1.39 6.61.E-05
GO:0048864~stem cell development 23 1.39 8.31.E-05
GO:0019953~sexual reproduction 386 4.85 1.23.E-04
GO:0000122~negative regulation of transcription from RNA polymerase II promoter 231 3.46 2.71.E-04
GO:0007548~sex differentiation 130 2.54 3.18.E-04
GO:0045596~negative regulation of cell differentiation 182 3.00 3.46.E-04
GO:0048863~stem cell differentiation 31 1.39 3.67.E-04
GO:0007276~gamete generation 331 4.16 4.42.E-04
GO:0051053~negative regulation of DNA metabolic process 20 1.15 6.24.E-04
GO:0048609~reproductive process in a multicellular organism 409 4.62 6.99.E-04
GO:0032504~multicellular organism reproduction 409 4.62 6.99.E-04
GO:0048610~reproductive cellular process 173 2.77 8.20.E-04
GO:0045165~cell fate commitment 147 2.54 8.38.E-04
E
Term Pop Hits % PValue
GO:0007507~heart development 223 4.27 1.09.E-06
GO:0042127~regulation of cell proliferation 538 6.10 1.18.E-04
GO:0035295~tube development 264 3.86 1.48.E-04
GO:0022604~regulation of cell morphogenesis 97 2.24 1.77.E-04
GO:0035239~tube morphogenesis 171 2.85 4.36.E-04
GO:0003007~heart morphogenesis 74 1.83 5.69.E-04
Supplementary Table 3. Gene Ontology from O'Malley sub-population data
Supplementary Table 5. Epidermis genes EST profile
Breakdown by Body Sites -Transcripts per million
Asprv1 Barx2 Cdkn2a Cnfn Ehf Elf5 Evpl Jun Krt17 Krt6a Krtdap Ngfr Ovol1 Pphln1 Scel SfnShroom3 Sprr2a1 Sprr2b Trpv1 Tsg101 total
tongue 2699 89 0 629 179 0 0 0 0 359 2429 0 89 0 0 359 0 1889 n.a. 0 269 8990
stomach 503 0 0 251 0 0 0 472 157 0 440 0 0 0 0 188 0 5383 n.a. 0 31 7425
vagina 613 0 0 0 766 0 153 0 306 766 0 0 153 0 0 0 0 0 n.a. 0 0 2757
intestine 0 0 0 0 172 0 0 241 11 0 0 0 46 34 0 126 57 1784 n.a. 0 80 2551
skin 201 0 0 92 58 33 100 193 353 67 109 25 67 117 100 311 8 8 n.a. 0 109 1951
turbinate 0 0 0 0 729 0 0 729 0 0 0 0 0 0 0 0 0 0 n.a. 0 0 1458
extraembryonic tissue 0 0 0 0 0 0 0 93 0 0 0 0 13 107 0 53 26 990 n.a. 0 174 1456
sympathetic ganglion 0 0 0 0 0 0 0 801 0 0 0 500 0 0 0 0 0 0 n.a. 0 0 1301
epididymis 0 0 0 0 645 0 0 0 0 0 0 0 0 0 645 0 0 0 n.a. 0 0 1290
mammary gland 16 13 9 0 270 260 13 178 82 9 0 9 26 89 0 42 42 0 n.a. 0 112 1170
lung 50 0 180 0 330 180 0 110 50 0 0 50 10 20 0 50 50 20 n.a. 0 70 1170
dorsal root ganglion 0 0 0 0 0 0 0 411 0 0 0 411 0 164 0 0 0 0 n.a. 164 0 1150
nasopharynx 0 0 0 0 0 0 0 125 251 125 0 0 0 251 0 0 125 0 n.a. 0 125 1002
bladder 0 0 0 0 368 0 0 61 0 0 0 61 0 0 0 0 61 368 n.a. 0 0 919
uterus 0 0 0 0 0 0 0 291 0 0 0 0 291 0 0 0 145 0 n.a. 0 145 872
molar 0 0 0 0 0 0 0 0 282 0 0 0 0 0 565 0 0 0 n.a. 0 0 847
embryonic tissue 75 1 1 4 8 1 13 51 19 13 47 23 16 82 10 67 36 67 n.a. 0 89 623
pancreas 0 0 0 0 28 0 9 103 0 0 0 28 0 37 18 9 169 150 n.a. 0 56 607
olfactory mucosa 0 0 0 0 0 0 0 591 0 0 0 0 0 0 0 0 0 0 n.a. 0 0 591
prostate 0 0 0 0 270 0 0 0 0 0 33 0 0 0 0 0 0 237 n.a. 0 33 573
thyroid 0 0 0 0 0 0 0 340 0 0 0 0 0 0 0 0 113 0 n.a. 0 113 566
eye 64 0 0 0 5 0 21 53 0 91 0 43 0 102 5 26 48 0 n.a. 0 102 560
bone 0 0 0 0 0 0 0 410 0 0 0 0 0 0 0 0 0 0 n.a. 0 58 468
ovary 0 0 0 0 91 0 0 0 0 0 0 0 18 36 18 0 127 0 n.a. 0 145 435
bone marrow 0 0 0 0 0 0 0 95 0 0 0 0 0 168 0 7 7 0 n.a. 0 139 416
connective tissue 0 0 151 0 0 0 0 0 0 0 0 0 0 50 0 0 0 0 n.a. 0 201 402
fertilized ovum 0 0 0 0 107 0 0 35 0 0 0 0 35 179 35 0 0 0 n.a. 0 0 391
thymus 0 0 0 0 0 0 0 33 16 16 0 0 8 206 0 0 0 0 n.a. 0 107 386
muscle 36 0 0 0 0 0 0 110 0 0 0 0 0 184 0 0 0 0 n.a. 0 36 366
spleen 10 0 21 0 32 0 0 32 0 0 0 43 10 0 21 0 10 21 n.a. 0 162 362
pituitary gland 0 0 0 0 0 0 0 110 0 0 0 0 0 55 0 0 0 0 n.a. 0 166 331
heart 0 0 0 18 0 0 0 73 0 0 0 0 0 128 0 18 0 0 n.a. 0 91 328
kidney 0 0 0 0 32 0 32 24 0 0 0 0 24 80 24 8 40 16 n.a. 0 40 320
salivary gland 0 0 0 0 51 51 0 0 51 0 0 0 0 0 0 0 0 0 n.a. 0 154 307
inner ear 0 0 0 0 0 0 0 106 0 0 0 26 0 80 0 0 0 0 n.a. 0 80 292
testis 0 0 0 0 0 0 0 90 0 8 0 0 16 49 8 0 32 0 n.a. 0 82 285
oviduct 0 0 0 0 261 0 0 0 0 0 0 0 0 0 0 0 0 0 n.a. 0 0 261
joint 0 0 117 0 0 0 0 117 0 0 0 0 0 0 0 0 0 0 n.a. 0 0 234
brain 0 2 0 0 0 0 4 69 0 0 0 8 0 29 0 0 48 0 n.a. 6 67 233
lymph node 0 0 0 0 0 0 0 0 0 0 0 0 0 68 0 0 0 0 n.a. 0 136 204
spinal cord 40 0 0 0 0 0 0 40 0 0 0 0 0 0 0 0 40 0 n.a. 0 80 200
liver 0 0 0 0 8 0 0 8 0 0 0 0 0 26 0 8 8 0 n.a. 0 62 120
blood 0 0 0 0 0 0 0 0 0 0 0 0 0 59 0 0 0 0 n.a. 0 59 118
adipose tissue 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 n.a. 0 0 0
adrenal gland 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 n.a. 0 0 0
pineal gland 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 n.a. 0 0 0
vesicular gland 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 n.a. 0 0 0
n.a. = not available
Breakdown by Developmental Stage -Transcripts per million
Asprv1 Barx2 Cdkn2a Cnfn Ehf Elf5 Evpl Jun Krt17 Krt6a Krtdap Ngfr Ovol1 Pphln1 Scel SfnShroom3 Sprr2a1 Sprr2b Trpv1 Tsg101 total
oocyte 0 0 0 0 206 0 0 0 0 0 0 0 0 51 0 0 0 0 n.a. 0 310 567
unfertilized ovum 0 0 0 0 49 0 0 0 0 0 0 0 0 0 49 0 0 0 n.a. 0 0 98
zygote 0 0 0 0 104 0 0 34 0 0 0 0 34 173 34 0 0 0 n.a. 0 0 379
cleavage 0 0 0 0 36 0 0 0 0 0 0 0 0 145 72 36 0 0 n.a. 0 181 470
morula 0 0 0 0 81 0 54 243 0 0 0 0 0 54 0 243 0 0 n.a. 0 27 702
blastocyst 0 0 0 0 0 14 0 0 0 0 0 0 43 87 0 204 0 0 n.a. 0 29 377
egg cylinder 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 n.a. 0 0 0
gastrula 0 0 0 0 0 0 0 33 0 0 0 67 0 135 0 67 0 0 n.a. 0 169 471
organogenesis 15 7 0 0 0 0 0 45 0 0 0 0 0 114 7 30 15 0 n.a. 0 99 332
fetus 99 4 0 19 7 0 8 96 34 23 71 51 11 75 5 32 99 103 n.a. 2 90 829
neonate 0 0 0 0 18 0 9 101 27 9 9 83 36 27 9 0 0 9 n.a. 0 18 355
juvenile 31 0 0 0 27 0 3 76 20 34 0 6 24 101 13 20 31 10 n.a. 0 59 455
adult 85 4 2 27 118 58 29 113 377 76 83 3 13 73 10 60 85 859 n.a. 0 76 2151
n.a. = not available
